tag:blogger.com,1999:blog-30088897052308335362024-03-13T12:27:56.342-07:00articulos MedicineClaudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.comBlogger175125tag:blogger.com,1999:blog-3008889705230833536.post-89692979110914894782011-11-16T02:41:00.001-08:002011-11-16T02:41:39.963-08:00guias enfermedad arterial ´periferica<a href="https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=1339d4b0a3c428c9&attid=0.1&disp=safe&realattid=f_guy4pe200&zw">https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=1339d4b0a3c428c9&attid=0.1&disp=safe&realattid=f_guy4pe200&zw</a><br> <br> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Claudio Mori gonzales</b> <span dir="ltr"><<a href="mailto:clagui57@gmail.com">clagui57@gmail.com</a>></span><br>Fecha: 13 de noviembre de 2011 09:18<br> Asunto: guias enfermedad arterial ´perifericva<br>Para: <a href="mailto:clagui57@gmail.com">clagui57@gmail.com</a><br><br><br></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com3tag:blogger.com,1999:blog-3008889705230833536.post-48078280231516880722011-11-01T08:48:00.001-07:002011-11-01T08:48:07.045-07:00drugs son seguras para ADHD<div id="content"><a name="articleTop" rel="10.1056/NEJMoa1110212"></a> <p class="articleType">Original Article</p> <h1>ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults</h1> <p class="authors">William O. Cooper, M.D., M.P.H., Laurel A. Habel, Ph.D., Colin M. Sox, M.D., K. Arnold Chan, M.D., Sc.D., Patrick G. Arbogast, Ph.D., T. Craig Cheetham, Pharm.D., Katherine T. Murray, M.D., Virginia P. Quinn, Ph.D., M.P.H., C. Michael Stein, M.B., Ch.B., S. Todd Callahan, M.D., M.P.H., Bruce H. Fireman, M.A., Frank A. Fish, M.D., Howard S. Kirshner, M.D., Anne O'Duffy, M.D., Frederick A. Connell, M.D., M.P.H., and Wayne A. Ray, Ph.D.</p> <p class="citationLine">November 1, 2011 (10.1056/NEJMoa1110212) </p> <p class="openUntilInfo"><img src="http://www.nejm.org/templates/jsp/_style2/_mms/_nejm/img/icon_comment.gif"> <a class="scrollDirectly" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#discussion" name="discussion">Comments</a> open through November 8, 2011 </p> <dl class="articleTabs tabPanel lastChild"> <dt id="abstractTab" class="active abstract firstChild sideBySide inactive">Abstract</dt> <dt id="articleTab" class="article sideBySide">Article</dt> <dt id="referencesTab" class="references sideBySide inactive">References</dt> <dt id="commentsTab" class="sideBySide inactive">Comments </dt> <dd style="DISPLAY: none" id="abstract"> <div class="left section"> <div class="section"></div> <div class="section"> <h3 id="abstractBackground">Background</h3> <p>Adverse-event reports from North America have raised concern that the use of drugs for attention deficit–hyperactivity disorder (ADHD) increases the risk of serious cardiovascular events.</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#Background" rel="gotofulltext">Full Text of Background...</a></p></div> <div class="section"></div> <div class="section"> <h3 id="abstractMethods">Methods</h3> <p>We conducted a retrospective cohort study with automated data from four health plans (Tennessee Medicaid, Washington State Medicaid, Kaiser Permanente California, and OptumInsight Epidemiology), with 1,200,438 children and young adults between the ages of 2 and 24 years and 2,579,104 person-years of follow-up, including 373,667 person-years of current use of ADHD drugs. We identified serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) from health-plan data and vital records, with end points validated by medical-record review. We estimated the relative risk of end points among current users, as compared with nonusers, with hazard ratios from Cox regression models.</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#Methods" rel="gotofulltext">Full Text of Methods...</a></p></div> <div class="section"></div> <div class="section"> <h3 id="abstractResults">Results</h3> <p>Cohort members had 81 serious cardiovascular events (3.1 per 100,000 person-years). Current users of ADHD drugs were not at increased risk for serious cardiovascular events (adjusted hazard ratio, 0.75; 95% confidence interval [CI], 0.31 to 1.85). Risk was not increased for any of the individual end points, or for current users as compared with former users (adjusted hazard ratio, 0.70; 95% CI, 0.29 to 1.72). Alternative analyses addressing several study assumptions also showed no significant association between the use of an ADHD drug and the risk of a study end point.</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#Results" rel="gotofulltext">Full Text of Results...</a></p></div> <div class="section"></div> <div class="section"> <h3 id="abstractConclusions">Conclusions</h3> <p>This large study showed no evidence that current use of an ADHD drug was associated with an increased risk of serious cardiovascular events, although the upper limit of the 95% confidence interval indicated that a doubling of the risk could not be ruled out. However, the absolute magnitude of such an increased risk would be low. (Funded by the Agency for Healthcare Research and Quality and the Food and Drug Administration.)</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#Discussion" rel="gotofulltext">Full Text of Discussion...</a></p></div> <div class="section"></div> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#Top" rel="gotofulltext">Read the Full Article...</a></p></div> <div class="right section"> <div class="articleMedia"> <h3 class="title">Media in This Article</h3> <div class="mediaRefs"> <div class="mediaRef"><span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=f01"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_f1.gif"></a><span class="figureCaption">Adjusted Rates of Serious Cardiovascular Events, According to the Use of ADHD Drugs.</span></span></div> <div class="mediaRef"><span class="table"><span class="figureTitle">Table 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t01"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_t1.gif"></a><span class="figureCaption">Study Cohorts, According to Site.</span></span></div> </div></div></div></dd> <dd style="DISPLAY: block" id="article"> <div class="section"> <p>Medications that are used to treat attention deficit–hyperactivity disorder (ADHD) are prescribed for more than 2.7 million children in the United States each year<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref1" rel="#refLayer">1</a></span> and have been considered to be relatively safe.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref2" rel="#refLayer">2-5</a></span> However, reports of adverse events from Canada and the United States that have included cases of sudden death, myocardial infarction, and stroke in conjunction with the use of these drugs have raised concern about their safety.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref6" rel="#refLayer">6,7</a></span> Although case reports from adverse-event reporting systems can be an important source for identifying medication safety signals, they cannot reliably quantify risk. Thus, there is a compelling need to obtain better safety data for these drugs. We used data from four large, geographically and demographically diverse U.S. health plans to conduct a retrospective cohort study of the use of ADHD drugs and the risk of serious cardiovascular events in children and young adults, with review of medical records to validate study end points. The study was conducted in parallel with a study of ADHD drug use and serious cardiovascular events in adults between the ages of 25 and 64 years.</p> </div> <div class="section"> <h3 id="articleMethods">Methods</h3> <div class="subSection"> <h3 id="articleData Sources">Data Sources</h3> <p>We obtained study data from computerized health records of four health plans that together annually covered 22.4 million persons during the study period: Tennessee Medicaid, Washington State Medicaid, Kaiser Permanente California (Northern and Southern regions), and OptumInsight Epidemiology (national private insurance health-plan data). We augmented health-plan data with linkage to state death certificates and the National Death Index. Health-plan data included enrollment records, outpatient and inpatient claims, and records of filled prescriptions (including the dispensing date, drug name, dose, quantity, and duration of supply), which have been shown to be good measures of medication use.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref8" rel="#refLayer">8-11</a></span> The initiation of the study differed according to site on the basis of the earliest availability of the site's computerized data (ranging from 1986 to 2002). Follow-up concluded for all sites at the end of 2005. Each site prepared standardized files from health-plan data and used computer programs from the lead site (Vanderbilt University) to define study variables and create files in which identifiers of patients had been removed. These files were sent to the lead site for analyses.</p> </div> <div class="subSection"> <h3 id="articleStudy Population">Study Population</h3> <p>To assemble the cohort, we identified patients who met the following criteria: use of an ADHD drug (methylphenidate, dexmethylphenidate, dextroamphetamines, amphetamine salts, atomoxetine, or pemoline) during the study period; an age of 2 to 24 years on the first day of qualifying use; continuous enrollment with drug benefits for 365 days preceding the first day of qualifying use (allowing for short administrative gaps in enrollment); and the absence of possibly life-threatening serious illness (Section 1 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). Because patients with congenital heart disease may be vulnerable to the effects of ADHD medications, such patients were included in the study. Exclusion criteria included a hospital discharge during the preceding 365 days with a primary diagnosis of acute myocardial infarction or stroke. The last day of study follow-up was the last day of the study or the date on which the patient no longer met study criteria. A given patient was allowed to reenter the cohort as long as all the cohort eligibility requirements were met.</p> <p>For each patient receiving an ADHD medication, we randomly selected up to two nonuser control subjects from health-plan members at the same site who were enrolled on the first day of qualifying use at the age of 2 to 24 years, who met continuous-enrollment requirements, and who did not have a serious illness. Nonusers were matched with users on the basis of calendar year, age, and sex and were allowed to have previous nonqualifying use of ADHD drugs before the first day of qualifying use. Follow-up for nonusers began on the first day of qualifying use for the matched users of ADHD drugs and ended on the nonuser's last day of study follow-up (Section 2 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). Follow-up time did not include the time during hospitalization and the 30 days after discharge because in-hospital deaths were not considered to be study end points and health-plan files did not include drugs dispensed in the hospital.</p> </div> <div class="subSection"> <h3 id="articleUse of Study Drugs">Use of Study Drugs</h3> <p>Every person-day during study follow-up was classified according to use of ADHD drugs (Section 2 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). Current use was defined as use during the period between the prescription start date and the end of the days of supply (including up to a 7-day carryover from previous prescriptions). Former use was defined as use during the period after current use through the end of study follow-up. Nonuse was defined as no prescribed use of ADHD drugs on the day being classified or any preceding days. Former users and nonusers could become current users of ADHD drugs during follow-up, and when this occurred, their user person-time was classified as described above.</p> </div> <div class="subSection"> <h3 id="articleStudy End Points">Study End Points</h3> <p>The primary study end point was a serious cardiovascular event, which was defined as sudden cardiac death, myocardial infarction, or stroke. Sudden cardiac death was defined as a sudden, pulseless condition or collapse consistent with a ventricular tachyarrhythmia occurring in a community setting and including both fatal and resuscitated cardiac arrest (cases in which an arrest occurred in the community but the patient was successfully resuscitated).<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref12" rel="#refLayer">12-16</a></span> The diagnosis of acute myocardial infarction required hospitalization and met the international diagnostic criteria for myocardial infarction.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref17" rel="#refLayer">17-19</a></span> Stroke was defined as an acute neurologic deficit of sudden onset that persisted for more than 24 hours, corresponded to a vascular territory, and was not explained by other causes (e.g., trauma, infection, vasculitis, or profound systemic hypotension).<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref17" rel="#refLayer">17,20,21</a></span> </p> <p>Potential end points were identified from claims and vital records and adjudicated through review of all pertinent medical records, including hospitalizations, reports of emergency medical services, autopsies, and death certificates (Section 3 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). Criteria for potential cases were intentionally broad to increase sensitivity because we anticipated that study end points would be rare and planned to review medical records for all potential cases. All events were adjudicated by two cardiologists (for sudden cardiac death and acute myocardial infarction) or two neurologists (for stroke). These adjudicators reviewed cases from all sites and were unaware of exposure status (Section 4 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). Disagreements among adjudicators (<5% of cases) were resolved by consensus with the study principal investigator.</p> <p>Cases were excluded if the documentation suggested a cause other than a cardiovascular cause (e.g., motor-vehicle accident or drug overdose) or for sudden cardiac death, if clinically severe heart disease was present and sudden cardiac death was not unexpected (e.g., end-stage congestive heart failure). Congenital heart defects that had not been diagnosed until autopsy were noted but did not result in the exclusion of the potential case. In cases in which we were unable to obtain pertinent medical records or had insufficient information for adjudication (21% of cases), we determined the case status using a computer case definition, derived from cases with completed adjudication. The positive predictive value of the computerized case definition for serious cardiovascular events was 91% (Section 5 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>).</p> </div> <div class="subSection"> <h3 id="articleStudy Oversight">Study Oversight</h3> <p>The study was approved by the institutional review board at each of the participating institutions and by the Food and Drug Administration (FDA) Research in Human Subjects Committee. In addition, permission was obtained from the data sources for each site. In all cases the need for informed consent was waived. The study was planned by the authors. Data were gathered from each site and analyzed by the study biostatistician, who vouches for the data and the analysis along with the first author.</p> </div> <div class="subSection"> <h3 id="articleStatistical Analysis">Statistical Analysis</h3> <p>We calculated the hazard ratio for users of ADHD drugs, as compared with nonusers, using Cox regression models with robust sandwich variance estimators to account for the matched study design and for persons entering the cohort multiple times.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref22" rel="#refLayer">22</a></span> The hazard ratio was adjusted for both baseline characteristics and changes in characteristics that occurred during follow-up. We calculated the adjusted incidence of end points by multiplying the incidence rate in the nonusers by the hazard ratio.</p> <p>Because the number of covariates that reflected baseline cohort characteristics was large in comparison to the number of end points, we adjusted for these covariates by including a site-specific propensity score in the regression models. The propensity score was defined as the probability that the patient was currently receiving an ADHD drug on the first day of study follow-up, estimated for each site by means of logistic regression.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref23" rel="#refLayer">23</a></span> The baseline variables in the propensity score included sociodemographic characteristics as well as information on medical care encounters consistent with psychiatric disorders, asthma and other respiratory illnesses, seizure and other neurologic disorders, unintentional injuries, cardiovascular diseases, and other diseases. For each site, we tested the adequacy of the propensity-score models by calculating the propensity-score adjusted means of baseline variables for users and nonusers of ADHD drugs; these values were similar (Section 6 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>).</p> <p>In our primary analysis, we adjusted for study site, propensity-score decile, and several time-dependent covariates (medical and psychiatric conditions, health care utilization, age, and calendar year) (Section 7 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). In order to test key study assumptions, we performed additional analyses that were stratified according to age group (2 to 17 years and 18 to 24 years) and that used alternative exposure groups, cohort inclusion criteria, and end-point exclusions. We performed all statistical analyses using SAS software, version 9.1 (SAS Institute).</p> </div></div> <div class="section"></div> <div class="section"> <h3 id="articleResults">Results</h3> <div class="subSection"> <h3 id="articleStudy Population">Study Population</h3> <p>The study cohort included 1,200,438 children and young adults. The mean age of cohort members at baseline was 11.1 years (mean range at the study sites, 8.7 to 12.0) (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t01">Table 1</a><span class="table"><span class="figureTitle">Table 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t01"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_t1.gif"></a><span class="figureCaption">Study Cohorts, According to Site.</span></span>). The mean length of follow-up for the cohort was 2.1 years (mean range at the study sites, 1.5 to 3.9) for a total follow-up of 2,579,104 person-years. The characteristics of current users and nonusers at baseline are shown in <a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t02">Table 2</a><span class="table"><span class="figureTitle">Table 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t02"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_t2.gif"></a><span class="figureCaption">Characteristics of Cohort Members, According to the Use of ADHD Drugs at Baseline.</span></span>. Generally, current users had more evidence of health care utilization of all types. In addition, they had greater prevalence of psychiatric illnesses and greater use of psychotropic medications. Current users were also more likely to have asthma, seizures, and congenital heart defects. For both current users and nonusers, alcohol and drug use, as determined from records of medical care encounters, were uncommon.</p> </div> <div class="subSection"> <h3 id="articleStudy End Points">Study End Points</h3> <p>A total of 81 cohort members had a serious cardiovascular event, or 3.1 per 100,000 person-years, including 33 sudden cardiac deaths (1.3 per 100,000 person-years), 9 acute myocardial infarctions (0.3 per 100,000 person-years), and 39 strokes (1.5 per 100,000 person-years). Characteristics of the confirmed cases according to exposure to an ADHD drug are shown in Section 8 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>. In the multivariate model, an older age, current use of an antipsychotic drug, a major psychiatric illness, a serious cardiovascular condition, and chronic illness were associated with an increased risk of serious cardiovascular events (Section 7 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>).</p> <p>There were 7 confirmed events among 373,667 person-years of follow-up for current users, 25 confirmed events among 607,475 person-years of follow-up for former users, and 49 confirmed events among 1,597,962 person-years of follow-up for nonusers. As compared with the nonusers, the adjusted rate of serious cardiovascular events did not differ significantly among current users of ADHD drugs (hazard ratio, 0.75; 95% confidence interval [CI], 0.31 to 1.85) or among former users (hazard ratio, 1.03; 95% CI, 0.57 to 1.89) (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=f01">Figure 1</a><span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=f01"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_f1.gif"></a><span class="figureCaption">Adjusted Rates of Serious Cardiovascular Events, According to the Use of ADHD Drugs.</span></span>). When former users served as the reference group (in which the possible effect of unmeasured confounding was assessed), there was no increased risk of serious cardiovascular events among current users (hazard ratio, 0.70; 95% CI, 0.29 to 1.72) (Section 9 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). There was also no evidence of increased risk for the individual end points of sudden cardiac death, acute myocardial infarction, or stroke (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t03">Table 3</a><span class="table"><span class="figureTitle">Table 3</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t03"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_t3.gif"></a><span class="figureCaption">Adjusted Hazard Ratios for Individual Cardiovascular End Points, According to the Use of ADHD Drugs.</span></span>). We found no evidence of increased risk for methylphenidate (hazard ratio, 0.96; 95% CI, 0.31 to 2.97), the most frequently used ADHD drug (Section 10 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). Data were too sparse for other individual drugs to fit regression models.</p> </div> <div class="subSection"> <h3 id="articleAlternative Analyses">Alternative Analyses</h3> <p>We performed several alternative analyses to test the robustness of study findings (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t04">Table 4</a><span class="table"><span class="figureTitle">Table 4</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1110212&iid=t04"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1110212/aop/images/small/nejmoa1110212_t4.gif"></a><span class="figureCaption">Alternative Analyses with Adjusted Hazard Ratios for Serious Cardiovascular Events, According to the Use of ADHD Drugs.</span></span>, and Section 11 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). To assess for possible bias from the inclusion of persons who used ADHD drugs before the beginning of follow-up,<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref10" rel="#refLayer">10</a></span> we restricted current users of ADHD drugs only to new users (which was defined as no use of ADHD drugs during the 365 days preceding the first day of qualifying use). Findings were essentially identical to those of the primary analysis (hazard ratio, 0.73; 95% CI, 0.24 to 2.10). When we included seven patients who had been excluded from the primary analysis because they had evidence of severe underlying cardiac disease for which sudden cardiac death would not be unexpected, we found no increased risk for current users (hazard ratio, 0.71; 95% CI, 0.29 to 1.72). In analyses that included only children 2 to 17 years of age, we found no association between the use of ADHD drugs and serious cardiovascular events (hazard ratio, 0.98; 95% CI, 0.41 to 2.36). When children with evidence of serious psychiatric disease were excluded, we also found no significant association (hazard ratio, 0.66; 95% CI, 0.20 to 2.16).</p> <p>We also performed analyses to test other key study assumptions. A site-specific analysis suggested a potential difference between Medicaid and non-Medicaid sites, although numbers were very small and we saw no evidence of significant heterogeneity in pooled analyses of rate differences between users and nonusers (Section 12 in the <a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_appendix.pdf">Supplementary Appendix</a>). Another analysis expanded the definition of current use to include the 89 days after the end of current use to account for a possible misclassification in exposure related to the clinical use of ADHD drugs or for drugs that were discontinued after prodromal symptoms of an end point (e.g., headache preceding stroke). Finally, we performed an analysis in which time-dependent variables were fixed at baseline. The findings of these analyses were essentially identical to those reported here.</p> </div></div> <div class="section"></div> <div class="section"> <h3 id="articleDiscussion">Discussion</h3> <p>Several regulatory and policy decisions resulted from the review of adverse-event reports of serious cardiovascular events associated with the use of ADHD drugs in Canada and the United States. In Canada, Health Canada removed and then reinstated marketing of extended-release mixed amphetamine salts.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref6" rel="#refLayer">6,7</a></span> In the United States, three different FDA advisory committees considered the issue and recommended a black-box warning for stimulants, as well as a medication guide for patients.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref24" rel="#refLayer">24</a></span> In a controversial policy statement, the American Heart Association stated that obtaining electrocardiograms in children who were initiating ADHD stimulant therapy was "reasonable,"<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref25" rel="#refLayer">25</a></span> a recommendation that was subsequently revised on the basis of input from several pediatric organizations.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref24" rel="#refLayer">24</a></span> This led to concern and confusion among health care providers, patients, and families about the risks of these drugs.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref26" rel="#refLayer">26</a></span> In this context, we studied the cardiovascular safety of ADHD drugs in more than 1.2 million children and young adults from four geographically diverse health plans with more than 2.5 million person-years of follow-up. The point estimate of the relative risk provided no evidence that the use of ADHD drugs increased the risk of serious cardiovascular events, although the upper limit of the 95% confidence interval was consistent with up to a doubling in the risk.</p> <p>In the study population, which excluded children with possibly life-threatening illness, the incidence of serious cardiovascular events was 3.1 per 100,000 person-years, a finding that was consistent with other studies.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref27" rel="#refLayer">27-30</a></span> The low number of events limited the statistical power of the study, particularly for individual end points and individual drugs, as well as for subgroups that might be particularly vulnerable to the effects of ADHD drugs. We also had limited information for longer durations of use.</p> <p>Could the study findings be the result of confounding? The comparison between current users and nonusers at baseline indicated a greater incidence of medical and psychiatric coexisting conditions among current users. The analyses were adjusted for an extensive set of cardiovascular disease variables, which were included in site-specific propensity scores. Using this method, we could account for many important risk factors for cardiovascular disease. However, differences in factors that we were unable to measure, such as adherence to a drug regimen, differential prescribing of ADHD drugs to children at lower risk for a study outcome, or illicit use of medications resulting in misclassification, may have affected the results.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref31" rel="#refLayer">31,32</a></span> </p> <p>We performed several alternative analyses to test the robustness of our findings. We used former users as the reference group, which could address many of the issues related to comparability between current users and nonusers. We performed an analysis restricted to new users to address bias that would be introduced from the inclusion of prevalent users in the cohort.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref10" rel="#refLayer">10</a></span> Another analysis included patients who had been excluded from the primary analysis because of preexisting severe cardiac disease for which sudden cardiac death would not be unexpected. We also performed analyses stratified according to age. The findings from these additional analyses were essentially identical to our primary analysis.</p> <p>Our findings that the use of ADHD drugs was not associated with an increased risk of serious cardiovascular events in children and young adults are consistent with the results of several reports<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref33" rel="#refLayer">33-36</a></span> that have appeared since the FDA safety review of adverse-event data for ADHD drugs,<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref6" rel="#refLayer">6,7</a></span> although our results differed from the findings of another report.<span class="ref"><a class="showRefLayer" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&#ref37" rel="#refLayer">37</a></span> Our study included nearly twice the person-time of the combined person-time in four recent cohort studies and included several provisions to ensure accurate case ascertainment, including a review of medical records and autopsies.</p> <p>In conclusion, in our study involving children and young adults with 2.5 million person-years of follow-up, there were 3.1 serious cardiovascular events per 100,000 person-years. Although the point estimates of the relative risks for ADHD drugs did not indicate increased risk, the upper limit of the 95% confidence interval suggested that a doubling in the risk could not be ruled out. However, the absolute magnitude of any increased risk would be low.</p> </div> <div class="section"></div> <p>Supported by contracts (HHSA290-2005-0042, to Vanderbilt University; and HHSA290-2005-0033, to Harvard Pilgrim Health Care Institute) from the Agency for Healthcare Research and Quality, Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness program; and by contracts (223-2005-10100C, to Vanderbilt University; 223-2005-10012, to Kaiser Permanente Northern California; 223-2005-10006C, to OptumInsight Epidemiology; and 223-2005-10012C, to Harvard Pilgrim Health Care Institute) from the FDA.</p> <p><a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110212/suppl_file/nejmoa1110212_disclosures.pdf">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</p> <p>This article (10.1056/NEJMoa1110212) was published on November 1, 2011, at NEJM.org.</p> <p>We thank the TennCare Bureau, Tennessee Department of Health, Washington State Health and Recovery Services Administration, Kaiser Permanente California (Northern and Southern regions), and OptumInsight Epidemiology for providing data needed to conduct the study; Patricia A. Gideon, Michelle DeRanieri, Leanne Balmer, Shannon D. Stratton, James R. Daugherty, Judith A. Dudley, Lynne Caples, Tracy Crowley, Ning Chen, and Eli Poe of Vanderbilt University School of Medicine; Sherry Quinn, Eva Ng, and Clorinda Hoffman of OptumInsight Epidemiology; Connie Uratsu and Ninah Achacoso of Kaiser Permanente Northern California; Chantal Avila and Yan Luo of Kaiser Permanente Southern California; and Li Zheng of the University of Washington.</p> <div class="section"> <div class="sourceInfo"> <h3>Source Information</h3> <p>From the Divisions of General Pediatrics (W.O.C.), Adolescent Medicine (S.T.C.), and Pediatric Cardiology (F.A.F.), Department of Pediatrics; the Department of Biostatistics (P.G.A.); the Division of Pharmacoepidemiology, Department of Preventive Medicine (W.O.C., W.A.R.); the Divisions of Cardiology (K.T.M.), Rheumatology (C.M. Stein), and Clinical Pharmacology (K.T.M., C.M. Stein), Department of Medicine; and the Stroke Division, Department of Neurology (H.S.K., A.O.) — all at Vanderbilt University, Nashville; the Division of Research, Kaiser Permanente Northern California, Oakland (L.A.H., B.H.F.); the Department of Population Medicine, Harvard Pilgrim Health Care, Harvard Medical School, and the Department of Pediatrics, Boston University School of Medicine — all in Boston (C.M. Sox); OptumInsight Epidemiology, Waltham, MA (K.A.C.); Pharmacy Analytical Service (T.C.C.) and the Research and Evaluation Department (V.P.Q.), Kaiser Permanente Southern California, Pasadena; and the School of Public Health, University of Washington, Seattle (F.A.C.).</p> <p>Address reprint requests to Dr. Cooper at Suite 313, Oxford House, 1313 21st Ave. S., Nashville, TN 37232-4313, or at <a class="email" href="mailto:william.cooper@vanderbilt.edu">william.cooper@vanderbilt.edu</a>. </p> </div></div></dd> <dd style="DISPLAY: none" id="references"> <div class="section"> <h3>References</h3> <ol class="striped"><a name="ref1"></a> <li id="refItem1" class="odd"> <p class="number">1</p> <p class="content">Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children -- United States, 2003 and 2007. <span class="NLM_source">MMWR Morb Mortal Wkly Rep</span> 2010;59:1439-1443<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r001&dbid=8&doi=10.1056%2FNEJMoa1110212&key=21063274">Medline</a></p></li><a name="ref2"></a> <li id="refItem2" class="even"> <p class="number">2</p> <p class="content">Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. <span class="NLM_source">Pediatrics</span> 2005;115:e749-e757<br><a href="http://www.nejm.org/servlet/linkout?suffix=r002&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1542%2Fpeds.2004-2560">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r002&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000229504800076">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r002&dbid=8&doi=10.1056%2FNEJMoa1110212&key=15930203">Medline</a></p> </li><a name="ref3"></a> <li id="refItem3" class="odd"> <p class="number">3</p> <p class="content">Buck ML. Methylphenidate: new information and new options. Pediatric pharmacotherapy. Vol. 8. No. 2. Charlottesville: University of Virginia, February 2002:1-4.<br></p></li><a name="ref4"></a> <li id="refItem4" class="even"> <p class="number">4</p> <p class="content">Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. <span class="NLM_source">N Engl J Med</span> 1999;340:780-788<br><a href="http://www.nejm.org/servlet/linkout?suffix=r004&dbid=20&doi=10.1056%2FNEJMoa1110212&key=10.1056%2FNEJM199903113401007">Full Text</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r004&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000079034100007">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r004&dbid=8&doi=10.1056%2FNEJMoa1110212&key=10072414">Medline</a></p> </li><a name="ref5"></a> <li id="refItem5" class="odd"> <p class="number">5</p> <p class="content">Rappley MD. Attention deficit-hyperactivity disorder. <span class="NLM_source">N Engl J Med</span> 2005;352:165-173<br><a href="http://www.nejm.org/servlet/linkout?suffix=r005&dbid=20&doi=10.1056%2FNEJMoa1110212&key=10.1056%2FNEJMcp032387">Full Text</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r005&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000226251700009">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r005&dbid=8&doi=10.1056%2FNEJMoa1110212&key=15647579">Medline</a></p> </li><a name="ref6"></a> <li id="refItem6" class="even"> <p class="number">6</p> <p class="content">Food and Drug Administration. Drug Safety and Risk Management Advisory Committee Meeting, February 9 and 10, 2006 (<a class="extLink" href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202_00_TOC.htm">http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202_00_TOC.htm</a>).<br> </p></li><a name="ref7"></a> <li id="refItem7" class="odd"> <p class="number">7</p> <p class="content">Nissen SE. ADHD drugs and cardiovascular risk. <span class="NLM_source">N Engl J Med</span> 2006;354:1445-1448<br><a href="http://www.nejm.org/servlet/linkout?suffix=r007&dbid=20&doi=10.1056%2FNEJMoa1110212&key=10.1056%2FNEJMp068049">Full Text</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r007&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000236539000001">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r007&dbid=8&doi=10.1056%2FNEJMoa1110212&key=16549404">Medline</a></p> </li><a name="ref8"></a> <li id="refItem8" class="even"> <p class="number">8</p> <p class="content">Johnson RE, Vollmer WM. Comparing sources of drug data about the elderly. <span class="NLM_source">J Am Geriatr Soc</span> 1991;39:1079-1084<br><a href="http://www.nejm.org/servlet/linkout?suffix=r008&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1991GN72900004">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r008&dbid=8&doi=10.1056%2FNEJMoa1110212&key=1753045">Medline</a></p> </li><a name="ref9"></a> <li id="refItem9" class="odd"> <p class="number">9</p> <p class="content">Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. <span class="NLM_source">Am J Epidemiol</span> 1989;129:837-849<br><a href="http://www.nejm.org/servlet/linkout?suffix=r009&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1989T805200019">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r009&dbid=8&doi=10.1056%2FNEJMoa1110212&key=2646920">Medline</a></p> </li><a name="ref10"></a> <li id="refItem10" class="even"> <p class="number">10</p> <p class="content">Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. <span class="NLM_source">Am J Epidemiol</span> 2003;158:915-920<br><a href="http://www.nejm.org/servlet/linkout?suffix=r010&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1093%2Faje%2Fkwg231">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r010&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000186321900010">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r010&dbid=8&doi=10.1056%2FNEJMoa1110212&key=14585769">Medline</a></p> </li><a name="ref11"></a> <li id="refItem11" class="odd"> <p class="number">11</p> <p class="content">West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. <span class="NLM_source">Am J Epidemiol</span> 1995;142:1103-1112<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r011&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1995TE77700011">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r011&dbid=8&doi=10.1056%2FNEJMoa1110212&key=7485055">Medline</a></p> </li><a name="ref12"></a> <li id="refItem12" class="even"> <p class="number">12</p> <p class="content">Marcus FI, Cobb LA, Edwards JE, et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. <span class="NLM_source">Am J Cardiol</span> 1988;61:8-15<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r012&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2F0002-9149%2888%2991295-7">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r012&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1988M618700002">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r012&dbid=8&doi=10.1056%2FNEJMoa1110212&key=3337021">Medline</a></p> </li><a name="ref13"></a> <li id="refItem13" class="odd"> <p class="number">13</p> <p class="content">Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. <span class="NLM_source">Circulation</span> 1982;65:457-464<br><a href="http://www.nejm.org/servlet/linkout?suffix=r013&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1161%2F01.CIR.65.3.457">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r013&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1982NC40100008">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r013&dbid=8&doi=10.1056%2FNEJMoa1110212&key=7055867">Medline</a></p> </li><a name="ref14"></a> <li id="refItem14" class="even"> <p class="number">14</p> <p class="content">Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. <span class="NLM_source">N Engl J Med</span> 1994;330:1852-1857<br><a href="http://www.nejm.org/servlet/linkout?suffix=r014&dbid=20&doi=10.1056%2FNEJMoa1110212&key=10.1056%2FNEJM199406303302603">Full Text</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r014&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1994NT53000003">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r014&dbid=8&doi=10.1056%2FNEJMoa1110212&key=8196728">Medline</a></p> </li><a name="ref15"></a> <li id="refItem15" class="odd"> <p class="number">15</p> <p class="content">Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. <span class="NLM_source">JAMA</span> 1998;279:23-28<br><a href="http://www.nejm.org/servlet/linkout?suffix=r015&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1001%2Fjama.279.1.23">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r015&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000071295100030">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r015&dbid=8&doi=10.1056%2FNEJMoa1110212&key=9424039">Medline</a></p> </li><a name="ref16"></a> <li id="refItem16" class="even"> <p class="number">16</p> <p class="content">Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ Jr. Classification of death in antiarrhythmia trials. <span class="NLM_source">J Am Coll Cardiol</span> 1996;27:433-442<br><a href="http://www.nejm.org/servlet/linkout?suffix=r016&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2F0735-1097%2895%2900482-3">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r016&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1996TR89000027">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r016&dbid=8&doi=10.1056%2FNEJMoa1110212&key=8557917">Medline</a></p> </li><a name="ref17"></a> <li id="refItem17" class="odd"> <p class="number">17</p> <p class="content">Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. <span class="NLM_source">Am Heart J</span> 1984;108:150-158<br><a href="http://www.nejm.org/servlet/linkout?suffix=r017&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2F0002-8703%2884%2990558-1">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r017&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1984SZ53700023">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r017&dbid=8&doi=10.1056%2FNEJMoa1110212&key=6731265">Medline</a></p> </li><a name="ref18"></a> <li id="refItem18" class="even"> <p class="number">18</p> <p class="content">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). <span class="NLM_source">J Am Coll Cardiol</span> 2004;44:e1-e211<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r018&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2Fj.jacc.2004.07.014">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r018&dbid=8&doi=10.1056%2FNEJMoa1110212&key=15358047">Medline</a></p> </li><a name="ref19"></a> <li id="refItem19" class="odd"> <p class="number">19</p> <p class="content">Mahaffey KW, Roe MT, Kilaru R, et al. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. <span class="NLM_source">Am J Cardiol</span> 2005;95:1404-1408<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r019&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2Fj.amjcard.2005.02.005">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r019&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000229952900002">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r019&dbid=8&doi=10.1056%2FNEJMoa1110212&key=15950560">Medline</a></p> </li><a name="ref20"></a> <li id="refItem20" class="even"> <p class="number">20</p> <p class="content">Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. <span class="NLM_source">N Engl J Med</span> 2003;349:1019-1026<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r020&dbid=20&doi=10.1056%2FNEJMoa1110212&key=10.1056%2FNEJMoa022913">Full Text</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r020&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000185223100003">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r020&dbid=8&doi=10.1056%2FNEJMoa1110212&key=12968085">Medline</a></p> </li><a name="ref21"></a> <li id="refItem21" class="odd"> <p class="number">21</p> <p class="content">Liu L, Reeder B, Shuaib A, Mazagri R. Validity of stroke diagnosis on hospital discharge records in Saskatchewan, Canada: implications for stroke surveillance. <span class="NLM_source">Cerebrovasc Dis</span> 1999;9:224-230<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r021&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1159%2F000015960">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r021&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000081195400006">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r021&dbid=8&doi=10.1056%2FNEJMoa1110212&key=10393410">Medline</a></p> </li><a name="ref22"></a> <li id="refItem22" class="even"> <p class="number">22</p> <p class="content">Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. <span class="NLM_source">Ann Intern Med</span> 2010;152:337-345<br><a href="http://www.nejm.org/servlet/linkout?suffix=r022&dbid=8&doi=10.1056%2FNEJMoa1110212&key=20231564">Medline</a></p> </li><a name="ref23"></a> <li id="refItem23" class="odd"> <p class="number">23</p> <p class="content">Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. <span class="NLM_source">Biometrika</span> 1983;70:41-55<br><a href="http://www.nejm.org/servlet/linkout?suffix=r023&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1093%2Fbiomet%2F70.1.41">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r023&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1983QH66900005">Web of Science</a></p> </li><a name="ref24"></a> <li id="refItem24" class="even"> <p class="number">24</p> <p class="content">Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <span class="NLM_source">Pediatrics</span> 2008;122:451-453<br><a href="http://www.nejm.org/servlet/linkout?suffix=r024&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1542%2Fpeds.2008-1573">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r024&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000258142500029">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r024&dbid=8&doi=10.1056%2FNEJMoa1110212&key=18676566">Medline</a></p> </li><a name="ref25"></a> <li id="refItem25" class="odd"> <p class="number">25</p> <p class="content">Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <span class="NLM_source">Circulation</span> 2008;117:2407-2423[Erratum, Circulation 2009;120(7):e55-e59.]<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r025&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1161%2FCIRCULATIONAHA.107.189473">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r025&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000255589300014">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r025&dbid=8&doi=10.1056%2FNEJMoa1110212&key=18427125">Medline</a></p> </li><a name="ref26"></a> <li id="refItem26" class="even"> <p class="number">26</p> <p class="content">Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? <span class="NLM_source">Pediatrics</span> 2006;118:1215-1219<br><a href="http://www.nejm.org/servlet/linkout?suffix=r026&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1542%2Fpeds.2006-0942">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r026&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000240959100045">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r026&dbid=8&doi=10.1056%2FNEJMoa1110212&key=16951018">Medline</a></p> </li><a name="ref27"></a> <li id="refItem27" class="odd"> <p class="number">27</p> <p class="content">Liberthson RR. Sudden death from cardiac causes in children and young adults. <span class="NLM_source">N Engl J Med</span> 1996;334:1039-1044<br><a href="http://www.nejm.org/servlet/linkout?suffix=r027&dbid=20&doi=10.1056%2FNEJMoa1110212&key=10.1056%2FNEJM199604183341607">Full Text</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r027&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1996UE73300007">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r027&dbid=8&doi=10.1056%2FNEJMoa1110212&key=8598843">Medline</a></p> </li><a name="ref28"></a> <li id="refItem28" class="even"> <p class="number">28</p> <p class="content">Mahle WT, Campbell RM, Favaloro-Sabatier J. Myocardial infarction in adolescents. <span class="NLM_source">J Pediatr</span> 2007;151:150-154<br><a href="http://www.nejm.org/servlet/linkout?suffix=r028&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2Fj.jpeds.2007.02.045">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r028&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000248464200014">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r028&dbid=8&doi=10.1056%2FNEJMoa1110212&key=17643766">Medline</a></p> </li><a name="ref29"></a> <li id="refItem29" class="odd"> <p class="number">29</p> <p class="content">Schoenberg BS, Mellinger JF, Schoenberg DG. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. <span class="NLM_source">Neurology</span> 1978;28:763-768<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r029&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1978FL89700004">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r029&dbid=8&doi=10.1056%2FNEJMoa1110212&key=567292">Medline</a></p> </li><a name="ref30"></a> <li id="refItem30" class="even"> <p class="number">30</p> <p class="content">Broderick J, Talbot GT, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. <span class="NLM_source">J Child Neurol</span> 1993;8:250-255<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r030&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1177%2F088307389300800308">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r030&dbid=128&doi=10.1056%2FNEJMoa1110212&key=A1993LN49200008">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r030&dbid=8&doi=10.1056%2FNEJMoa1110212&key=8409267">Medline</a></p> </li><a name="ref31"></a> <li id="refItem31" class="odd"> <p class="number">31</p> <p class="content">Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. <span class="NLM_source">Lancet</span> 2005;366:2005-2011<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r031&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1016%2FS0140-6736%2805%2967760-4">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r031&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000233826900019">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r031&dbid=8&doi=10.1056%2FNEJMoa1110212&key=16338449">Medline</a></p> </li><a name="ref32"></a> <li id="refItem32" class="even"> <p class="number">32</p> <p class="content">Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. <span class="NLM_source">J Am Acad Child Adolesc Psychiatry</span> 2008;47:21-31<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r032&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1097%2Fchi.0b013e31815a56f1">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r032&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000251827300005">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r032&dbid=8&doi=10.1056%2FNEJMoa1110212&key=18174822">Medline</a></p> </li><a name="ref33"></a> <li id="refItem33" class="odd"> <p class="number">33</p> <p class="content">Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. <span class="NLM_source">Pediatrics</span> 2011;127:1102-1110<br><a href="http://www.nejm.org/servlet/linkout?suffix=r033&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1542%2Fpeds.2010-3371">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r033&dbid=8&doi=10.1056%2FNEJMoa1110212&key=21576311">Medline</a></p> </li><a name="ref34"></a> <li id="refItem34" class="even"> <p class="number">34</p> <p class="content">Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. <span class="NLM_source">Pediatrics</span> 2007;120:e1494-e1501<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r034&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1542%2Fpeds.2007-0675">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r034&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000251317200016">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r034&dbid=8&doi=10.1056%2FNEJMoa1110212&key=18055666">Medline</a></p> </li><a name="ref35"></a> <li id="refItem35" class="odd"> <p class="number">35</p> <p class="content">Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. <span class="NLM_source">Pediatrics</span> 2009;124:e75-e80<br><a href="http://www.nejm.org/servlet/linkout?suffix=r035&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1542%2Fpeds.2008-3138">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r035&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000267448100066">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r035&dbid=8&doi=10.1056%2FNEJMoa1110212&key=19564272">Medline</a></p> </li><a name="ref36"></a> <li id="refItem36" class="even"> <p class="number">36</p> <p class="content">McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. <span class="NLM_source">Drug Saf</span> 2009;32:1089-1096<br> <a href="http://www.nejm.org/servlet/linkout?suffix=r036&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.2165%2F11317630-000000000-00000">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r036&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000271600600008">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r036&dbid=8&doi=10.1056%2FNEJMoa1110212&key=19810780">Medline</a></p> </li><a name="ref37"></a> <li id="refItem37" class="lastChild odd"> <p class="number">37</p> <p class="content">Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. <span class="NLM_source">Am J Psychiatry</span> 2009;166:992-1001<br><a href="http://www.nejm.org/servlet/linkout?suffix=r037&dbid=16&doi=10.1056%2FNEJMoa1110212&key=10.1176%2Fappi.ajp.2009.09040472">CrossRef</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r037&dbid=128&doi=10.1056%2FNEJMoa1110212&key=000269483600010">Web of Science</a> | <a href="http://www.nejm.org/servlet/linkout?suffix=r037&dbid=8&doi=10.1056%2FNEJMoa1110212&key=19528194">Medline</a></p> </li></ol></div></dd> <dd style="DISPLAY: none" id="comments" class="lastChild"> <div class="section"> <div class="discussion"><a id="discussion"></a> <div style="BORDER-TOP: medium none" id="commentForm_40823981" class="commentForm"><a id="commentForm"></a> <h3>Sign In or Create an Account to Post a Comment</h3> <div id="signInForm" class="newContent"> <h2>Sign In </h2> <form class="layerForm " method="post" name="frmLogin" action="https://www.nejm.org/action/doLogin"><input id="redirectUri" value="/doi/full/10.1056/NEJMoa1110212?query=OF&#t=article" type="hidden" name="redirectUri"> <input id="loginUri" value="/doi/full/10.1056/NEJMoa1110212?query=OF&#t=article" type="hidden" name="loginUri"> <span class="moreLink athensLink"><a href="http://www.nejm.org/action/ssostart?redirectUri=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1110212%3Fquery%3DOF%26">Sign in Via Athens</a></span> <div id="formResponse"></div> <fieldset> <div class="formLine"><label for="login">Email Address</label> <input id="login" class="text" size="15" name="login"> </div> <div class="formLine"><label for="password">Password</label> <input id="password" class="text" type="password" name="password"> </div> <div class="formLine"><span class="leftButton"><input value="Search" src="/templates/jsp/_style2/_mms/_nejm/img/signInButton.gif" type="image"></span> </div> <div class="rightSection"> <div class="formLine"><input id="savePassword" class="checkbox" value="1" checked type="checkbox" name="savePassword"> <label class="checkbox" for="savePassword">Remember me</label> </div> <div class="formLine"><span class="moreLink"><a class="viewType-Layer viewClass-MediumLayer" href="http://www.nejm.org/action/requestResetPassword">Forgot password?</a> </span></div></div></fieldset></form></div> <div class="registrationInfo"> <h2>Create a FREE My NEJM account</h2> <ul> <li class="firstChild">Sign up for alerts and newsletters</li> <li>Save articles and searches for easy retrieval</li> <li class="lastChild">Comment on articles</li></ul><br><a id="cdfRegister" href="http://www.nejm.org/action/cdfProxy?action=registerOneStep&promo=ONFLNAR1&url=http://www.nejm.org/doi/full/10.1056/NEJMoa1110212?query=OF&"><img alt="Register" src="http://www.nejm.org/templates/jsp/_style2/_mms/_nejm/img/btnRegister.jpg"></a> </div> </div></div></div></dd></dl></div> <div id="rightRail"> <div id="toolsContainer"> <div id="toolsBox"> <h3>Tools</h3> <ul class="firstGroup"> <li class="downloadPDF firstChild"><a class="zone-tools-articlePdf" href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1110212">PDF </a></li> <li class="printPage"><a class="viewType-Print viewClass-Print event-zone-tools-articlePrint" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1110212">Print </a></li> <li class="downloadCitation"><a class="viewType-Layer viewClass-MediumLayer event-zone-tools-downloadCitation" href="http://www.nejm.org/action/showCitFormats?doi=10.1056%2FNEJMoa1110212">Download Citation </a></li> <li class="supplementaryMaterial lastChild"><a id="supplLink" class="viewType-Popup viewClass-Suppl event-viewClass-Suppl" href="http://www.nejm.org/action/showSupplements?doi=10.1056%2FNEJMoa1110212" rel="10.1056/NEJMoa1110212">Supplementary Material </a></li> </ul> <ul class="secondGroup"> <li class="emailPage firstChild"><a class="viewType-Layer viewClass-MediumLayer event-zone-tools-articleEmail" href="http://www.nejm.org/action/showMailPage?href=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1110212%3Fquery%3DOF%26&title=ADHD+Drugs+and+Serious+Cardiovascular+Events+in+Children+and+Young+Adults&doi=10.1056%2FNEJMoa1110212">E-Mail </a></li> <li class="savePage"><a id="savePage" class="viewType-Layer viewClass-MediumLayer event-zone-tools-articleSave" href="http://www.nejm.org/action/addTag?uactid=savePage&uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1110212%3Fquery%3DOF%26&doi=10.1056%2FNEJMoa1110212">Save </a></li> <li class="getAlert"><a id="getAlert" class="viewType-Layer viewClass-MediumLayer event-zone-tools-articleEmailAlert" href="http://www.nejm.org/action/addCitationAlert?context=add&uactid=getAlert&uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1110212%3Fquery%3DOF%26&doi=10.1056%2FNEJMoa1110212">Article Alert </a></li> <li class="reprints"><a class="zone-tools-reprintsPermissions" href="http://www.nejm.org/page/about-nejm/reprints-and-permissions">Reprints & Permissions</a></li> <li class="addThisIcon lastChild"><a class="addthis_button zone-tools-share-click" href="http://www.addthis.com/bookmark.php" target="_blank">Share/Bookmark</a></li></ul></div> <div style="DISPLAY: none" class="toolsAd"> <div class="bottomAd"> <div class="ad"> <div id="CM8ShowAd1320162080206" class="MicroTools CM8" title=""> <div style="DISPLAY: none" id="CM8_FORMAT_MicroTools"></div></div></div></div></div></div> <div id="related"> <div id="topics"> <h3>Topics</h3> <ul> <li class="firstChild"><a href="http://www.nejm.org/browse?subtopic=4_4">Adolescent Medicine</a></li> <li><a href="http://www.nejm.org/browse?subtopic=14_1">Cardiology General</a></li> <li><a href="http://www.nejm.org/browse?subtopic=1_1">Neurology/Neurosurgery General</a></li> <li><a href="http://www.nejm.org/browse?subtopic=10_1">Emergency Medicine General</a></li> <li class="lastChild"><a href="http://www.nejm.org/browse?subtopic=7_1">Psychiatry General</a></li></ul></div> <div id="moreIn"> <h3>More In</h3> <ul> <li class="firstChild lastChild"><a href="http://www.nejm.org/browse?category=research">Research</a></li></ul></div></div> <div style="DISPLAY: none" id="rightRailAd"> <div class="bannerAdTower"> <div class="rightTower"> <div id="CM8ShowAd1320162080206" class="MedRectangle CM8" title=""> <div style="DISPLAY: none" id="CM8_FORMAT_MedRectangle"></div></div></div></div></div> <div id="trendsBox"> <h3>Trends: Most Viewed <span>(Last Week)</span></h3> <ul> <li class="firstChild"> <p class="articleLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMp1112191">Prostate-Cancer Screening — What the U.S. Preventive Services Task Force Left Out</a> </p> <p class="articleDate"></p></li> <li> <p class="articleLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMcp1103642">Screening for Prostate Cancer</a> </p> <p class="articleDate"></p></li> <li class="lastChild"> <p class="articleLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMp1107075">The 2010 Dietary Guidelines — The Best Recipe for Health?</a> </p> <p class="articleDate">October 27, 2011</p></li></ul> <p class="moreTrends"><a href="http://www.nejm.org/journal-articles">More Trends</a></p> <div style="DISPLAY: none" class="bottomAd"> <div class="ad"> <div id="CM8ShowAd1320162080209" class="MicroTrends CM8" title=""> <div style="DISPLAY: none" id="CM8_FORMAT_MicroTrends"></div></div></div></div></div> <div class="emailAlert"><a href="http://www.nejm.org/action/clickThrough?id=1132&url=%2Faction%2FcdfProxy%3Faction%3Dcampaign%26promo%3D%26cpc%3DGMMODULELP%26alertType%3Dcustom%26alertCode%3Dnejm-toc%26backURI%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1110212%253Fquery%253DOF%2526&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1110212%3Fquery%3DOF%26&pubId=40823942"><img src="http://www.nejm.org/sda/1132/eTOC_signUp.gif"></a></div> <a href="http://www.nejm.org/action/clickThrough?id=2597&url=%2Foncology-hematology%3Fcm%3Dmarcomtr&loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1110212%3Fquery%3DOF%26&pubId=40823942"><img src="http://www.nejm.org/sda/2597/Editorial_ProstateCancerScreening_300x159.jpg"></a> </div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-40947237342071613932011-10-25T12:23:00.001-07:002011-10-25T12:23:12.713-07:00mi desorden favorito:TDAH - trastorno por déficit de atención/hiperactividad [Archivo adjunto 1] <div> <div> <div><span style="DISPLAY: block; MARGIN-BOTTOM: 20px; FONT-SIZE: 12px; FONT-WEIGHT: 700">[Más abajo se incluyen <a style="TEXT-DECORATION: none" href="https://mail.google.com/mail/?ui=2&view=bsp&ver=ohhl4rw8mbn4#1333c5185b344d15_TopText"><font color="#336633">archivos adjuntos</font></a> de =?iso-8859-1?Q?M=E1ximo_Cuadros?=]</span> <p> <div style="BACKGROUND-COLOR: #fff; FONT-FAMILY: arial, helvetica, sans-serif; COLOR: #000; FONT-SIZE: 18pt"><span></span><font size="4"><span style="FONT-WEIGHT: bold">Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents</span></font> <br> <div><font size="2">American Academy of Pediatrics</font><br><font size="2">10/2011</font><br><font color="#336633" size="3"><a href="http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654.full.pdf" target="_blank">http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654.full.pdf</a></font><br> <font size="1">y tambien va como adjunto</font><br></div> <div> <div> <div> <div class="MsoNormal"> <div> <div> <div> <div class="MsoNormal"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt">Atte.</span><span></span></div> <div class="MsoNormal"><font size="5"><span style="FONT-FAMILY: 'Brush Script MT'; FONT-SIZE: 18pt"><b>Dr.Máximo Cuadros Chávez</b></span></font></div> <div class="MsoNormal"><b><span style="FONT-FAMILY: 'Arial Rounded MT Bold'; COLOR: red; FONT-WEIGHT: normal"><font size="2">Celular 99199698<br>rpm #800515</font><br></span></b></div></div></div></div><span></span></div> <font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" size="1"><span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif" size="1"><span style="COLOR: rgb(0,0,255)"></span></font></div> </div></div> <div style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 18pt"> <div style="FONT-FAMILY: times new roman, new york, times, serif; FONT-SIZE: 12pt"><font size="2" face="Arial"> <hr size="1"> <b><span style="FONT-WEIGHT: bold">De:</span></b> Máximo Cuadros <<a href="mailto:maximocuadros@yahoo.es" target="_blank"><font color="#336633">maximocuadros@yahoo.es</font></a>><br><b><span style="FONT-WEIGHT: bold">Para:</span></b> <a href="mailto:interno_residente_medico_PERU@yahoogroups.com" target="_blank"><font color="#336633">interno_residente_medico_PERU@yahoogroups.com</font></a><br> <b><span style="FONT-WEIGHT: bold">Enviado:</span></b> miércoles 9 de marzo de 2011 14:47<br><b><span style="FONT-WEIGHT: bold">Asunto:</span></b> TDAH - trastorno por déficit de atención/hiperactividad<br></font><br> <div> <div> <div style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 12pt"> <div style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: #000000; FONT-SIZE: 14pt"> <table border="1" cellspacing="0" cellpadding="0" width="100%" align="center"> <tbody> <tr style="FONT-WEIGHT: bold"> <td width="100%"><font size="4"><span>Consenso del GEITDAH sobre el trastorno por déficit de atención/hiperactividad</span></font> </td></tr> <tr> <td width="70%"><span>Documento de Consenso</span> </td> <td width="30%" nowrap align="right"><span></span><br></td></tr> <tr> <td width="100%"><font size="2"><span>[REV NEUROL 2010;51:633-637] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21069642&itool=iconfft" rel="nofollow" target="_blank"><font color="#336633">PMID: 21069642</font></a> - Documento de Consenso - Fecha de publicación: 16/11/2010 </span></font></td> </tr></tbody></table><span><br><font size="3">El GEITDAH, Grupo de Especial Interés en el Trastorno por Déficit de Atención/Hiperactividad (TDAH), presenta en este artículo un consenso de expertos de toda España sobre el manejo del TDAH. Se han consensuado aspectos básicos que deberían ser el punto de partida para futuros consensos locales o regionales. Es también un objetivo de este consenso disminuir la variabilidad en la asistencia que se da en nuestro país al TDAH y servir de estímulo para fines docentes. Su reducida extensión permitirá una mayor difusión a fin de lograr todos estos fines de forma más efectiva. Las conclusiones del consenso se han articulado en torno a una introducción sobre aspectos básicos y recomendaciones para: diagnóstico, tratamiento (farmacológico y psicoterapéutico), flujo de pacientes y aspectos organizativos. </font></span> <div> <div> <div> <div> <div> <div> <div> <div><font size="2"><span><br>Por palabra clave</span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%20&dispmax=50" rel="nofollow" target="_blank"><font face="Arial"></font></a></span></font><span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=ADHD&dispmax=50" rel="nofollow" target="_blank"><font color="#336633" size="1" face="Arial">ADHD</font></a></span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Consensus&dispmax=50" rel="nofollow" target="_blank"><font color="#336633" size="1" face="Arial">Consensus</font></a></span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=GEITDAH&dispmax=50" rel="nofollow" target="_blank"><font color="#336633" size="1" face="Arial">GEITDAH</font></a></span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Guide&dispmax=50" rel="nofollow" target="_blank"><font color="#336633" size="1" face="Arial">Guide</font></a></span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"><br> <a href="http://www.neurologia.com/pdf/Web/5110/be100633.pdf" rel="nofollow" target="_blank"><font color="#336633">http://www.neurologia.com/pdf/Web/5110/be100633.pdf</font></a><br><br>Atte.</span><span></span></div> <div><font size="5"><span style="FONT-FAMILY: 'Brush Script MT'; FONT-SIZE: 18pt"><b>Dr.Máximo Cuadros Chávez</b></span></font></div> <div><b><span style="FONT-FAMILY: 'Arial Rounded MT Bold'; COLOR: red; FONT-WEIGHT: normal"><font size="2">Celular 99199698<br>rpm #800515</font><br></span></b></div></div></div></div><span></span></div><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" size="1"><span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif" size="1"><span style="COLOR: rgb(0,0,255)"></span></font></div> </div></div> <div><br></div></div></div><br></div></div><br><br></div></div></div> <p></p></p></div> <div style="MIN-HEIGHT: 0px; COLOR: #fff">__._,_.___</div><a name="1333c5185b344d15_TopText"> <p style="PADDING-BOTTOM: 3px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; CLEAR: both; PADDING-TOP: 0px"><span style="COLOR: #628c2a; FONT-SIZE: 13px; FONT-WEIGHT: 700">Archivos adjuntos de =?iso-8859-1?Q?M=E1ximo_Cuadros?=</span></p> </a> <p style="PADDING-BOTTOM: 0px; MARGIN: 0px 0px 2px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 10px"><span style="COLOR: #628c2a; FONT-WEIGHT: 700">Archivo 1 de 1 </span></p> <div> <div style="MARGIN: 2px 0px; WHITE-SPACE: nowrap; FLOAT: left; CLEAR: both"> <div><img style="VERTICAL-ALIGN: middle; MARGIN-RIGHT: 5px" src="http://l.yimg.com/kq/static/images/yg/img/doc/pdf16x16.gif"> <a style="TEXT-DECORATION: none" title="TDAH - American Academy of Pediatrics.pdf" href="http://xa.yimg.com/kq/groups/10856927/2020761681/name/TDAH%20-%20American%20Academy%20of%20Pediatrics.pdf" target="_blank"><font color="#336633">TDAH - American Academy of Pediatrics.pdf</font></a></div> </div></div><br><br></div></div> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Máximo Cuadros</b> <span dir="ltr"><<a href="mailto:maximocuadros@yahoo.es">maximocuadros@yahoo.es</a>></span><br> Fecha: 25 de octubre de 2011 13:21<br>Asunto: [SANFERNANDOPERU] Re: TDAH - trastorno por déficit de atención/hiperactividad [Archivo adjunto 1]<br>Para: "<a href="mailto:interno_residente_medico_PERU@yahoogroups.com">interno_residente_medico_PERU@yahoogroups.com</a>" <<a href="mailto:interno_residente_medico_PERU@yahoogroups.com">interno_residente_medico_PERU@yahoogroups.com</a>><br> <br><br><u></u> <div style="BACKGROUND-COLOR: #fff"><span> </span> <div> <div> <div><span style="DISPLAY: block; MARGIN-BOTTOM: 20px; FONT-SIZE: 12px; FONT-WEIGHT: 700">[Más abajo se incluyen <a style="TEXT-DECORATION: none" href="https://mail.google.com/mail/?ui=2&view=js&name=main,tlist&ver=VowXp-Acbuw.es.&am=!FPZIAwhQBq9lJX3a9RUeYsp2oYtFqeUcwE8JSjQoH01UpJ1C3p3SDXtcxaCDrdLI#1333c5185b344d15_TopText">archivos adjuntos</a> de =?iso-8859-1?Q?M=E1ximo_Cuadros?=]</span> <p> <div style="BACKGROUND-COLOR: #fff; FONT-FAMILY: arial, helvetica, sans-serif; COLOR: #000; FONT-SIZE: 18pt"><span></span><font size="4"><span style="FONT-WEIGHT: bold">Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents</span></font> <br> <div><font size="2">American Academy of Pediatrics</font><br><font size="2">10/2011</font><br><font size="3"><a href="http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654.full.pdf" target="_blank">http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654.full.pdf</a></font><br> <font size="1">y tambien va como adjunto</font><br></div> <div> <div> <div> <div class="MsoNormal"> <div> <div> <div> <div class="MsoNormal"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt">Atte.</span><span></span></div> <div class="MsoNormal"><font size="5"><span style="FONT-FAMILY: 'Brush Script MT'; FONT-SIZE: 18pt"><b>Dr.Máximo Cuadros Chávez</b></span></font></div> <div class="MsoNormal"><b><span style="FONT-FAMILY: 'Arial Rounded MT Bold'; COLOR: red; FONT-WEIGHT: normal"><font size="2">Celular 99199698<br>rpm #800515</font><br></span></b></div></div></div></div><span></span></div> <font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" size="1"><span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif" size="1"><span style="COLOR: rgb(0,0,255)"></span></font></div> </div></div> <div style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 18pt"> <div style="FONT-FAMILY: times new roman, new york, times, serif; FONT-SIZE: 12pt"><font size="2" face="Arial"> <hr size="1"> <b><span style="FONT-WEIGHT: bold">De:</span></b> Máximo Cuadros <<a href="mailto:maximocuadros@yahoo.es" target="_blank">maximocuadros@yahoo.es</a>><br><b><span style="FONT-WEIGHT: bold">Para:</span></b> <a href="mailto:interno_residente_medico_PERU@yahoogroups.com" target="_blank">interno_residente_medico_PERU@yahoogroups.com</a><br> <b><span style="FONT-WEIGHT: bold">Enviado:</span></b> miércoles 9 de marzo de 2011 14:47<br><b><span style="FONT-WEIGHT: bold">Asunto:</span></b> TDAH - trastorno por déficit de atención/hiperactividad<br></font><br> <div> <div> <div style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 12pt"> <div style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: #000000; FONT-SIZE: 14pt"> <table border="1" cellspacing="0" cellpadding="0" width="100%" align="center"> <tbody> <tr style="FONT-WEIGHT: bold"> <td width="100%"><font size="4"><span>Consenso del GEITDAH sobre el trastorno por déficit de atención/hiperactividad</span></font> </td></tr> <tr> <td width="70%"><span>Documento de Consenso</span> </td> <td width="30%" nowrap align="right"><span></span><br></td></tr> <tr> <td width="100%"><font size="2"><span>[REV NEUROL 2010;51:633-637] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21069642&itool=iconfft" rel="nofollow" target="_blank">PMID: 21069642</a> - Documento de Consenso - Fecha de publicación: 16/11/2010 </span></font></td> </tr></tbody></table><span><br><font size="3">El GEITDAH, Grupo de Especial Interés en el Trastorno por Déficit de Atención/Hiperactividad (TDAH), presenta en este artículo un consenso de expertos de toda España sobre el manejo del TDAH. Se han consensuado aspectos básicos que deberían ser el punto de partida para futuros consensos locales o regionales. Es también un objetivo de este consenso disminuir la variabilidad en la asistencia que se da en nuestro país al TDAH y servir de estímulo para fines docentes. Su reducida extensión permitirá una mayor difusión a fin de lograr todos estos fines de forma más efectiva. Las conclusiones del consenso se han articulado en torno a una introducción sobre aspectos básicos y recomendaciones para: diagnóstico, tratamiento (farmacológico y psicoterapéutico), flujo de pacientes y aspectos organizativos. </font></span> <div> <div> <div> <div> <div> <div> <div> <div><font size="2"><span><br>Por palabra clave</span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%20&dispmax=50" rel="nofollow" target="_blank"><font face="Arial"></font></a></span></font><span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=ADHD&dispmax=50" rel="nofollow" target="_blank"><font size="1" face="Arial">ADHD</font></a></span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Consensus&dispmax=50" rel="nofollow" target="_blank"><font size="1" face="Arial">Consensus</font></a></span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=GEITDAH&dispmax=50" rel="nofollow" target="_blank"><font size="1" face="Arial">GEITDAH</font></a></span> <span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Guide&dispmax=50" rel="nofollow" target="_blank"><font size="1" face="Arial">Guide</font></a></span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"><br> <a href="http://www.neurologia.com/pdf/Web/5110/be100633.pdf" rel="nofollow" target="_blank">http://www.neurologia.com/pdf/Web/5110/be100633.pdf</a><br><br>Atte.</span><span></span></div> <div><font size="5"><span style="FONT-FAMILY: 'Brush Script MT'; FONT-SIZE: 18pt"><b>Dr.Máximo Cuadros Chávez</b></span></font></div> <div><b><span style="FONT-FAMILY: 'Arial Rounded MT Bold'; COLOR: red; FONT-WEIGHT: normal"><font size="2">Celular 99199698<br>rpm #800515</font><br></span></b></div></div></div></div><span></span></div><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" size="1"><span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif" size="1"><span style="COLOR: rgb(0,0,255)"></span></font></div> </div></div> <div><br></div></div></div><br></div></div><br><br></div></div></div> <p></p></p></div> <div style="MIN-HEIGHT: 0px; COLOR: #fff">__._,_.___</div><a name="1333c5185b344d15_TopText"> <p style="PADDING-BOTTOM: 3px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; CLEAR: both; PADDING-TOP: 0px"><span style="COLOR: #628c2a; FONT-SIZE: 13px; FONT-WEIGHT: 700">Archivos adjuntos de =?iso-8859-1?Q?M=E1ximo_Cuadros?=</span></p> </a> <p style="PADDING-BOTTOM: 0px; MARGIN: 0px 0px 2px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 10px"><span style="COLOR: #628c2a; FONT-WEIGHT: 700">Archivo 1 de 1 </span></p> <div> <div style="MARGIN: 2px 0px; WHITE-SPACE: nowrap; FLOAT: left; CLEAR: both"> <div><img style="VERTICAL-ALIGN: middle; MARGIN-RIGHT: 5px" src="http://l.yimg.com/kq/static/images/yg/img/doc/pdf16x16.gif"> <a style="TEXT-DECORATION: none" title="TDAH - American Academy of Pediatrics.pdf" href="http://xa.yimg.com/kq/groups/10856927/2020761681/name/TDAH%20-%20American%20Academy%20of%20Pediatrics.pdf" target="_blank">TDAH - American Academy of Pediatrics.pdf</a></div> </div></div> <div style="WHITE-SPACE: nowrap; MARGIN-BOTTOM: 10px; COLOR: #666; CLEAR: both; PADDING-TOP: 15px"> </div></div></div></div></div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-61152198912216200312011-09-22T11:57:00.001-07:002011-09-22T11:57:51.059-07:00THANK YOUGreetings to you, <p>Please if for any reason you find this mail offensive you can ignore it and do accept my apology for any inconveniences this mail most have cost you to read, I don't want you to feel sorry for me, because I believe everyone will die someday my name is MR. ALI MALIK a United Arab Emirate and a merchant in Dubai, I have been diagnosed with esophageal cancer. It has defiled all forms of medical treatment and right now I have only about a few months to live according to medical experts. I have not particularly lived my life so well since my wife and 3 children died in a car accident, since then I never really cared for anyone (not even myself) but only my business.<br>Though I am very rich, I was never generous, I was always hostile to people and only focused on my business as that was the only thing I cared for. But now I regret all this as I now know that there is more to life than just wanting to have or make all the money in the world. I believe when God gives me a second chance to come to this world, I would live my life a different way from how I have lived it.<br>Now that God has called me, I have willed and given most of my property and assets to my immediate and extended family members as well as a few close friends. I want God to be merciful to me and accept my soul so I have decided to give also to charity organizations, as I want this to be one of the last good deeds I do on earth. So far, I have distributed money to some charity organizations in the U.A.E, Algeria and Malaysia, Thailand.<br>Now that my health has deteriorated so badly, I cannot do this myself anymore. I once asked members of my family to close one of my accounts and distribute the money which I have there to charity organizations in Asia and America; they refused and kept the money to themselves. Hence, I do not trust them anymore, as they seem not to be contended with what I have left for them. The last of my money which no one knows of is the huge cash deposit of USD$55 million dollars (Fifty five million united states dollars) that I have with a finance institution in Europe. I will want you to help me collect this deposit and dispatch it to charity organizations. I have set aside 10% for your time and effort.<p>Please reply me back if you are willing to assist me ON MY EMAIL: <a href="mailto:alimalik42@aim.com">alimalik42@aim.com</a><br> <br>God bless you.<p>MR.ALI MALIKClaudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-20969627821832196082011-09-18T17:34:00.001-07:002011-09-18T17:34:33.829-07:00Guías colombianas para el manejo del acné: una...<p>Pedro Arellano posted in cibermedicos.<br>Pedro Arellano6:39am Sep 18 <br>Guías colombianas para el manejo del acné: una revisión basada en la<br>evidencia por el Grupo Colombiano de Estudio en Acné<br>Revista de la Asociación Colombiana de <a href="http://xn--dermatologawww-9lb.revistasocolderma.com">Dermatologíawww.revistasocolderma.com</a><br> El acné es una enfermedad inflamatoria crónica que afecta, principalmente, adolescentes y adultos jó</p> <p> </p> <p><br>View Post on Facebook · Edit Email Settings · Reply to this email to add a comment.<br><br></p> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Pedro Arellano</b> <span dir="ltr"><<a href="mailto:notification%2Byfo6tzj9@facebookmail.com">notification+yfo6tzj9@facebookmail.com</a>></span><br> Fecha: 18 de septiembre de 2011 06:39<br>Asunto: [cibermedicos] Guías colombianas para el manejo del acné: una...<br>Para: cibermedicos <<a href="mailto:internetymedicos@groups.facebook.com">internetymedicos@groups.facebook.com</a>><br> <br><br><u></u> <div style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" dir="ltr"> <table border="0" cellspacing="0" cellpadding="8" width="98%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif" bgcolor="#ffffff" width="100%"> <table border="0" cellspacing="0" cellpadding="0" width="500"> <tbody> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px" valign="top" colspan="2"> <table style="COLOR: #000000; FONT-SIZE: 11px" width="100%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif; COLOR: #000000; FONT-SIZE: 11px" valign="top" width="100%" align="left"> <div style="BORDER-BOTTOM: #e9e9e9 1px solid; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; COLOR: #666666; PADDING-TOP: 0px">Pedro Arellano <a style="COLOR: #3b5998; TEXT-DECORATION: underline" href="http://www.facebook.com/n/?groups%2Finternetymedicos%2F&id=229540683749066&mid=4dfd5b6G5ae37904G2be688eG96&bcode=2gi4uZtl&n_m=clagui57%40gmail.com" target="_blank">posted in cibermedicos</a>.</div> <div style="MARGIN-BOTTOM: 15px"> <table style="WIDTH: 100%; PADDING-TOP: 7px" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; WIDTH: 57px; PADDING-RIGHT: 5px; PADDING-TOP: 3px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=815664378&mid=4dfd5b6G5ae37904G2be688eG96&bcode=2gi4uZtl&n_m=clagui57%40gmail.com" target="_blank"><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 50px; WIDTH: 50px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" alt="Guías colombianas para el manejo del acné: una..." src="http://profile.ak.fbcdn.net/hprofile-ak-snc4/274934_815664378_321811874_q.jpg"></a></td> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif; PADDING-TOP: 5px" valign="top" align="left"> <table style="PADDING-BOTTOM: 5px; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif; COLOR: #000000; FONT-SIZE: 11px"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=815664378&mid=4dfd5b6G5ae37904G2be688eG96&bcode=2gi4uZtl&n_m=clagui57%40gmail.com" target="_blank">Pedro Arellano</a></td> <td style="TEXT-ALIGN: right; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif; COLOR: #999999; FONT-SIZE: 11px">6:39am Sep 18 </td></tr></tbody></table> <div style="PADDING-BOTTOM: 7px; WIDTH: 458px; WORD-WRAP: break-word; COLOR: #000000; FONT-SIZE: 11px">Guías colombianas para el manejo del acné: una revisión basada en la<br>evidencia por el Grupo Colombiano de Estudio en Acné</div> <div style="PADDING-BOTTOM: 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px"> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-RIGHT: 10px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/l/EAQDAHKm9AQAhOKNN4FKNNt4FQuOCAmA1vwfGSXk1e_Y83w/www.revistasocolderma.com/numeros/Junio%252011/revision.html" target="_blank"><img style="WIDTH: 90px" alt="" src="http://external.ak.fbcdn.net/safe_image.php?d=AQAClz8Qc4q4ayQC&w=90&h=90&url=http%3A%2F%2Fwww.revistasocolderma.com%2Fnumeros%2FJunio+11%2Fimag%2Fguias-de-acne.jpg" width="90"></a></td> <td valign="top"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/l/oAQDsBDVoAQAaM1cYTG_DcEplAtl159oGd5tS0-kozg1QAQ/www.revistasocolderma.com/numeros/Junio%252011/revision.html" target="_blank">Revista de la Asociación Colombiana de Dermatología</a><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/l/QAQCUqr5SAQD9DvyNfivscqCfq8OPl3yI4AUJu86LyeJRbA/www.revistasocolderma.com/numeros/Junio%252011/revision.html" target="_blank"> <table style="BORDER-COLLAPSE: collapse; MARGIN-BOTTOM: 10px" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: 'Lucida Grande', 'Lucida Sans', Tahoma, Verdana, Arial, sans-serif; COLOR: #333333; FONT-SIZE: 11px; BORDER-TOP: medium none; FONT-WEIGHT: bold; BORDER-RIGHT: medium none; PADDING-TOP: 0px"> www.revistasocolderma.com</td></tr></tbody></table></a><span>El acné es una enfermedad inflamatoria crónica que afecta, principalmente, adolescentes y adultos jó</span></td></tr></tbody></table></div></td></tr></tbody></table> </div></td></tr></tbody></table><span><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 1px; WIDTH: 1px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" src="http://www.facebook.com/email_open_log_pic.php?mid=4dfd5b6G5ae37904G2be688eG96"><u></u></span><br> </td></tr> <tr> <td style="PADDING-BOTTOM: 15px; LINE-HEIGHT: 18px; PADDING-LEFT: 10px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande',tahoma,verdana,arial,sans-serif; COLOR: #666666; FONT-SIZE: 12px; BORDER-TOP: #e9e9e9 1px solid; PADDING-TOP: 10px" colspan="2"> <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?groups%2Finternetymedicos%2F&id=229540683749066&mid=4dfd5b6G5ae37904G2be688eG96&bcode=2gi4uZtl&n_m=clagui57%40gmail.com" target="_blank">View Post on Facebook</a> · <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?groups%2Finternetymedicos%2F&view=notifications&mid=4dfd5b6G5ae37904G2be688eG96&bcode=2gi4uZtl&n_m=clagui57%40gmail.com" target="_blank">Edit Email Settings</a> · Reply to this email to add a comment.<br> </td></tr></tbody></table></td></tr></tbody></table></div></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-35732781966123446002011-09-01T13:59:00.001-07:002011-09-01T13:59:35.114-07:00Devolucion de DineroHola <br>Es ((Nelson Yaya))<br>Pedir la devolución de mi dinero.<p><p><p><br>Quiero saludarte deseándote el mejor de los éxitos <br>En todos tus emprendimientos.<br>No te preocupes que no quiero ningún dinero<br> De vuelta, es solo para llamar tu atención.<p><p><p>Seré directo, necesito de tu apoyo ya que a raíz de la crisis <br>Tuve que declararme en quiebra de una pequeña empresa<br>Que tenia y desde entonces no he contado con el apoyo <br>Económico de ninguna entidad financiera, pues<br>Estoy reportado en las centrales de riesgo.<br>Mi blog leer mas.<br><a href="http://nestoryayagarzon.blogspot.com/2011/08/mi-nombre-es-nelson-yaya.html">http://nestoryayagarzon.blogspot.com/2011/08/mi-nombre-es-nelson-yaya.html</a><p><p><p>Decidí enviar 850 Emails para pedirles me apoyen con 2 dólares<br>Cada uno y si los multiplico por 850 contactos que me apoyen<br>Esto me dará unos 1.700 dólares con este presupuesto puedo <br>Comenzar de nuevo mi empresa, te estoy siendo totalmente sincero.<br>Si decides apoyarme con esos 2 dólares te mantendré al tanto<br> Con informes mensuales para que tu sepas en que he invertido<br> Tu donacion, si por el contrario no me quieres apoyar <br> Te agradezco el haber leído este email.<p><p><p>Para mayor información visita mi blog donde te contare <br>En que estaba invirtiendo antes de la crisis y de paso<br>Darte ideas de negocios que tú podrías copiar para tu<br>Propio beneficio.<br>Leer mas.<br><a href="http://nestoryayagarzon.blogspot.com/2011/08/mi-nombre-es-nelson-yaya.html">http://nestoryayagarzon.blogspot.com/2011/08/mi-nombre-es-nelson-yaya.html</a><p><p><p><p><br>Me despido agradeciéndote tu atención y te mando un <br>Fuerte abrazo.<p>Nelson Yaya G.<br>Mi país es Colombia<br>Mi ciudad es Bogotá<br><a href="http://nestoryayagarzon.blogspot.com/2011/08/mi-nombre-es-nelson-yaya.html">http://nestoryayagarzon.blogspot.com/2011/08/mi-nombre-es-nelson-yaya.html</a><p><p><br>If you wish to cancel your subscription, simply click once on the link below.<br><a href="http://www.poderdelmatrimonio.com/cgi-bin/arp3/arp3-un.pl?c=86696&p=1cc6bb">http://www.poderdelmatrimonio.com/cgi-bin/arp3/arp3-un.pl?c=86696&p=1cc6bb</a><p><p>Powered by AutoResponse Plus<br><a href="http://www.poderdelmatrimonio.com/cgi-bin/arp3/arp3-aff.pl">http://www.poderdelmatrimonio.com/cgi-bin/arp3/arp3-aff.pl</a>Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-43496821688267997942011-08-13T15:07:00.000-07:002011-08-13T15:08:12.132-07:00Nueva tarifa plana movil<DIV align=center> <TABLE style="BORDER-RIGHT: rgb(153,153,153) 1px solid; BORDER-TOP: rgb(153,153,153) 1px solid; BORDER-LEFT: rgb(153,153,153) 1px solid; BORDER-BOTTOM: rgb(153,153,153) 1px solid" cellSpacing=0 cellPadding=0 width=600 border=0> <TBODY> <TR> <TD> <TABLE cellSpacing=0 cellPadding=0 width=600 align=left border=0> <TBODY> <TR> <TD><A href="http://www.oxi55.com/c3.php?ec=2&l=hoKKqn2sdWhr&idlot=ZWRummKZ&type=ZA&email=lqCXy6XMZm5hkdemmcWno9GhypWcxpyiyaSXo6abyselYpnTnQ&url=m6iq1GqSYJqio9mTnMVgnNVj"><IMG style="DISPLAY: block" height=70 alt="Costalc Technologies logo" src="http://costalc.net/news/logo.png" width=360 border=0></A> </TD> <TD><A href="http://www.oxi55.com/c3.php?ec=2&l=hoKKqn2sdWhr&idlot=ZWRummKZ&type=ZA&email=lqCXy6XMZm5hkdemmcWno9GhypWcxpyiyaSXo6abyselYpnTnQ&url=m6iq1GqSYK6qp5OVn9WmmM6Xk5amkqOm08iqmqujkptiqJfWmcmSZKOcxqCRj5+m2J3RX5vXoKA"><IMG style="DISPLAY: block" height=70 alt="49,99 € al mes" src="http://costalc.net/news/haut.gif" width=240 border=0></A></TD></TR></TBODY></TABLE></TD></TR> <TR> <TD> <TABLE cellSpacing=0 cellPadding=0 width=600 align=left bgColor=#cc0000 border=0> <TBODY> <TR> <TD width=18><IMG style="DISPLAY: block" height=47 alt="" src="http://costalc.net/news/0511_r2_c1.gif" width=18 border=0></TD> <TD width=342 height=47><FONT style="FONT-SIZE: 25px" face="Arial, Helvetica,sans-serif" color=#ffffff><STRONG>Tarifa Plana móvil ilimitado</STRONG></FONT></TD> <TD width=240><A href="http://www.oxi55.com/c3.php?ec=2&l=hoKKqn2sdWhr&idlot=ZWRummKZ&type=ZA&email=lqCXy6XMZm5hkdemmcWno9GhypWcxpyiyaSXo6abyselYpnTnQ&url=m6iq1GqSYK6qp5OVn9WmmM6Xk5amkqOm08iqmqujkptiqJfWmcmSZKOcxqCRj5+m2J3RX5vXoKA"><IMG style="DISPLAY: block" height=47 alt="antes del 5 de septiembre de 201" src="http://costalc.net/news/bas.jpg" width=240 border=0></A></A></TD></TR></TBODY></TABLE></TD></TR> <TR> <TD> <TABLE cellSpacing=0 cellPadding=0 width=600 align=left bgColor=#cc0000 border=0> <TBODY> <TR> <TD><IMG style="DISPLAY: block" height=49 alt="" src="http://costalc.net/news/0511_r3_c1.gif" width=18 border=0></TD> <TD width=575 height=49><FONT style="FONT-SIZE: 20px" face="Arial, Helvetica,sans-serif" color=#ffffff><STRONG>Sin cambiar tu número de teléfono!</STRONG></FONT></TD> <TD><IMG style="DISPLAY: block" height=49 alt="" src="http://costalc.net/news/0511_r3_c5.gif" width=7 border=0></TD></TR></TBODY></TABLE></TD></TR> <TR> <TD> <TABLE cellSpacing=0 cellPadding=0 width=601 align=left border=0> <TBODY> <TR> <TD width=18><IMG style="DISPLAY: block" height=250 alt="" src="http://costalc.net/news/0511_r4_c1.gif" width=18 border=0></TD> <TD width=356 height=78><IMG height=192 src="http://costalc.net/news/tel.png" width="90%"></TD> <TD width=215> <P><FONT style="FONT-SIZE: 14px" face="Arial, Helvetica,sans-serif" color=#000000>Llamadas ilimitadas a teléfonos móviles y fijos de España <BR>+ 64 países.</FONT></P> <P><A href="http://www.oxi55.com/c3.php?ec=2&l=hoKKqn2sdWhr&idlot=ZWRummKZ&type=ZA&email=lqCXy6XMZm5hkdemmcWno9GhypWcxpyiyaSXo6abyselYpnTnQ&url=m6iq1GqSYK6qp5OVn9WmmM6Xk5amkqOm08iqmqujkptiqJfWmcmSZKOcxqCRj5+m2J3RX5vXoKA"><IMG height=73 src="http://costalc.net/news/offre2.png" width=215 border=0></A><BR><BR><FONT style="FONT-SIZE: 14px" face="Arial, Helvetica,sans-serif" color=#000000>Con tu número de siempre,<BR>sin portabilidad.</FONT></P></TD> <TD width=12><IMG height=250 src="http://costalc.net/news/sep.png" width=11></TD></TR></TBODY></TABLE></TD></TR> <TR> <TD height=160> <TABLE cellSpacing=0 cellPadding=0 width=600 align=left bgColor=#cc0000 border=0> <TBODY> <TR> <TD width=18><IMG style="DISPLAY: block" height=160 alt="" src="http://costalc.net/news/0511_r6_c1.gif" width=18 border=0></TD> <TD width=575 height=160> <TABLE cellSpacing=0 cellPadding=0 width=434 border=0> <TBODY> <TR> <TD align=left width=340 height=26><SPAN style="FONT-SIZE: 18px"><FONT style="FONT-SIZE: 20px" face="Arial, Helvetica,sans-serif" color=#ffffff><STRONG>Sin límites, las 24 horas del día <SPAN class=Style2>(3<SPAN class=Style3></SPAN>) </SPAN></STRONG></FONT></SPAN></TD></TR> <TR> <TD align=left height=26><FONT style="FONT-SIZE: 16px" face="Arial, Helvetica,sans-serif" color=#ffffff><STRONG>Tecnología VoIP de alta calidad</STRONG></FONT></TD></TR> <TR> <TD align=left height=26><FONT style="FONT-SIZE: 16px" face="Arial, Helvetica,sans-serif" color=#ffffff><STRONG>Sin compromiso de permanencia</STRONG></FONT></TD></TR> <TR> <TD align=left height=26><FONT style="FONT-SIZE: 16px" face="Arial, Helvetica, sans-serif" color=#ffffff><STRONG>Funciona en tu casa,oficina y tus desplazamientos <SPAN class=Style2>(2)</SPAN> </STRONG></FONT></TD></TR> <TR> <TD align=left height=26><FONT style="FONT-SIZE: 16px" face="Arial, Helvetica, sans-serif" color=#ffffff><STRONG>Nuestros operadores te contestan inmediatamente</STRONG></FONT></TD></TR></TBODY></TABLE></TD> <TD width=7><IMG style="DISPLAY: block" height=160 alt="" src="http://costalc.net/news/0511_r6_c5.gif" width=7 border=0></TD></TR></TBODY></TABLE></TD></TR> <TR> <TD><IMG style="DISPLAY: block" height=12 alt="" src="http://costalc.net/news/0511_r7_c1.gif" width=600 border=0></TD></TR> <TR> <TD> <TABLE cellSpacing=0 cellPadding=0 width=600 align=left border=0> <TBODY> <TR> <TD><IMG style="DISPLAY: block" height=215 alt="" src="http://costalc.net/news/0511_r8_c1.gif" width=6 border=0></TD> <TD width=594 height=210> <P align=left><FONT style="FONT-SIZE: 11px" face="Arial, Helvetica, sans-serif" color=#000000>(1) Si te das de alta antes del 5 de septiembre de 2011, beneficiaras gratuitamente de la opción SMS internacional.<BR><BR>(2) Compatible con todos los terminales de VoIP, Smartphones y Softphones.<BR><BR>(3) Llamadas gratis a móviles : ESPAÑA, VENEZUELA, ESTADOS UNIDOS, CANADÁ Y CHINA</FONT>.</P> <P align=left><FONT style="FONT-SIZE: 11px" face="Arial, Helvetica, sans-serif" color=#000000>Llamadas gratis a fijos (excepto números especiales) : <BR>Alemania, Andorra, Argentina, Australia, Austria, Bahrein, Bélgica, Brasil, Brunei, Canadá, Chile, China, Chipre, Colombia, Corea del Sur,Costa Rica, Croacia, Dinamarca, Eslovaquia, España, Estados Unidos, Estonia, Finlandia, Francia, Georgia, Grecia, Guadalupe, Guam, Hong-Kong, Hungría, India, Irlanda, Islandia, Israel, Italia, Japón, Letonia, Lituania, Luxemburgo, Malasia, Malta, Martinica, Noruega, nueva Zelanda, Países Bajos, Panamá, Paraguay, Perú, Polonia, Portugal, Puerto Rico, Reino Unido, República Checa, República Dominicana, Rumania, Rusia, Singapur, Suecia, Suiza, Tailandia, Taiwan, Turquía, Uruguay, Venezuela, Vietnam.</FONT></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE> <TABLE cellSpacing=0 cellPadding=0 width=600 align=center border=0> <TBODY> <TR> <TD style="FONT-SIZE: 10px; COLOR: rgb(51,51,51); FONT-FAMILY: Arial,Helvetica,sans-serif" align=middle width=600 height=59>En cumplimiento de la Ley 34/2002, de 11 de julio, de Servicios de la Sociedad de la Información y de Comercio Electrónico, le informamos que su email ha sido incluido en las listas de correo de las cuales Costalc Technologie es responsable.<BR>Si no desea recibir más comunicaciones de Costalc Technologie, haga <A href="http://www.oxi55.com/d3.php?ec=2&l=hoKKqn2sdWhr&e=lqCXy6XMZm5hkdemmcWno9GhypWcxpyiyaSXo6abyselYpnTnQ&idlot=ZWRummKZ" ds="2">clic aquí</A> para darse de baja.</TD></TR></TBODY></TABLE></DIV> <img border="0" width="1" height="1" src="http://www.oxi55.com/o3.php?ec=2&l=hoKKqn2sdWhr&idlot=ZWRummKZ&email=lqCXy6XMZm5hkdemmcWno9GhypWcxpyiyaSXo6abyselYpnTnQ">Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com1tag:blogger.com,1999:blog-3008889705230833536.post-91188735093801316342011-07-14T07:12:00.000-07:002011-07-14T07:13:02.271-07:00] Consenso de Infección Urinaria. Pautas de...<p> Rengifo posted in cibermedicos.Joel Rivera Rengifo12:15am Jul 14 </p> <p>Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento<br>Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento - Dialnet<br><a href="http://dialnet.unirioja.es">dialnet.unirioja.es</a></p> <p>Información del artículo Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento<br><br></p> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Joel Rivera Rengifo</b> <span dir="ltr"><<a href="mailto:notification%2Byfo6tzj9@facebookmail.com">notification+yfo6tzj9@facebookmail.com</a>></span><br> Fecha: 14 de julio de 2011 00:15<br>Asunto: [cibermedicos] Consenso de Infección Urinaria. Pautas de...<br>Para: cibermedicos <<a href="mailto:internetymedicos@groups.facebook.com">internetymedicos@groups.facebook.com</a>><br> <br><br><u></u> <div style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" dir="ltr"> <table border="0" cellspacing="0" cellpadding="8" width="98%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif" bgcolor="#ffffff" width="100%"> <table border="0" cellspacing="0" cellpadding="0" width="500"> <tbody> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px" valign="top" colspan="2"> <table style="COLOR: #000000; FONT-SIZE: 11px" width="100%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px" valign="top" width="100%" align="left"> <div style="BORDER-BOTTOM: #e9e9e9 1px solid; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; COLOR: #666666; PADDING-TOP: 0px">Joel Rivera Rengifo <a style="COLOR: #3b5998; TEXT-DECORATION: underline" href="http://www.facebook.com/n/?groups%2Finternetymedicos&id=203112289725239&mid=48878afG5ae37904G2987be8G96&bcode=gtp2jbl7&n_m=clagui57%40gmail.com" target="_blank">posted in cibermedicos</a>.</div> <div style="MARGIN-BOTTOM: 15px"> <table style="WIDTH: 100%; PADDING-TOP: 7px" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; WIDTH: 57px; PADDING-RIGHT: 5px; PADDING-TOP: 3px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=1164467726&mid=48878afG5ae37904G2987be8G96&bcode=gtp2jbl7&n_m=clagui57%40gmail.com" target="_blank"><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 50px; WIDTH: 50px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" alt="Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento" src="http://profile.ak.fbcdn.net/hprofile-ak-snc4/276168_1164467726_1050240_q.jpg"></a></td> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; PADDING-TOP: 5px" valign="top" align="left"> <table style="PADDING-BOTTOM: 5px; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=1164467726&mid=48878afG5ae37904G2987be8G96&bcode=gtp2jbl7&n_m=clagui57%40gmail.com" target="_blank">Joel Rivera Rengifo</a></td> <td style="TEXT-ALIGN: right; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #999999; FONT-SIZE: 11px">12:15am Jul 14 </td></tr></tbody></table> <div style="PADDING-BOTTOM: 7px; COLOR: #000000; FONT-SIZE: 11px">Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento</div> <div style="PADDING-BOTTOM: 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px"> <div style="BORDER-LEFT: #ccc 2px solid; PADDING-BOTTOM: 0px; MARGIN: 10px 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; COLOR: #808080; PADDING-TOP: 0px"> <div><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/l/QAQCBqk8pAQAQ-4o5rMsulZLUsMqTbhc34IyYILn6RI3IJw/dialnet.unirioja.es/servlet/articulo?codigo=3673838" target="_blank">Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento - Dialnet</a></div> <div><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/l/_AQAw3-7YAQCHQOoyVE3a2cejatwV1j5ROZs91F-eM3cxPw/dialnet.unirioja.es/servlet/articulo?codigo=3673838" target="_blank"> <table style="BORDER-COLLAPSE: collapse; MARGIN-BOTTOM: 10px" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: 'Lucida Grande', 'Lucida Sans', Tahoma, Verdana, Arial, sans-serif; COLOR: #333333; FONT-SIZE: 11px; BORDER-TOP: medium none; FONT-WEIGHT: bold; BORDER-RIGHT: medium none; PADDING-TOP: 0px"> dialnet.unirioja.es</td></tr></tbody></table></a></div> <div><span>Información del artículo Consenso de Infección Urinaria. Pautas de Diagnóstico y Tratamiento</span></div></div></div></td></tr></tbody></table></div></td></tr></tbody></table><br></td></tr> <tr> <td style="PADDING-BOTTOM: 15px; LINE-HEIGHT: 18px; PADDING-LEFT: 10px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #666666; FONT-SIZE: 12px; BORDER-TOP: #e9e9e9 1px solid; PADDING-TOP: 10px" colspan="2"> <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?groups%2Finternetymedicos&id=203112289725239&mid=48878afG5ae37904G2987be8G96&bcode=gtp2jbl7&n_m=clagui57%40gmail.com" target="_blank">View Post on Facebook</a> · <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?groups%2Finternetymedicos&view=notifications&mid=48878afG5ae37904G2987be8G96&bcode=gtp2jbl7&n_m=clagui57%40gmail.com" target="_blank">Edit Email Settings</a> · Reply to this email to add a comment.<br> </td></tr></tbody></table></td></tr></tbody></table></div></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-30338950702346113092011-07-10T08:41:00.001-07:002011-07-10T08:41:35.288-07:00Clinical Practice Guidelines<p>Maximo Cuadros Chavez posted in cibermedicos.Maximo Cuadros Chavez4:04am Jul 9 </p> <p>Clinical Practice Guidelines<br>About Clinical Practice Guidelines<br>Current Guidelines and Reports<br>Asthma, Expert Panel Report 3<br>ATP III Cholesterol<br>JNC 7 Hypertension<br>von Willebrand Disease<br>More...</p> <p>Guidelines in Development<br>Cardiovascular Disease Risk Reduction in Adults<br>ATP IV Cholesterol Guidelines Update<br>JNC 8 Hypertension Guidelines Update<br>Obesity Guidelines Update, Adults<br>Pediatric Cardiovascular Risk Reduction<br> Sickle Cell Disease Guidelines</p> <p>Guidelines Archive<br>Expert Panel and Review Groups<br>NHLBI: Clinical <a href="http://Guidelineswww.nhlbi.nih.gov">Guidelineswww.nhlbi.nih.gov</a><br>Contains NHLBI clinical guidelines for asthma, cholesterol and cholesterol screening, hypertension,<br> <br></p> <div class="gmail_quote">---------- Forwarded message ----------<br>From: <b class="gmail_sendername">Maximo Cuadros Chavez</b> <span dir="ltr"><<a href="mailto:notification%2Byfo6tzj9@facebookmail.com">notification+yfo6tzj9@facebookmail.com</a>></span><br> Date: 2011/7/9<br>Subject: [cibermedicos] Clinical Practice Guidelines<br>To: cibermedicos <<a href="mailto:internetymedicos@groups.facebook.com">internetymedicos@groups.facebook.com</a>><br><br><br><u></u> <div style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" dir="ltr"> <table border="0" cellspacing="0" cellpadding="8" width="98%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif" bgcolor="#ffffff" width="100%"> <table border="0" cellspacing="0" cellpadding="0" width="500"> <tbody> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px" valign="top" colspan="2"> <table style="COLOR: #000000; FONT-SIZE: 11px" width="100%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px" valign="top" width="100%" align="left"> <div style="BORDER-BOTTOM: #e9e9e9 1px solid; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; COLOR: #666666; PADDING-TOP: 0px">Maximo Cuadros Chavez <a style="COLOR: #3b5998; TEXT-DECORATION: underline" href="http://www.facebook.com/n/?groups%2Finternetymedicos&id=201185266584608&mid=48216c0G5ae37904G2962282G96&bcode=n5cmldzw&n_m=clagui57%40gmail.com" target="_blank">posted in cibermedicos</a>.</div> <div style="MARGIN-BOTTOM: 15px"> <table style="WIDTH: 100%; PADDING-TOP: 7px" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; WIDTH: 57px; PADDING-RIGHT: 5px; PADDING-TOP: 3px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=48216c0G5ae37904G2962282G96&bcode=n5cmldzw&n_m=clagui57%40gmail.com" target="_blank"><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 50px; WIDTH: 50px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" alt="Clinical Practice Guidelines About Clinical Practice Guidelines Current Guidelines and Reports Asthma, Expert Panel Report 3 ATP III Cholesterol JNC 7 Hypertension von Willebrand Disease More... Guidelines in Development Cardiovascular Disease Risk Reduction in Adults ATP IV Cholesterol Guidelines Update JNC 8 Hypertension Guidelines Update Obesity Guidelines Update, Adults Pediatric Cardiovascular Risk Reduction Sickle Cell Disease Guidelines Guidelines Archive Expert Panel and Review Groups" src="http://profile.ak.fbcdn.net/hprofile-ak-snc4/27419_100001101314342_6017_q.jpg"></a></td> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; PADDING-TOP: 5px" valign="top" align="left"> <table style="PADDING-BOTTOM: 5px; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=48216c0G5ae37904G2962282G96&bcode=n5cmldzw&n_m=clagui57%40gmail.com" target="_blank">Maximo Cuadros Chavez</a></td> <td style="TEXT-ALIGN: right; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #999999; FONT-SIZE: 11px">4:04am Jul 9 </td></tr></tbody></table> <div style="PADDING-BOTTOM: 7px; COLOR: #000000; FONT-SIZE: 11px">Clinical Practice Guidelines<br>About Clinical Practice Guidelines<br>Current Guidelines and Reports<br>Asthma, Expert Panel Report 3<br>ATP III Cholesterol<br> JNC 7 Hypertension<br>von Willebrand Disease<br>More...<br><br>Guidelines in Development<br>Cardiovascular Disease Risk Reduction in Adults<br>ATP IV Cholesterol Guidelines Update<br>JNC 8 Hypertension Guidelines Update<br> Obesity Guidelines Update, Adults<br>Pediatric Cardiovascular Risk Reduction<br>Sickle Cell Disease Guidelines<br><br>Guidelines Archive<br>Expert Panel and Review Groups</div> <div style="PADDING-BOTTOM: 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px"> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-RIGHT: 10px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/l/fAQAaKB1uAQArZDrdWhpAnM9GbBkcaRhJSe-HBtK82wjMdQ/www.nhlbi.nih.gov/guidelines/index.htm" target="_blank"><img style="WIDTH: 90px" alt="" src="http://external.ak.fbcdn.net/safe_image.php?d=AQDyi-PKvO_aPF_s&w=90&h=90&url=https%3A%2F%2Fchat.nhlbihin.net%2F%2FSightMaxAgentInterface%2Fchat.smgif%3FaccountID%3D1%26siteID%3D6%26queueID%3D10" width="90"></a></td> <td valign="top"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/l/OAQCMubYYAQC0zt02_f9KXFx2rqmuoiTzNKVEZ2d8LhJZ-A/www.nhlbi.nih.gov/guidelines/index.htm" target="_blank">NHLBI: Clinical Guidelines</a><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/l/9AQAQheABAQBzUR5Pv39FSjfvlOpyy_vGG8JDXFExYoFpPA/www.nhlbi.nih.gov/guidelines/index.htm" target="_blank"> <table style="BORDER-COLLAPSE: collapse; MARGIN-BOTTOM: 10px" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: 'Lucida Grande', 'Lucida Sans', Tahoma, Verdana, Arial, sans-serif; COLOR: #333333; FONT-SIZE: 11px; BORDER-TOP: medium none; FONT-WEIGHT: bold; BORDER-RIGHT: medium none; PADDING-TOP: 0px"> www.nhlbi.nih.gov</td></tr></tbody></table></a><span>Contains NHLBI clinical guidelines for asthma, cholesterol and cholesterol screening, hypertension,</span></td></tr></tbody></table></div></td></tr></tbody></table></div> </td></tr></tbody></table><br></td></tr> <tr> <td style="PADDING-BOTTOM: 15px; LINE-HEIGHT: 18px; PADDING-LEFT: 10px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #666666; FONT-SIZE: 12px; BORDER-TOP: #e9e9e9 1px solid; PADDING-TOP: 10px" colspan="2"> <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?groups%2Finternetymedicos&id=201185266584608&mid=48216c0G5ae37904G2962282G96&bcode=n5cmldzw&n_m=clagui57%40gmail.com" target="_blank">View Post on Facebook</a> · <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?groups%2Finternetymedicos&view=notifications&mid=48216c0G5ae37904G2962282G96&bcode=n5cmldzw&n_m=clagui57%40gmail.com" target="_blank">Edit Email Settings</a> · Reply to this email to add a comment.<br> </td></tr></tbody></table></td></tr></tbody></table></div></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-22872365305998817332011-06-27T10:47:00.001-07:002011-06-27T10:47:53.426-07:00Feocromocitoma<p>Cuadros Chavez posted in cibermedicos.Maximo Cuadros Chavez10:07am Jun 26 </p> <p>Feocromocitoma<br><a href="http://www.facebook.com/l/338ffmF_D4jZcTuKUtQ1Hnnl8Eg/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13125936&pident_usuario=0&pident_revista=62&fichero=62v10n15a13125936pdf001.pdf&ty=147&accion=L&origen=medicine&web=www.medicineonline.es&lan=es">http://www.facebook.com/l/338ffmF_D4jZcTuKUtQ1Hnnl8Eg/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13125936&pident_usuario=0&pident_revista=62&fichero=62v10n15a13125936pdf001.pdf&ty=147&accion=L&origen=medicine&web=www.medicineonline.es&lan=es</a><br> Medicine. 2008;10:997-1005.</p> <p>PUNTOS CLAVE:<br>Concepto. El feocromocitoma es un tumor poco frecuente, pero su malignidad funcional y su 10% de malignidad histológica obligan a pensar en él. Debemos tener en cuenta que el 15-20% es de localización extraadrenal.</p> <p>Clínica. La clínica está marcada por la hipertensión arterial, frecuentemente paroxística, en la que puede haber graves complicaciones: infarto de miocardio, accidente vascular cerebral, etc. ¿ Es imprescindible establecer el tratamiento quirúrgico lo antes posible.</p> <p>Preparación preoperatoria. El paciente debe llegar a la cirugía con bloqueo alfa-adrenérgico. ¿ El anestesista debe conocer el manejo de estos tumores, tanto para la inducción de la anestesia como para solventar los problemas que surjan en el acto quirúrgico.</p> <p>Feocromocitoma: actualización diagnóstica y terapéutica<br><a href="http://www.facebook.com/l/338ffgVppqwxv9qOUEFcGQ-GJYw/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es">http://www.facebook.com/l/338ffgVppqwxv9qOUEFcGQ-GJYw/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es</a><br> Endocrinol Nutr. 2008;55:202-16.<br><a href="http://www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident">http://www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident</a>_<br> <a href="http://apps.elsevier.es">apps.elsevier.es</a><br><br></p> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Maximo Cuadros Chavez</b> <span dir="ltr"><<a href="mailto:notification%2Byfo6tzj9@facebookmail.com">notification+yfo6tzj9@facebookmail.com</a>></span><br> Fecha: 26 de junio de 2011 10:07<br>Asunto: [cibermedicos] Feocromocitoma<br>Para: cibermedicos <<a href="mailto:internetymedicos@groups.facebook.com">internetymedicos@groups.facebook.com</a>><br><br><br><u></u> <div style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" dir="ltr"> <table border="0" cellspacing="0" cellpadding="8" width="98%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif" bgcolor="#ffffff" width="100%"> <table border="0" cellspacing="0" cellpadding="0" width="500"> <tbody> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px" valign="top" colspan="2"> <table style="COLOR: #000000; FONT-SIZE: 11px" width="100%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px" valign="top" width="100%" align="left"> <div style="BORDER-BOTTOM: #e9e9e9 1px solid; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; COLOR: #666666; PADDING-TOP: 0px">Maximo Cuadros Chavez <a style="COLOR: #3b5998; TEXT-DECORATION: underline" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&id=196803980356070&mid=4714864G5ae37904G28e445aG96&bcode=ML57y2s2&n_m=clagui57%40gmail.com" target="_blank">posted in cibermedicos</a>.</div> <div style="MARGIN-BOTTOM: 15px"> <table style="WIDTH: 100%; PADDING-TOP: 7px" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; WIDTH: 57px; PADDING-RIGHT: 5px; PADDING-TOP: 3px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=4714864G5ae37904G28e445aG96&bcode=ML57y2s2&n_m=clagui57%40gmail.com" target="_blank"><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 50px; WIDTH: 50px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" alt="Feocromocitoma http://www.facebook.com/l/338ffmF_D4jZcTuKUtQ1Hnnl8Eg/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13125936&pident_usuario=0&pident_revista=62&fichero=62v10n15a13125936pdf001.pdf&ty=147&accion=L&origen=medicine&web=www.medicineonline.es&lan=es Medicine. 2008;10:997-1005. PUNTOS CLAVE: Concepto. El feocromocitoma es un tumor poco frecuente, pero su malignidad funcional y su 10% de malignidad histológica obligan a pensar en él. Debemos tener en cuenta que el 15-20% es de localización extraadrenal. Clínica. La clínica está marcada por la hipertensión arterial, frecuentemente paroxística, en la que puede haber graves complicaciones: infarto de miocardio, accidente vascular cerebral, etc. ¿ Es imprescindible establecer el tratamiento quirúrgico lo antes posible. Preparación preoperatoria. El paciente debe llegar a la cirugía con bloqueo alfa-adrenérgico. ¿ El anestesista debe conocer el manejo de estos tumores, tanto para la inducción de la anestesia como para solventar los problemas que surjan en el acto quirúrgico. Feocromocitoma: actualización diagnóstica y terapéutica http://www.facebook.com/l/338ffgVppqwxv9qOUEFcGQ-GJYw/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es Endocrinol Nutr. 2008;55:202-16." src="http://profile.ak.fbcdn.net/hprofile-ak-snc4/27419_100001101314342_6017_q.jpg"></a></td> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; PADDING-TOP: 5px" valign="top" align="left"> <table style="PADDING-BOTTOM: 5px; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=4714864G5ae37904G28e445aG96&bcode=ML57y2s2&n_m=clagui57%40gmail.com" target="_blank">Maximo Cuadros Chavez</a></td> <td style="TEXT-ALIGN: right; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #999999; FONT-SIZE: 11px">10:07am Jun 26 </td></tr></tbody></table> <div style="PADDING-BOTTOM: 7px; COLOR: #000000; FONT-SIZE: 11px">Feocromocitoma<br><a href="http://www.facebook.com/l/338ffmF_D4jZcTuKUtQ1Hnnl8Eg/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13125936&pident_usuario=0&pident_revista=62&fichero=62v10n15a13125936pdf001.pdf&ty=147&accion=L&origen=medicine&web=www.medicineonline.es&lan=es" rel="nofollow" target="_blank">http://www.facebook.com/l/338ffmF_D4jZcTuKUtQ1Hnnl8Eg/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13125936&pident_usuario=0&pident_revista=62&fichero=62v10n15a13125936pdf001.pdf&ty=147&accion=L&origen=medicine&web=www.medicineonline.es&lan=es</a><br> Medicine. 2008;10:997-1005.<br><br>PUNTOS CLAVE:<br>Concepto. El feocromocitoma es un tumor poco frecuente, pero su malignidad funcional y su 10% de malignidad histológica obligan a pensar en él. Debemos tener en cuenta que el 15-20% es de localización extraadrenal.<br> <br>Clínica. La clínica está marcada por la hipertensión arterial, frecuentemente paroxística, en la que puede haber graves complicaciones: infarto de miocardio, accidente vascular cerebral, etc. ¿ Es imprescindible establecer el tratamiento quirúrgico lo antes posible.<br> <br>Preparación preoperatoria. El paciente debe llegar a la cirugía con bloqueo alfa-adrenérgico. ¿ El anestesista debe conocer el manejo de estos tumores, tanto para la inducción de la anestesia como para solventar los problemas que surjan en el acto quirúrgico.<br> <br>Feocromocitoma: actualización diagnóstica y terapéutica<br><a href="http://www.facebook.com/l/338ffgVppqwxv9qOUEFcGQ-GJYw/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es" rel="nofollow" target="_blank">http://www.facebook.com/l/338ffgVppqwxv9qOUEFcGQ-GJYw/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es</a><br> Endocrinol Nutr. 2008;55:202-16.</div> <div style="PADDING-BOTTOM: 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px"> <div style="BORDER-LEFT: #ccc 2px solid; PADDING-BOTTOM: 0px; MARGIN: 10px 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; COLOR: #808080; PADDING-TOP: 0px"> <div><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/l/338ffVZ1dpkelBUQfBQwpZZ5dZw/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es" target="_blank">http://www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_</a></div> <div><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/l/338ffwYyx9KDhBTtFnvaOqAByag/www.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13120617&pident_usuario=0&pident_revista=12&fichero=12v55n05a13120617pdf001.pdf&ty=129&accion=L&origen=medicine&web=www.medicineonline.es&lan=es" target="_blank"> <table style="BORDER-COLLAPSE: collapse; MARGIN-BOTTOM: 10px" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: 'Lucida Grande', 'Lucida Sans', Tahoma, Verdana, Arial, sans-serif; COLOR: #333333; FONT-SIZE: 11px; BORDER-TOP: medium none; FONT-WEIGHT: bold; BORDER-RIGHT: medium none; PADDING-TOP: 0px"> apps.elsevier.es</td></tr></tbody></table></a></div> <div></div></div></div></td></tr></tbody></table></div></td></tr></tbody></table><br></td></tr> <tr> <td style="PADDING-BOTTOM: 15px; LINE-HEIGHT: 18px; PADDING-LEFT: 10px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #666666; FONT-SIZE: 12px; BORDER-TOP: #e9e9e9 1px solid; PADDING-TOP: 10px" colspan="2"> <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&id=196803980356070&mid=4714864G5ae37904G28e445aG96&bcode=ML57y2s2&n_m=clagui57%40gmail.com" target="_blank">View Post on Facebook</a> · <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&view=notifications&mid=4714864G5ae37904G28e445aG96&bcode=ML57y2s2&n_m=clagui57%40gmail.com" target="_blank">Edit Email Settings</a> · Reply to this email to add a comment.<br> </td></tr></tbody></table></td></tr></tbody></table></div></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-90776516972608135052011-06-12T22:43:00.001-07:002011-06-12T22:43:06.816-07:00terapia antiretroviralClaudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-50947217158608380122011-06-12T18:37:00.001-07:002011-06-12T18:37:10.925-07:00mecanismos de resistencia a aspirina<a href="http://www.ncbi.nlm.nih.gov/pubmed/16371762">http://www.ncbi.nlm.nih.gov/pubmed/16371762</a> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-18124216595654376182011-06-09T21:19:00.001-07:002011-06-09T21:19:10.427-07:00FISIOPATOLOGIA DE LA MALARIA EN NIÑOS [Archivos adjuntos 2]<p>[Más abajo se incluyen archivos adjuntos de JESUS]<br> <br>Espero ayude en algo, Maestro.Saludos</p> <p> </p> <p>-- </p> <p> </p> <p><br>__._,_.___Archivos adjuntos de JESUS<br>Archivo 2 de 2 <br> 777.pdf Pathogenesis of malaria.pdf<br><br></p> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">JESUS</b> <span dir="ltr"><<a href="mailto:jesus.huayta@gmail.com">jesus.huayta@gmail.com</a>></span><br>Fecha: 9 de junio de 2011 23:02<br> Asunto: Re: [SALUD_LORETO] FISIOPATOLOGIA DE LA MALARIA EN NIÑOS [Archivos adjuntos 2]<br>Para: <a href="mailto:SALUD_LORETO@yahoogroups.com">SALUD_LORETO@yahoogroups.com</a><br><br><br> <div style="BACKGROUND-COLOR: #fff"><span> </span> <div> <div> <div><span style="DISPLAY: block; MARGIN-BOTTOM: 20px; FONT-SIZE: 12px; FONT-WEIGHT: 700">[Más abajo se incluyen <a style="TEXT-DECORATION: none" href="https://mail.google.com/mail/html/compose/static_files/blank_quirks.html#13077b702b128cd7_TopText">archivos adjuntos</a> de JESUS]</span> <p>Espero ayude en algo, Maestro.Saludos<br><br><br clear="all"><br>-- <br> <div style="TEXT-ALIGN: center"><img width="96" height="65"></div><br> <p></p></p></div> <div style="MIN-HEIGHT: 0px; COLOR: #fff">__._,_.___</div><a name="13077b702b128cd7_TopText"> <p style="PADDING-BOTTOM: 3px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; CLEAR: both; PADDING-TOP: 0px"><span style="COLOR: #628c2a; FONT-SIZE: 13px; FONT-WEIGHT: 700">Archivos adjuntos de JESUS</span></p></a> <p style="PADDING-BOTTOM: 0px; MARGIN: 0px 0px 2px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 10px"><span style="COLOR: #628c2a; FONT-WEIGHT: 700">Archivo 2 de 2 </span></p> <div> <div style="MARGIN: 2px 0px; WHITE-SPACE: nowrap; FLOAT: left; CLEAR: both"> <div><img style="VERTICAL-ALIGN: middle; MARGIN-RIGHT: 5px"> <a style="TEXT-DECORATION: none" title="777.pdf" href="http://xa.yimg.com/kq/groups/17358357/884441275/name/777.pdf" target="_blank">777.pdf</a></div></div> <div style="MARGIN: 2px 0px; WHITE-SPACE: nowrap; FLOAT: left; CLEAR: both"> <div><img style="VERTICAL-ALIGN: middle; MARGIN-RIGHT: 5px"> <a style="TEXT-DECORATION: none" title="Pathogenesis of malaria.pdf" href="http://xa.yimg.com/kq/groups/17358357/920140982/name/Pathogenesis%20of%20malaria.pdf" target="_blank">Pathogenesis of malaria.pdf</a></div> </div></div> <div style="WHITE-SPACE: nowrap; MARGIN-BOTTOM: 10px; COLOR: #666; CLEAR: both; PADDING-TOP: 15px"> </div></div></div></div></div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-14951607360487500182011-06-09T09:19:00.001-07:002011-06-09T09:19:07.041-07:00Chest Table of Contents for 1 June 2011; Vol. 139, No. 6<p>De: Sanofi (<a href="mailto:sanofi-aventis@virtualmedica.com">sanofi-aventis@virtualmedica.com</a>)</p> <p>Estimado Dr. Maximo Cuadros,En nombre de Sanofi-Aventis Latinoamérica les damos una cordial bienvenida a esta plataforma de educación médica. El propósito de este sitio es brindar información actualizada sobre temas de interés en diferentes áreas de la medicina.</p> <p>Esta plataforma contiene información científica en diferentes formatos, tales como resúmenes de artículos, cursos digitales y contenido de simposios o presentaciones médicas a cargo de expertos, entre otros.</p> <p>Simultaneamente, en forma mensual le haremos llegar un newsletter, que contendrá una selección de resumenes de mas de 20 artículos científicos publicados en renombradas revistas de actualidad médica, que Ud. podrá personalizar seleccionando,los temas de su interés para que solo, le enviemos las novedades concernientes a los mismos.</p> <p>Confiamos que el sitio resultará de interés para usted y que le servirá como apoyo para mantener actualizados sus conocimientos. Esperamos contar con su visita en forma frecuente!</p> <p>Acceda desde aquí a <a href="http://www.conocimientomedicoactual.com/">http://www.conocimientomedicoactual.com</a></p> <p>Maximo Cuadros</p> <p>Enviado desde mi BlackBerry de Movistar</p> <p>------------------------------------</p> <p>Para cancelar su suscripción a este grupo, envíe un mensaje de correo-e a:<br><a href="mailto:SANFERNANDOPERU-unsubscribe@yahoogroups.com">SANFERNANDOPERU-unsubscribe@yahoogroups.com</a></p> <p>Enlaces a Yahoo! Grupos</p> <p><*> Para visitar tu grupo en la web, ve a:<br> <a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/">http://es.groups.yahoo.com/group/SANFERNANDOPERU/</a></p> <p><*> La configuración de tu correo:<br> Mensajes individuales | Tradicional</p> <p><*> Para modificar la configuración desde la Web, visita:<br> <a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/join">http://es.groups.yahoo.com/group/SANFERNANDOPERU/join</a><br> (ID de Yahoo! obligatoria)</p> <p><*> Para modificar la configuración mediante el correo:<br> <a href="mailto:SANFERNANDOPERU-digest@yahoogroups.com">SANFERNANDOPERU-digest@yahoogroups.com</a><br> <a href="mailto:SANFERNANDOPERU-fullfeatured@yahoogroups.com">SANFERNANDOPERU-fullfeatured@yahoogroups.com</a></p> <p><*> Para cancelar tu suscripción en este grupo, envía<br> un mensaje en blanco a:<br> <a href="mailto:SANFERNANDOPERU-unsubscribe@yahoogroups.com">SANFERNANDOPERU-unsubscribe@yahoogroups.com</a></p> <p><*> El uso que hagas de Yahoo! Grupos está sujeto a<br> las Condiciones del servicio de Yahoo!:<br> <a href="http://es.docs.yahoo.com/info/utos.html">http://es.docs.yahoo.com/info/utos.html</a><br><br></p> <div class="gmail_quote">---------- Forwarded message ----------<br>From: <b class="gmail_sendername">Murillo Santucci Cesar de Assunção</b> <span dir="ltr"><<a href="mailto:murilloa@uol.com.br">murilloa@uol.com.br</a>></span><br> Date: 2011/6/7<br>Subject: [SALUD_LORETO] Chest Table of Contents for 1 June 2011; Vol. 139, No. 6<br>To: salud loreto <<a href="mailto:SALUD_LORETO@yahoogroups.com">SALUD_LORETO@yahoogroups.com</a>>, <a href="mailto:interno_residente_medico_PERU@yahoogroups.com">interno_residente_medico_PERU@yahoogroups.com</a><br> <br><br> <div style="BACKGROUND-COLOR: #fff"><span> </span> <div> <div> <div> <p> <div> <blockquote type="cite"> <div><span style="FONT-FAMILY: 'Helvetica'; FONT-SIZE: medium"><br></span></div><br> <div> <div> <blockquote type="cite"> <div><span style="FONT-FAMILY: 'Helvetica'; FONT-SIZE: medium">Segue com alguns textos deste mês!!</span></div></blockquote>Fiz upload pois os arquios são pesados total =9mB</div> <div>Link</div> <div><b><font size="6"><span style="FONT-SIZE: 24px"><a href="http://www.mediafire.com/?gzvbimn1ydqcjpi" target="_blank">http://www.mediafire.com/?gzvbimn1ydqcjpi</a><br></span></font></b><br> <blockquote type="cite"><br> <div><br>Learn about an ASTHMA TREATMENT OPTION you may not have considered for your<br>patients 12 and older. Find out more<br><br>Chest -- Table of Contents Alert<br><br>A new issue of Chest <br>has been made available:<br> <br><br>June 2011; Vol. 139, No. 6 <br><br>URL: <a href="http://chestjournal.chestpubs.org/content/vol139/issue6/?etoc" target="_blank">http://chestjournal.chestpubs.org/content/vol139/issue6/?etoc</a><br><br><br><br>-----------------------------------------------------------------<br> <br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Predicting Survival in Pulmonary Arterial Hypertension: Time to Combine <br>Markers<br>Marc Humbert, David Montani, and Rogerio Souza<br> Chest 2011;139 1263-1264<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1263?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1263?etoc</a><br><br><br>Retro Is the Rage!: Ventilation-Perfusion Scanning Is Alive and Well in the<br> Diagnosis of Pulmonary Embolism<br>Lisa K. Moores<br>Chest 2011;139 1264-1266<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1264?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1264?etoc</a><br> <br><br>Achieving Adherence to Positive Airway Pressure Therapy: Modifying Pressure<br>and the Holy Grail<br>Lee K. Brown<br>Chest 2011;139 1266-1268<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1266?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1266?etoc</a><br> <br><br>Second Opinion<br>Rob Rogers<br>Chest 2011;139 1269<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1269?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1269?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Point: Is Measuring Sputum Eosinophils Useful in the Management of Severe <br> Asthma? Yes<br>Frederick E. Hargreave and Parameswaran Nair<br>Chest 2011;139 1270-1272<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1270?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1270?etoc</a><br> <br><br>Counterpoint: Is Measuring Sputum Eosinophils Useful in the Management of <br>Severe Asthma? No, Not for the Vast Majority of Patients<br>Stephen P. Peters<br>Chest 2011;139 1273-1275<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1273?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1273?etoc</a><br> <br><br>Rebuttal From Drs Hargreave and Nair<br>Frederick E. Hargreave and Parameswaran Nair<br>Chest 2011;139 1275-1277<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1275?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1275?etoc</a><br> <br><br>Rebuttal From Dr Peters<br>Stephen P. Peters<br>Chest 2011;139 1277-1278<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1277?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1277?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Translational Behavioral Research in Respiratory Medicine<br> Bruce G. Bender, Mark S. Aloia, Allison E. Rankin, and Frederick S. <br>Wamboldt<br>Chest 2011;139 1279-1284<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1279?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1279?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Integration of Clinical and Hemodynamic Parameters in the Prediction of <br> Long-term Survival in Patients With Pulmonary Arterial Hypertension<br>Garvan C. Kane, Hilal Maradit-Kremers, Josh P. Slusser, Chris G. Scott, <br>Robert P. Frantz, and Michael D. McGoon<br>Chest 2011;139 1285-1293<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1285?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1285?etoc</a><br> <br><br>Noninvasive Diagnosis of Pulmonary Embolism<br>Pierre-Yves Salaun, Francis Couturaud, Alexandra Le Duc-Pennec, Karine <br>Lacut, Pierre-Yves Le Roux, Philippe Guillo, Pierre-Yves Pennec, <br>Jean-Christophe Cornily, Christophe Leroyer, and Gregoire Le Gal<br> Chest 2011;139 1294-1298<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1294?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1294?etoc</a><br><br><br>Right Ventricular Strain for Prediction of Survival in Patients With <br> Pulmonary Arterial Hypertension<br>Arun Sachdev, Hector R. Villarraga, Robert P. Frantz, Michael D. McGoon, <br>Ju-Feng Hsiao, Joseph F. Maalouf, Naser M. Ammash, Robert B. McCully, <br>Fletcher A. Miller, Patricia A. Pellikka, Jae K. Oh, and Garvan C. Kane<br> Chest 2011;139 1299-1309<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1299?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1299?etoc</a><br><br><br>Human {gamma}-Herpesviruses Epstein-Barr Virus and Human Herpesvirus-8 Are <br> Not Detected in the Lungs of Patients With Severe Pulmonary Arterial <br>Hypertension<br>Severine Valmary, Peter Dorfmuller, David Montani, Marc Humbert, Pierre <br>Brousset, and Bruno Degano<br>Chest 2011;139 1310-1316<br> <a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1310?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1310?etoc</a><br><br><br>Is the Campaign to Prevent VTE in Hospitalized Patients Working?<br> Paul D. Stein, Fadi Matta, and James E. Dalen<br>Chest 2011;139 1317-1321<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1317?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1317?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Flexible Pressure Delivery Modification of Continuous Positive Airway <br> Pressure for Obstructive Sleep Apnea Does Not Improve Compliance With <br>Therapy: Systematic Review and Meta-analysis<br>Jessie P. Bakker and Nathaniel S. Marshall<br>Chest 2011;139 1322-1330<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1322?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1322?etoc</a><br> <br><br>Influence of Oral and Craniofacial Dimensions on Mandibular Advancement <br>Splint Treatment Outcome in Patients With Obstructive Sleep Apnea<br>Whitney Mostafiz, Oyku Dalci, Kate Sutherland, Atul Malhotra, Vasanth <br> Srinivasan, M. Ali Darendeliler, and Peter A. Cistulli<br>Chest 2011;139 1331-1339<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1331?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1331?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Quality of Life, Pulmonary Function, and Tomographic Scan Abnormalities <br> After ARDS<br>Joan R. Masclans, Oriol Roca, Xavier Munoz, Esther Pallisa, Ferran Torres, <br>Jordi Rello, and Ferran Morell<br>Chest 2011;139 1340-1346<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1340?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1340?etoc</a><br> <br><br>Impact of Nonphysician Staffing on Outcomes in a Medical ICU<br>Hayley B. Gershengorn, Hannah Wunsch, Romina Wahab, David Leaf, Daniel <br>Brodie, Guohua Li, and Phillip Factor<br>Chest 2011;139 1347-1353<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1347?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1347?etoc</a><br> <br><br>Impact of Nonexacerbated COPD on Mortality in Critically Ill Patients<br>Alejandro Rodriguez, Thiago Lisboa, Jorge Sole-Violan, Federico Gomez, <br>Oriol Roca, Sandra Trefler, Joaquim Gea, Joan R. Masclans, and Jordi Rello<br> Chest 2011;139 1354-1360<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1354?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1354?etoc</a><br><br><br>Rapid Response Team in an Academic Institution: Does It Make a Difference?<br> Shiwan K. Shah, Victor J. Cardenas, Jr, Yong-Fang Kuo, and Gulshan Sharma<br>Chest 2011;139 1361-1367<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1361?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1361?etoc</a><br> <br><br>Neighborhood Poverty Rate and Mortality in Patients Receiving Critical Care<br>in the Academic Medical Center Setting<br>Sam Zager, Mallika L. Mendu, Domingo Chang, Heidi S. Bazick, Andrea B. <br>Braun, Fiona K. Gibbons, and Kenneth B. Christopher<br> Chest 2011;139 1368-1379<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1368?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1368?etoc</a><br><br><br>-----------------------------------------------------------------<br> <br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Persistent Airway Inflammation and Emphysema Progression on CT Scan in <br>Ex-Smokers Observed for 4 Years<br>Marina Miller, Jae Youn Cho, Alexa Pham, Paul J. Friedman, Joe Ramsdell, <br> and David H. Broide<br>Chest 2011;139 1380-1387<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1380?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1380?etoc</a><br> <br><br>Characterizing and Quantifying the Symptomatic Features of COPD <br>Exacerbations<br>Paul W. Jones, Wen-Hung Chen, Teresa K. Wilcox, Sanjay Sethi, Nancy Kline <br>Leidy for the EXACT-PRO Study Group<br>Chest 2011;139 1388-1394<br> <a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1388?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1388?etoc</a><br><br><br>-----------------------------------------------------------------<br> <br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Predictors of Airway Hyperresponsiveness Differ Between Old and Young <br>Patients With Asthma<br>Kate M. Hardaker, Sue R. Downie, Jessica A. Kermode, Claude S. Farah, <br> Nathan J. Brown, Norbert Berend, Gregory G. King, and Cheryl M. Salome<br>Chest 2011;139 1395-1401<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1395?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1395?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>An Evaluation of the CHADS2 Stroke Risk Score in Patients With Atrial <br> Fibrillation Who Undergo Percutaneous Coronary Revascularization<br>Juan M. Ruiz-Nodar, Francisco Marin, Sergio Manzano-Fernandez, Jose <br>Valencia-Martin, Jose A. Hurtado, Vanessa Roldan, Javier Pineda, Eduardo <br>Pinar, Francisco Sogorb, Mariano Valdes, and Gregory Y. H. Lip<br> Chest 2011;139 1402-1409<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1402?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1402?etoc</a><br><br><br>-----------------------------------------------------------------<br> <br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With <br>Community-Acquired Pneumonia or Exacerbation of Asthma or COPD<br> Mona Bafadhel, Tristan W. Clark, Carlene Reid, Marie-jo Medina, Sally <br>Batham, Michael R. Barer, Karl G. Nicholson, and Christopher E. Brightling<br>Chest 2011;139 1410-1418<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1410?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1410?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Rapid Pleurodesis for Malignant Pleural Effusions: A Pilot Study<br> Chakravarthy Reddy, Armin Ernst, Carla Lamb, and David Feller-Kopman<br>Chest 2011;139 1419-1423<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1419?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1419?etoc</a><br> <br><br>Improvements in the 6-Min Walk Test and Spirometry Following Thoracentesis <br>for Symptomatic Pleural Effusions<br>Ana Maria Cartaxo, Francisco S. Vargas, Joao Marcos Salge, Bianca F. <br>Marcondes, Eduardo H. Genofre, Leila Antonangelo, Evaldo Marchi, and Lisete<br> R. Teixeira<br>Chest 2011;139 1424-1429<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1424?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1424?etoc</a><br><br> <br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Early and Long-term Validation of an Algorithm Assessing Fitness for <br> Surgery in Patients With Postoperative FEV1 and Diffusing Capacity of the <br>Lung for Carbon Monoxide < 40%<br>Luis Puente-Maestu, Felipe Villar, Guillermo Gonzalez-Casurran, Nicolas <br>Moreno, Yolanda Martinez, Carlos Simon, Rafael Penalver, and Federico <br> Gonzalez-Aragoneses<br>Chest 2011;139 1430-1438<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1430?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1430?etoc</a><br> <br><br>Maximal Flow at Functional Residual Capacity in Healthy Children From Birth<br>to 7 Years, and Beyond<br>Daphna Vilozni, Lea Bentur, Simon Godfrey, Michael Barker, and Ephraim <br>Bar-Yishay<br>Chest 2011;139 1439-1444<br> <a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1439?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1439?etoc</a><br><br><br>-----------------------------------------------------------------<br> <br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Bronchoarterial Ratio on High-Resolution CT Scan of the Chest in Children <br>Without Pulmonary Pathology: Need to Redefine Bronchial Dilatation<br> Nitin Kapur, John P. Masel, Debbie Watson, Ian B. Masters, and Anne B. <br>Chang<br>Chest 2011;139 1445-1450<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1445?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1445?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Mediastinal Lymphadenopathy in Patients Undergoing Cardiac Transplant <br> Evaluation<br>Nicholas J. Pastis, Jr, Adrian B. Van Bakel, Timothy M. Brand, James G. <br>Ravenel, Gregory E. Gilbert, Gerard A. Silvestri, and Marc A. Judson<br>Chest 2011;139 1451-1457<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1451?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1451?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Severe Occupational Pneumoconiosis Among West Virginian Coal Miners: One <br> Hundred Thirty-eight Cases of Progressive Massive Fibrosis Compensated <br>Between 2000 and 2009<br>W. Alex Wade, Edward L. Petsonk, Byron Young, and Idrees Mogri<br>Chest 2011;139 1458-1462<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1458?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1458?etoc</a><br> <br><br>131I-Labeled Lipiodol-Induced Interstitial Pneumonia: A Series of 15 Cases<br>Stephane Jouneau, Elodie Vauleon, Sylvie Caulet-Maugendre, Elisabeth <br>Polard, Anne-Claire Volatron, Catherine Meunier, Pierre Tattevin, David <br> Montani, Etienne Garin, Jean-Luc Raoul, and Philippe Delaval<br>Chest 2011;139 1463-1469<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1463?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1463?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>p38 Mitogen-Activated Protein Kinase Pathways in Asthma and COPD<br> Kian Fan Chung<br>Chest 2011;139 1470-1479<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1470?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1470?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Cystic Fibrosis Transmembrane Conductance Regulator Intracellular <br> Processing, Trafficking, and Opportunities for Mutation-Specific Treatment<br>Mark P. Rogan, David A. Stoltz, and Douglas B. Hornick<br>Chest 2011;139 1480-1490<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1480?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1480?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>A Brief Historical and Theoretical Perspective on Patient Autonomy and <br> Medical Decision Making: Part II: The Autonomy Model<br>Jonathan F. Will<br>Chest 2011;139 1491-1497<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1491?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1491?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Pulmonary Rehabilitation: A Classic Tune With a New Beat, But Is Anyone <br> Listening?<br>Sam Birnbaum<br>Chest 2011;139 1498-1502<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1498?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1498?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Warfarin-Induced Pulmonary Metastatic Calcification and Calciphylaxis in a <br> Patient With End-stage Renal Disease<br>Juan C. Cadavid, Matthew L. DiVietro, Elio A. Torres, Peter Fumo, and Glenn<br>Eiger<br>Chest 2011;139 1503-1506<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1503?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1503?etoc</a><br> <br><br>Endovascular Embolization of the Complete Type of Anomalous Systemic <br>Arterial Supply to Normal Basal Lung Segments: A Report of Four Cases and <br>Literature Review<br>Sen Jiang, Jing-Yun Shi, Xiao-Hua Zhu, Chang Chen, Xi-Wen Sun, Dong Yu, and<br> Bing Jie<br>Chest 2011;139 1506-1513<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1506?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1506?etoc</a><br><br><br> -----------------------------------------------------------------<br><br><br> postgraduate education corner CONTEMPORARY REVIEWS IN SLEEP MEDICINE<br><br><br>-----------------------------------------------------------------<br> <br>Wrist Actigraphy<br>Jennifer L. Martin and Alex D. Hakim<br>Chest 2011;139 1514-1527<br><a href="http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1514?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/abstract/139/6/1514?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br> postgraduate education corner CHEST IMAGING AND PATHOLOGY FOR <br> CLINICIANS<br><br><br>-----------------------------------------------------------------<br> <br>A 70-Year-Old Man With Hypoglycemia, Clubbing of Fingers and Toes, and a <br>Large Mass of the Right Hemithorax<br>Zhi-Gang Sun, Zhou Wang, and Min Zhang<br>Chest 2011;139 1528-1531<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1528?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1528?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br> postgraduate education corner PULMONARY AND CRITICAL CARE PEARLS<br><br><br>-----------------------------------------------------------------<br> <br>A 47-Year-Old Woman With Progressive Dyspnea and Hypoxemia After Lung <br>Transplantation<br>Shambhu Aryal, Rayan Ihle, Don Hayes, Jr, and Ketan P. Buch<br>Chest 2011;139 1532-1535<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1532?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1532?etoc</a><br> <br><br>An 83-Year-Old Man With Bilateral Spontaneous Pneumothoraces and Multiple <br>Cysts<br>Shambhu Aryal, Chau Chu, and R. Scott Morehead<br>Chest 2011;139 1536-1539<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1536?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1536?etoc</a><br> <br><br>-----------------------------------------------------------------<br><br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Stenosis<br>John Olsen<br>Chest 2011;139 1540-1541<br> <a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1540?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1540?etoc</a><br><br><br>Measured Breaths<br>Marty Lynn Silverthorne<br> Chest 2011;139 1542<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1542?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1542?etoc</a><br><br><br>Swollen<br>Stella J. Padnos-Shea<br> Chest 2011;139 1542<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1542-a?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1542-a?etoc</a><br><br><br>How to Lumbar Puncture a Child<br> Leah Kaminsky<br>Chest 2011;139 1543<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1543?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1543?etoc</a><br><br><br>-----------------------------------------------------------------<br> <br><br><br><br><br><br>-----------------------------------------------------------------<br><br>Revisiting the Issue of VTE in the Setting of Chronic Liver Disease: An <br>Examination of National Surgical Quality Improvement Program Data<br> Jason Schwartz, Gabriela Vargas, Heather Thiesset, Greg Stoddard, Robin <br>Kim, John Sorensen, and Larry Kraiss<br>Chest 2011;139 1544-1545<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1544?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1544?etoc</a><br> <br><br>2009 Influenza A(H1N1) Infection and Associated Myocardial Dysfunction<br>Rashmi Ranjan Das<br>Chest 2011;139 1545-1546<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1545?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1545?etoc</a><br> <br><br>Femoral Venous Oxygen Saturation May Still Be a Valuable Tool<br>Issam El-Rassi and Alexander Yazigi<br>Chest 2011;139 1546-1547<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1546?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1546?etoc</a><br> <br><br>Response<br>Seth S. Martin, Caroline L. Hollingsworth, Stephanie G. Norfolk, Cameron R.<br>Wolfe, and John W. Hollingsworth<br>Chest 2011;139 1546<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1546-a?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1546-a?etoc</a><br> <br><br>Survival in Pulmonary Hypertension Registries: The Importance of Incident <br>Cases<br>Robin Condliffe, David G. Kiely, J. Gerry Coghlan, J. Simon R. Gibbs, S. <br>John Wort, Paul A. Corris, Andrew J. Peacock, Joanna Pepke-Zaba On behalf <br> of the Adult Pulmonary Hypertension Service of the United Kingdom<br>Chest 2011;139 1547-1548<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1547?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1547?etoc</a><br> <br><br>Response<br>Danielle L. Davison, Lakhmir S. Chawla, and Michael G. Seneff<br>Chest 2011;139 1547<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1547-a?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1547-a?etoc</a><br> <br><br>Response<br>Lorinda Chung, Juliana Liu, Lori S. Parsons, Paul M. Hassoun, Michael D. <br>McGoon, David B. Badesch, Dave P. Miller, Mark R. Nicolls, and Roham T. <br>Zamanian<br>Chest 2011;139 1548-1549<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1548?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1548?etoc</a><br> <br><br>Pulmonary Diseases: First Cause of Mortality in the World<br>Jose Luis Sandoval-Gutierrez, Edgar Sevilla Reyes, and Edgar Bautista <br>Bautista<br>Chest 2011;139 1550<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1550?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1550?etoc</a><br> <br><br>Response<br>Kalpalatha K. Guntupalli, David Gutterman, Suhail Raoof, and Paul A. <br>Markowski<br>Chest 2011;139 1550<br><a href="http://chestjournal.chestpubs.org/cgi/content/full/139/6/1550-a?etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/content/full/139/6/1550-a?etoc</a><br> <br><br><br>* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *<br><br>This message was sent to <a href="mailto:murilloa@sti.com.br" target="_blank">murilloa@sti.com.br</a>.<br>To unsubscribe from this service, go to <br> <a href="http://chestjournal.chestpubs.org/cgi/alerts/etoc?action=unsubscribe" target="_blank">http://chestjournal.chestpubs.org/cgi/alerts/etoc?action=unsubscribe</a><br>To edit your subscriptions for this service, go to <br> <a href="http://chestjournal.chestpubs.org/cgi/alerts/etoc" target="_blank">http://chestjournal.chestpubs.org/cgi/alerts/etoc</a><br><br>Or by mail:<br>Customer Service * 1454 Page Mill Road * Palo Alto, CA 94304 * U.S.A.<br> <br><br>_______________________________________________________________________<br>Copyright (c) 2011 by the American College of Chest Physicians.<br><br><br></div></blockquote></div><br> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-WEIGHT: normal; WORD-SPACING: 0px"><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-WEIGHT: normal; WORD-SPACING: 0px"><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-WEIGHT: normal; WORD-SPACING: 0px"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-WEIGHT: normal; WORD-SPACING: 0px"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-WEIGHT: normal; WORD-SPACING: 0px"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-SIZE: medium; FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-SIZE: medium; FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; FONT-SIZE: medium; FONT-WEIGHT: normal"> <div> <div>Murillo Santucci Cesar de Assunção</div> <div>Unidade de Terapia Intensiva adulto</div> <div>Disciplina de Anestesiologia, Dor e Terapia Intensiva</div> <div>Escola Paulista de Medicina</div> <div>Rua Napoleão de Barros,715</div> <div>Vila Clementino - São Paulo - CEP: 04024-002</div> <div>Tel/Fax: +55-11-55757768</div> <div>Tel/Fax: +55-11- 55764069</div> <div><a href="mailto:m.assuncao@unifesp.br" target="_blank">m.assuncao@unifesp.br</a></div> <div><a href="mailto:murilloassuncao@gmail.com" target="_blank">murilloassuncao@gmail.com</a></div><br><br></div></span></div></span></div></span></div></span></div></span></div></span></span></span></div><br></div></blockquote> </div><br> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-WEIGHT: normal"><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-WEIGHT: normal"><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: medium; FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: medium; FONT-WEIGHT: normal"> <div><span style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT-FAMILY: Cambria; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: medium; FONT-WEIGHT: normal"> <div> <div>Murillo Santucci Cesar de Assunção</div> <div>Unidade de Terapia Intensiva adulto</div> <div>Disciplina de Anestesiologia, Dor e Terapia Intensiva</div> <div>Escola Paulista de Medicina</div> <div>Rua Napoleão de Barros,715</div> <div>Vila Clementino - São Paulo - CEP: 04024-002</div> <div>Tel/Fax: +55-11-55757768</div> <div>Tel/Fax: +55-11- 55764069</div> <div><a href="mailto:m.assuncao@unifesp.br" target="_blank">m.assuncao@unifesp.br</a></div> <div><a href="mailto:murilloassuncao@gmail.com" target="_blank">murilloassuncao@gmail.com</a></div><br><br></div></span></div></span></div></span></div></span></div></span></div></span></span></span></div><br> <p></p></p></div> <div style="MIN-HEIGHT: 0px; COLOR: #fff">__._,_.___</div></div></div></div></div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-42485168688369937772011-06-09T09:17:00.001-07:002011-06-09T09:17:02.611-07:00] Sanofi-Aventis<p>De: Sanofi (<a href="mailto:sanofi-aventis@virtualmedica.com">sanofi-aventis@virtualmedica.com</a>)</p> <p>Estimado Dr. Maximo Cuadros,En nombre de Sanofi-Aventis Latinoamérica les damos una cordial bienvenida a esta plataforma de educación médica. El propósito de este sitio es brindar información actualizada sobre temas de interés en diferentes áreas de la medicina.</p> <p>Esta plataforma contiene información científica en diferentes formatos, tales como resúmenes de artículos, cursos digitales y contenido de simposios o presentaciones médicas a cargo de expertos, entre otros.</p> <p>Simultaneamente, en forma mensual le haremos llegar un newsletter, que contendrá una selección de resumenes de mas de 20 artículos científicos publicados en renombradas revistas de actualidad médica, que Ud. podrá personalizar seleccionando,los temas de su interés para que solo, le enviemos las novedades concernientes a los mismos.</p> <p>Confiamos que el sitio resultará de interés para usted y que le servirá como apoyo para mantener actualizados sus conocimientos. Esperamos contar con su visita en forma frecuente!</p> <p>Acceda desde aquí a <a href="http://www.conocimientomedicoactual.com/">http://www.conocimientomedicoactual.com</a></p> <p>Maximo Cuadros</p> <p>Enviado desde mi BlackBerry de Movistar</p> <p>------------------------------------</p> <p>Para cancelar su suscripción a este grupo, envíe un mensaje de correo-e a:<br><a href="mailto:SANFERNANDOPERU-unsubscribe@yahoogroups.com">SANFERNANDOPERU-unsubscribe@yahoogroups.com</a></p> <p>Enlaces a Yahoo! Grupos</p> <p><*> Para visitar tu grupo en la web, ve a:<br> <a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/">http://es.groups.yahoo.com/group/SANFERNANDOPERU/</a></p> <p><*> La configuración de tu correo:<br> Mensajes individuales | Tradicional</p> <p><*> Para modificar la configuración desde la Web, visita:<br> <a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/join">http://es.groups.yahoo.com/group/SANFERNANDOPERU/join</a><br> (ID de Yahoo! obligatoria)</p> <p><*> Para modificar la configuración mediante el correo:<br> <a href="mailto:SANFERNANDOPERU-digest@yahoogroups.com">SANFERNANDOPERU-digest@yahoogroups.com</a><br> <a href="mailto:SANFERNANDOPERU-fullfeatured@yahoogroups.com">SANFERNANDOPERU-fullfeatured@yahoogroups.com</a></p> <p><*> Para cancelar tu suscripción en este grupo, envía<br> un mensaje en blanco a:<br> <a href="mailto:SANFERNANDOPERU-unsubscribe@yahoogroups.com">SANFERNANDOPERU-unsubscribe@yahoogroups.com</a></p> <p><*> El uso que hagas de Yahoo! Grupos está sujeto a<br> las Condiciones del servicio de Yahoo!:<br> <a href="http://es.docs.yahoo.com/info/utos.html">http://es.docs.yahoo.com/info/utos.html</a><br><br></p> <div class="gmail_quote"><br><br>De: Sanofi (<a href="mailto:sanofi-aventis@virtualmedica.com">sanofi-aventis@virtualmedica.com</a>)<br><br>Estimado Dr. Maximo Cuadros,En nombre de Sanofi-Aventis Latinoamérica les damos una cordial bienvenida a esta plataforma de educación médica. El propósito de este sitio es brindar información actualizada sobre temas de interés en diferentes áreas de la medicina.<br> <br>Esta plataforma contiene información científica en diferentes formatos, tales como resúmenes de artículos, cursos digitales y contenido de simposios o presentaciones médicas a cargo de expertos, entre otros.<br><br>Simultaneamente, en forma mensual le haremos llegar un newsletter, que contendrá una selección de resumenes de mas de 20 artículos científicos publicados en renombradas revistas de actualidad médica, que Ud. podrá personalizar seleccionando,los temas de su interés para que solo, le enviemos las novedades concernientes a los mismos.<br> <br>Confiamos que el sitio resultará de interés para usted y que le servirá como apoyo para mantener actualizados sus conocimientos. Esperamos contar con su visita en forma frecuente!<br><br>Acceda desde aquí a <a href="http://www.conocimientomedicoactual.com/" target="_blank">http://www.conocimientomedicoactual.com</a><br> <br>Maximo Cuadros<br><br>Enviado desde mi BlackBerry de Movistar<br><br>------------------------------------<br><br>Para cancelar su suscripción a este grupo, envíe un mensaje de correo-e a:<br><a href="mailto:SANFERNANDOPERU-unsubscribe@yahoogroups.com">SANFERNANDOPERU-unsubscribe@yahoogroups.com</a><br> <br>Enlaces a Yahoo! Grupos<br><br><*> Para visitar tu grupo en la web, ve a:<br> <a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/" target="_blank">http://es.groups.yahoo.com/group/SANFERNANDOPERU/</a><br> <br><*> La configuración de tu correo:<br> Mensajes individuales | Tradicional<br><br><*> Para modificar la configuración desde la Web, visita:<br> <a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/join" target="_blank">http://es.groups.yahoo.com/group/SANFERNANDOPERU/join</a><br> (ID de Yahoo! obligatoria)<br><br><*> Para modificar la configuración mediante el correo:<br> <a href="mailto:SANFERNANDOPERU-digest@yahoogroups.com">SANFERNANDOPERU-digest@yahoogroups.com</a><br> <a href="mailto:SANFERNANDOPERU-fullfeatured@yahoogroups.com">SANFERNANDOPERU-fullfeatured@yahoogroups.com</a><br> <br><*> Para cancelar tu suscripción en este grupo, envía<br> un mensaje en blanco a:<br> <a href="mailto:SANFERNANDOPERU-unsubscribe@yahoogroups.com">SANFERNANDOPERU-unsubscribe@yahoogroups.com</a><br><br><*> El uso que hagas de Yahoo! Grupos está sujeto a<br> las Condiciones del servicio de Yahoo!:<br> <a href="http://es.docs.yahoo.com/info/utos.html" target="_blank">http://es.docs.yahoo.com/info/utos.html</a><br><br></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-42048258969135676152011-06-05T13:20:00.001-07:002011-06-05T13:20:03.470-07:00REMPLAZO DE VALVULA AORTICA CON CATETER<div><a href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103510">http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103510</a></div> <div> </div> <div> <p class="articleType">Original Article</p> <h1>Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients</h1> <p class="authors">Craig R. Smith, M.D., Martin B. Leon, M.D., Michael J. Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D., Raj R. Makkar, M.D., Mathew Williams, M.D., Todd Dewey, M.D., Samir Kapadia, M.D., Vasilis Babaliaros, M.D., Vinod H. Thourani, M.D., Paul Corso, M.D., Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D., Howard C. Herrmann, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D., and Stuart J. Pocock, Ph.D. for <span class="NLM_on-behalf-of">the PARTNER Trial Investigators</span></p> <p class="citationLine">June 5, 2011 (10.1056/NEJMoa1103510) </p> <p class="openUntilInfo"><img src="http://www.nejm.org/templates/jsp/_style2/_mms/_nejm/img/icon_comment.gif"> <a class="scrollDirectly" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103510?query=OF#discussion" name="discussion">Comments</a> open through June 15, 2011 </p> <dl class="articleTabs tabPanel lastChild"> <dt id="abstractTab" class="active abstract firstChild sideBySide">Abstract</dt> <dt id="articleTab" class="article sideBySide inactive">Article</dt> <dt id="referencesTab" class="references sideBySide inactive">References</dt> <dt id="commentsTab" class="sideBySide inactive">Comments </dt> <dd style="DISPLAY: block" id="abstract"> <div class="left section"> <div class="section"></div> <div class="section"> <h3 id="abstractBackground">Background</h3> <p>The use of transcatheter aortic-valve replacement has been shown to reduce mortality among high-risk patients with aortic stenosis who are not candidates for surgical replacement. However, the two procedures have not been compared in a randomized trial involving high-risk patients who are still candidates for surgical replacement.</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103510?query=OF#Background" rel="gotofulltext">Full Text of Background...</a></p></div> <div class="section"></div> <div class="section"> <h3 id="abstractMethods">Methods</h3> <p>At 25 centers, we randomly assigned 699 high-risk patients with severe aortic stenosis to undergo either transcatheter aortic-valve replacement with a balloon-expandable bovine pericardial valve (either a transfemoral or a transapical approach) or surgical replacement. The primary end point was death from any cause at 1 year. The primary hypothesis was that transcatheter replacement is not inferior to surgical replacement.</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103510?query=OF#Methods" rel="gotofulltext">Full Text of Methods...</a></p></div> <div class="section"></div> <div class="section"> <h3 id="abstractResults">Results</h3> <p>The rates of death from any cause were 3.4% in the transcatheter group and 6.5% in the surgical group at 30 days (P=0.07) and 24.2% and 26.8%, respectively, at 1 year (P=0.44), a reduction of 2.6 percentage points in the transcatheter group (upper limit of the 95% confidence interval, 3.0 percentage points; predefined margin, 7.5 percentage points; P=0.001 for noninferiority). The rates of major stroke were 3.8% in the transcatheter group and 2.1% in the surgical group at 30 days (P=0.20) and 5.1% and 2.4%, respectively, at 1 year (P=0.07). At 30 days, major vascular complications were significantly more frequent with transcatheter replacement (11.0% vs. 3.2%, P<0.001); adverse events that were more frequent after surgical replacement included major bleeding (9.3% vs. 19.5%, P<0.001) and new-onset atrial fibrillation (8.6% vs. 16.0%, P=0.006). More patients undergoing transcatheter replacement had an improvement in symptoms at 30 days, but by 1 year, there was not a significant between-group difference.</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103510?query=OF#Results" rel="gotofulltext">Full Text of Results...</a></p></div> <div class="section"></div> <div class="section"> <h3 id="abstractConclusions">Conclusions</h3> <p>In high-risk patients with severe aortic stenosis, transcatheter and surgical procedures for aortic-valve replacement were associated with similar rates of survival at 1 year, although there were important differences in periprocedural risks. (Funded by Edwards Lifesciences; Clinical Trials.gov number, <a class="ref" href="http://clinicaltrials.gov/show/NCT00530894" target="url">NCT00530894</a>.)</p> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103510?query=OF#Discussion" rel="gotofulltext">Full Text of Discussion...</a></p></div> <div class="section"></div> <p class="fullTextLink"><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103510?query=OF#Top" rel="gotofulltext">Read the Full Article...</a></p></div> <div class="right section"> <div class="articleMedia"> <h3 class="title">Media in This Article</h3> <div class="mediaRefs"> <div class="mediaRef"> <p class="mediaType">Video</p> <p class="preview"><a class="viewType-Layer viewClass-WideLayer event-articleThumbMedia" href="http://www.nejm.org/action/showMediaPlayer?doi=10.1056%2FNEJMoa1103510&aid=NEJMoa1103510_attach_1&area=aop"><img alt="Transcatheter Aortic-Valve Replacement." src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1103510/aop/images/nejmoa1103510_attach_1_smit_oa1103510thumb71x71.jpg"></a></p> <p>Transcatheter Aortic-Valve Replacement.</p></div> <div class="mediaRef"><span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMoa1103510&iid=f01"><img alt="" src="http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1103510/aop/images/small/nejmoa1103510_f1.gif"></a><span class="figureCaption">Transcatheter Aortic-Valve Replacement.</span></span></div> </div></div></div></dd></dl></div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-29444126764901500402011-06-02T12:39:00.001-07:002011-06-02T12:39:53.178-07:00mas sobre labetalol en crisis<a href="http://www.ncbi.nlm.nih.gov/pubmed/7093106">http://www.ncbi.nlm.nih.gov/pubmed/7093106</a><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-72039048746032602922011-06-02T12:26:00.001-07:002011-06-02T12:26:15.557-07:00Emergencias hipertensivas<a href="http://www.ncbi.nlm.nih.gov/pubmed/1417052">http://www.ncbi.nlm.nih.gov/pubmed/1417052</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/2686494">http://www.ncbi.nlm.nih.gov/pubmed/2686494</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/2826083">http://www.ncbi.nlm.nih.gov/pubmed/2826083</a><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-46778339720369472052011-06-02T12:22:00.001-07:002011-06-02T12:22:42.162-07:00articulos sobre labetalol<a href="http://www.ncbi.nlm.nih.gov/pubmed/18827911">http://www.ncbi.nlm.nih.gov/pubmed/18827911</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/18779419">http://www.ncbi.nlm.nih.gov/pubmed/18779419</a><br><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706703/pdf/nihms104083.pdf">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706703/pdf/nihms104083.pdf</a><br> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515421/pdf/vhrm-0403-615.pdf">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515421/pdf/vhrm-0403-615.pdf</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/16871481">http://www.ncbi.nlm.nih.gov/pubmed/16871481</a><br> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18827911/?tool=pubmed">http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18827911/?tool=pubmed</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/16103490">http://www.ncbi.nlm.nih.gov/pubmed/16103490</a><br> <a href="http://www.ncbi.nlm.nih.gov/pubmed/15687755">http://www.ncbi.nlm.nih.gov/pubmed/15687755</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/12082488">http://www.ncbi.nlm.nih.gov/pubmed/12082488</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/10893382">http://www.ncbi.nlm.nih.gov/pubmed/10893382</a><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-90983698242072263492011-06-02T07:12:00.001-07:002011-06-02T07:12:51.555-07:00MDGuidelines<div> <div> <div> <p> <div style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: #000000; FONT-SIZE: 10pt"> <img align="absMiddle" src="http://www.mdguidelines.com/themeResources/spacer.gif" width="15" height="15"><br> <div><a href="http://www.mdguidelines.com/" target="_blank"><img title="MD Guidelines" border="0" alt="MD Guidelines" src="http://www.mdguidelines.com/themeResources/md-guidelines-logostacked.jpg" width="260" height="111"></a></div> <img align="absMiddle" src="http://www.mdguidelines.com/themeResources/spacer.gif" width="15" height="15"><br> <div><span style="FONT-WEIGHT: bold">MDGuidelines</span> is your one-stop portal for return-to-work and treatment guidelines!<br><a style="BACKGROUND-COLOR: rgb(255,255,0)" href="http://www.mdguidelines.com/" target="_blank"><font color="#336633">http://www.mdguidelines.com/</font></a><br> <br>Revised Topics</div> <div> <ol> <li><a href="http://www.mdguidelines.com/abdominal-adhesions" target="_blank" nowrap><font color="#336633">Abdominal Adhesions</font></a></li> <li><a href="http://www.mdguidelines.com/abdominal-aneurysm" target="_blank" nowrap><font color="#336633">Abdominal Aneurysm</font></a></li> <li><a href="http://www.mdguidelines.com/abdominoperineal-resection-of-rectum" target="_blank" nowrap><font color="#336633">Abdominoperineal Resection of Rectum</font></a></li> <li><a href="http://www.mdguidelines.com/abortion-surgical" target="_blank" nowrap><font color="#336633">Abortion, Surgical</font></a></li> <li><a href="http://www.mdguidelines.com/abscess" target="_blank" nowrap><font color="#336633">Abscess</font></a></li> <li><a href="http://www.mdguidelines.com/abscess-peritonsillar" target="_blank" nowrap><font color="#336633">Abscess, Peritonsillar</font></a></li> <li><a href="http://www.mdguidelines.com/actinomycosis" target="_blank" nowrap><font color="#336633">Actinomycosis</font></a></li> <li><a href="http://www.mdguidelines.com/anemia" target="_blank" nowrap><font color="#336633">Anemia</font></a></li> <li><a href="http://www.mdguidelines.com/angina-pectoris" target="_blank" nowrap><font color="#336633">Angina Pectoris</font></a></li> <li><a href="http://www.mdguidelines.com/appendectomy" target="_blank" nowrap><font color="#336633">Appendectomy</font></a></li> <li><a href="http://www.mdguidelines.com/appendicitis" target="_blank" nowrap><font color="#336633">Appendicitis</font></a></li> <li><a href="http://www.mdguidelines.com/arterial-graft" target="_blank" nowrap><font color="#336633">Arterial Graft</font></a></li> <li><a href="http://www.mdguidelines.com/atherosclerosis-and-arteriosclerosis" target="_blank" nowrap><font color="#336633">Atherosclerosis and Arteriosclerosis</font></a></li> <li><a href="http://www.mdguidelines.com/atrial-fibrillation" target="_blank" nowrap><font color="#336633">Atrial Fibrillation</font></a></li> <li><a href="http://www.mdguidelines.com/back-pain" target="_blank" nowrap><font color="#336633">Back Pain</font></a></li> <li><a href="http://www.mdguidelines.com/bells-palsy" target="_blank" nowrap><font color="#336633">Bell's Palsy</font></a></li> <li><a href="http://www.mdguidelines.com/body-contouring" target="_blank" nowrap><font color="#336633">Body Contouring</font></a></li> <li><a href="http://www.mdguidelines.com/bone-spur" target="_blank" nowrap><font color="#336633">Bone Spur</font></a></li> <li><a href="http://www.mdguidelines.com/bone-tumors-benign-and-malignant" target="_blank" nowrap><font color="#336633">Bone Tumors (Benign and Malignant)</font></a></li> <li><a href="http://www.mdguidelines.com/brachial-neuropathy" target="_blank" nowrap><font color="#336633">Brachial Neuropathy</font></a></li> <li><a href="http://www.mdguidelines.com/bronchitis-chronic" target="_blank" nowrap><font color="#336633">Bronchitis, Chronic</font></a></li> <li><a href="http://www.mdguidelines.com/burn-of-head-and-neck-includes-face" target="_blank" nowrap><font color="#336633">Burn of Head and Neck (Includes Face)</font></a></li> <li><a href="http://www.mdguidelines.com/burn-of-wrist-and-hand" target="_blank" nowrap><font color="#336633">Burn of Wrist and Hand</font></a></li> <li><a href="http://www.mdguidelines.com/calculus-renal-and-ureter" target="_blank" nowrap><font color="#336633">Calculus, Renal and Ureter</font></a></li> <li><a href="http://www.mdguidelines.com/cancer" target="_blank" nowrap><font color="#336633">Cancer</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-brain" target="_blank" nowrap><font color="#336633">Cancer, Brain</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-cervix" target="_blank" nowrap><font color="#336633">Cancer, Cervix</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-colon" target="_blank" nowrap><font color="#336633">Cancer, Colon</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-kidney" target="_blank" nowrap><font color="#336633">Cancer, Kidney</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-lung" target="_blank" nowrap><font color="#336633">Cancer, Lung</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-oral-cavity-and-oropharynx" target="_blank" nowrap><font color="#336633">Cancer, Oral Cavity and Oropharynx</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-ovary" target="_blank" nowrap><font color="#336633">Cancer, Ovary</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-prostate" target="_blank" nowrap><font color="#336633">Cancer, Prostate</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-rectum" target="_blank" nowrap><font color="#336633">Cancer, Rectum</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-skin-melanoma" target="_blank" nowrap><font color="#336633">Cancer, Skin (Melanoma)</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-thyroid-gland" target="_blank" nowrap><font color="#336633">Cancer, Thyroid Gland</font></a></li> <li><a href="http://www.mdguidelines.com/cancer-uterus" target="_blank" nowrap><font color="#336633">Cancer, Uterus</font></a></li> <li><a href="http://www.mdguidelines.com/candidiasis" target="_blank" nowrap><font color="#336633">Candidiasis</font></a></li> <li><a href="http://www.mdguidelines.com/cardiac-catheterization" target="_blank" nowrap><font color="#336633">Cardiac Catheterization</font></a></li> <li><a href="http://www.mdguidelines.com/cardiomyopathy" target="_blank" nowrap><font color="#336633">Cardiomyopathy</font></a></li> <li><a href="http://www.mdguidelines.com/cat-scratch-disease" target="_blank" nowrap><font color="#336633">Cat Scratch Disease</font></a></li> <li><a href="http://www.mdguidelines.com/cataract" target="_blank" nowrap><font color="#336633">Cataract</font></a></li> <li><a href="http://www.mdguidelines.com/cervical-dysplasia" target="_blank" nowrap><font color="#336633">Cervical Dysplasia</font></a></li> <li><a href="http://www.mdguidelines.com/cesarean-delivery" target="_blank" nowrap><font color="#336633">Cesarean Delivery</font></a></li> <li><a href="http://www.mdguidelines.com/chickenpox" target="_blank" nowrap><font color="#336633">Chickenpox</font></a></li> <li><a href="http://www.mdguidelines.com/chronic-obstructive-pulmonary-disease" target="_blank" nowrap><font color="#336633">Chronic Obstructive Pulmonary Disease</font></a></li> <li><a href="http://www.mdguidelines.com/cirrhosis-of-the-liver" target="_blank" nowrap><font color="#336633">Cirrhosis of the Liver</font></a></li> <li><a href="http://www.mdguidelines.com/coccydynia" target="_blank" nowrap><font color="#336633">Coccydynia</font></a></li> <li><a href="http://www.mdguidelines.com/colitis" target="_blank" nowrap><font color="#336633">Colitis</font></a></li> <li><a href="http://www.mdguidelines.com/colon-resection" target="_blank" nowrap><font color="#336633">Colon Resection</font></a></li> <li><a href="http://www.mdguidelines.com/colostomy-and-ileostomy" target="_blank" nowrap><font color="#336633">Colostomy and Ileostomy</font></a></li> <li><a href="http://www.mdguidelines.com/concussion-cerebral" target="_blank" nowrap><font color="#336633">Concussion, Cerebral</font></a></li> <li><a href="http://www.mdguidelines.com/contusion-upper-limb" target="_blank" nowrap><font color="#336633">Contusion, Upper Limb</font></a></li> <li><a href="http://www.mdguidelines.com/corneal-transplant" target="_blank" nowrap><font color="#336633">Corneal Transplant</font></a></li> <li><a href="http://www.mdguidelines.com/coronary-balloon-angioplasty" target="_blank" nowrap><font color="#336633">Coronary Balloon Angioplasty</font></a></li> <li><a href="http://www.mdguidelines.com/craniotomy" target="_blank" nowrap><font color="#336633">Craniotomy</font></a></li> <li><a href="http://www.mdguidelines.com/crohns-disease" target="_blank" nowrap><font color="#336633">Crohn's Disease</font></a></li> <li><a href="http://www.mdguidelines.com/cystocele-or-rectocele" target="_blank" nowrap><font color="#336633">Cystocele or Rectocele</font></a></li> <li><a href="http://www.mdguidelines.com/deep-vein-thrombosis" target="_blank" nowrap><font color="#336633">Deep Vein Thrombosis</font></a></li> <li><a href="http://www.mdguidelines.com/deviated-nasal-septum" target="_blank" nowrap><font color="#336633">Deviated Nasal Septum</font></a></li> <li><a href="http://www.mdguidelines.com/diabetes-mellitus-type-i" target="_blank" nowrap><font color="#336633">Diabetes Mellitus Type I</font></a></li> <li><a href="http://www.mdguidelines.com/diabetes-with-peripheral-circulatory-disorders" target="_blank" nowrap><font color="#336633">Diabetes with Peripheral Circulatory Disorders</font></a></li> <li><a href="http://www.mdguidelines.com/dilation-and-curettage" target="_blank" nowrap><font color="#336633">Dilation and Curettage</font></a></li> <li><a href="http://www.mdguidelines.com/disc-calcification" target="_blank" nowrap><font color="#336633">Disc Calcification</font></a></li> <li><a href="http://www.mdguidelines.com/diverticulosis-and-diverticulitis-of-colon" target="_blank" nowrap><font color="#336633">Diverticulosis and Diverticulitis of Colon</font></a></li> <li><a href="http://www.mdguidelines.com/dizziness-and-giddiness" target="_blank" nowrap><font color="#336633">Dizziness and Giddiness</font></a></li> <li><a href="http://www.mdguidelines.com/dysfunctional-uterine-bleeding" target="_blank" nowrap><font color="#336633">Dysfunctional Uterine Bleeding</font></a></li> <li><a href="http://www.mdguidelines.com/dyspnea" target="_blank" nowrap><font color="#336633">Dyspnea</font></a></li> <li><a href="http://www.mdguidelines.com/embolism-pulmonary" target="_blank" nowrap><font color="#336633">Embolism, Pulmonary</font></a></li> <li><a href="http://www.mdguidelines.com/excision-of-bone-spur-foot" target="_blank" nowrap><font color="#336633">Excision of Bone Spur, Foot</font></a></li> <li><a href="http://www.mdguidelines.com/fissurectomy-anal" target="_blank" nowrap><font color="#336633">Fissurectomy, Anal</font></a></li> <li><a href="http://www.mdguidelines.com/fracture" target="_blank" nowrap><font color="#336633">Fracture</font></a></li> <li><a href="http://www.mdguidelines.com/gastric-bypass" target="_blank" nowrap><font color="#336633">Gastric Bypass</font></a></li> <li><a href="http://www.mdguidelines.com/gastritis" target="_blank" nowrap><font color="#336633">Gastritis</font></a></li> <li><a href="http://www.mdguidelines.com/gastroenteritis" target="_blank" nowrap><font color="#336633">Gastroenteritis</font></a></li> <li><a href="http://www.mdguidelines.com/gastroesophageal-reflux" target="_blank" nowrap><font color="#336633">Gastroesophageal Reflux</font></a></li> <li><a href="http://www.mdguidelines.com/glaucoma-acute-angle-closure" target="_blank" nowrap><font color="#336633">Glaucoma, Acute (Angle-Closure)</font></a></li> <li><a href="http://www.mdguidelines.com/gout" target="_blank" nowrap><font color="#336633">Gout</font></a></li> <li><a href="http://www.mdguidelines.com/guillain-barre-syndrome" target="_blank" nowrap><font color="#336633">Guillain-Barré Syndrome</font></a></li> <li><a href="http://www.mdguidelines.com/hallux-rigidus" target="_blank" nowrap><font color="#336633">Hallux Rigidus</font></a></li> <li><a href="http://www.mdguidelines.com/hammertoe" target="_blank" nowrap><font color="#336633">Hammertoe</font></a></li> <li><a href="http://www.mdguidelines.com/head-injury-superficial" target="_blank" nowrap><font color="#336633">Head Injury, Superficial</font></a></li> <li><a href="http://www.mdguidelines.com/heart-failure-congestive" target="_blank" nowrap><font color="#336633">Heart Failure, Congestive</font></a></li> <li><a href="http://www.mdguidelines.com/hepatitis-a" target="_blank" nowrap><font color="#336633">Hepatitis A</font></a></li> <li><a href="http://www.mdguidelines.com/hepatitis-c" target="_blank" nowrap><font color="#336633">Hepatitis C</font></a></li> <li><a href="http://www.mdguidelines.com/hernia-repair-vaginal" target="_blank" nowrap><font color="#336633">Hernia Repair, Vaginal</font></a></li> <li><a href="http://www.mdguidelines.com/hernia-hiatal" target="_blank" nowrap><font color="#336633">Hernia, Hiatal</font></a></li> <li><a href="http://www.mdguidelines.com/hernia-incisional" target="_blank" nowrap><font color="#336633">Hernia, Incisional</font></a></li> <li><a href="http://www.mdguidelines.com/herpes-zoster" target="_blank" nowrap><font color="#336633">Herpes Zoster</font></a></li> <li><a href="http://www.mdguidelines.com/hydatidiform-mole" target="_blank" nowrap><font color="#336633">Hydatidiform Mole</font></a></li> <li><a href="http://www.mdguidelines.com/hyperemesis-gravidarum" target="_blank" nowrap><font color="#336633">Hyperemesis Gravidarum</font></a></li> <li><a href="http://www.mdguidelines.com/high-blood-pressure-benign" target="_blank" nowrap><font color="#336633">Hypertension</font></a></li> <li><a href="http://www.mdguidelines.com/high-blood-pressure-malignant" target="_blank" nowrap><font color="#336633">Hypertensive Emergency</font></a></li> <li><a href="http://www.mdguidelines.com/incision-and-drainage-of-ischiorectal-and-or-perirectal-abscess" target="_blank" nowrap><font color="#336633">Incision and Drainage of Ischiorectal and/or Perirectal Abscess</font></a></li> <li><a href="http://www.mdguidelines.com/infection" target="_blank" nowrap><font color="#336633">Infection</font></a></li> <li><a href="http://www.mdguidelines.com/influenza" target="_blank" nowrap><font color="#336633">Influenza</font></a></li> <li><a href="http://www.mdguidelines.com/influenza-a-h1n1" target="_blank" nowrap><font color="#336633">Influenza, A H1N1</font></a></li> <li><a href="http://www.mdguidelines.com/intervertebral-disc-disorders" target="_blank" nowrap><font color="#336633">Intervertebral Disc Disorders</font></a></li> <li><a href="http://www.mdguidelines.com/intestinal-obstruction" target="_blank" nowrap><font color="#336633">Intestinal Obstruction</font></a></li> <li><a href="http://www.mdguidelines.com/intracranial-hemorrhage" target="_blank" nowrap><font color="#336633">Intracranial Hemorrhage</font></a></li> <li><a href="http://www.mdguidelines.com/joint-disorders" target="_blank" nowrap><font color="#336633">Joint Disorders</font></a></li> <li><a href="http://www.mdguidelines.com/kidney-transplantation" target="_blank" nowrap><font color="#336633">Kidney Transplantation</font></a></li> <li><a href="http://www.mdguidelines.com/labyrinthitis" target="_blank" nowrap><font color="#336633">Labyrinthitis</font></a></li> <li><a href="http://www.mdguidelines.com/laparoscopy" target="_blank" nowrap><font color="#336633">Laparoscopy</font></a></li> <li><a href="http://www.mdguidelines.com/laparotomy" target="_blank" nowrap><font color="#336633">Laparotomy</font></a></li> <li><a href="http://www.mdguidelines.com/leukemia" target="_blank" nowrap><font color="#336633">Leukemia</font></a></li> <li><a href="http://www.mdguidelines.com/lipoma" target="_blank" nowrap><font color="#336633">Lipoma</font></a></li> <li><a href="http://www.mdguidelines.com/lithotripsy-extracorporeal-shock-wave" target="_blank" nowrap><font color="#336633">Lithotripsy, Extracorporeal Shock Wave</font></a></li> <li><a href="http://www.mdguidelines.com/lupus-erythematosus-systemic" target="_blank" nowrap><font color="#336633">Lupus Erythematosus, Systemic</font></a></li> <li><a href="http://www.mdguidelines.com/lymph-node-disorders" target="_blank" nowrap><font color="#336633">Lymph Node Disorders</font></a></li> <li><a href="http://www.mdguidelines.com/malunion-and-nonunion-of-fracture" target="_blank" nowrap><font color="#336633">Malunion and Nonunion of Fracture</font></a></li> <li><a href="http://www.mdguidelines.com/mammoplasty-reduction" target="_blank" nowrap><font color="#336633">Mammoplasty, Reduction</font></a></li> <li><a href="http://www.mdguidelines.com/mastectomy" target="_blank" nowrap><font color="#336633">Mastectomy</font></a></li> <li><a href="http://www.mdguidelines.com/menieres-disease" target="_blank" nowrap><font color="#336633">Ménière's Disease</font></a></li> <li><a href="http://www.mdguidelines.com/migraine-headache" target="_blank" nowrap><font color="#336633">Migraine Headache</font></a></li> <li><a href="http://www.mdguidelines.com/miscarriage" target="_blank" nowrap><font color="#336633">Miscarriage</font></a></li> <li><a href="http://www.mdguidelines.com/multiple-sclerosis" target="_blank" nowrap><font color="#336633">Multiple Sclerosis</font></a></li> <li><a href="http://www.mdguidelines.com/myeloid-leukemia" target="_blank" nowrap><font color="#336633">Myeloid Leukemia</font></a></li> <li><a href="http://www.mdguidelines.com/myomectomy-uterine" target="_blank" nowrap><font color="#336633">Myomectomy, Uterine</font></a></li> <li><a href="http://www.mdguidelines.com/nerve-injury" target="_blank" nowrap><font color="#336633">Nerve Injury</font></a></li> <li><a href="http://www.mdguidelines.com/non-hodgkins-lymphoma" target="_blank" nowrap><font color="#336633">Non-Hodgkin's Lymphoma</font></a></li> <li><a href="http://www.mdguidelines.com/obesity" target="_blank" nowrap><font color="#336633">Obesity</font></a></li> <li><a href="http://www.mdguidelines.com/oophorectomy" target="_blank" nowrap><font color="#336633">Oophorectomy</font></a></li> <li><a href="http://www.mdguidelines.com/osler-weber-rendu-disease" target="_blank" nowrap><font color="#336633">Osler-Weber-Rendu Disease</font></a></li> <li><a href="http://www.mdguidelines.com/osteotomy" target="_blank" nowrap><font color="#336633">Osteotomy</font></a></li> <li><a href="http://www.mdguidelines.com/otitis-media" target="_blank" nowrap><font color="#336633">Otitis Media</font></a></li> <li><a href="http://www.mdguidelines.com/ovarian-cyst-benign" target="_blank" nowrap><font color="#336633">Ovarian Cyst, Benign</font></a></li> <li><a href="http://www.mdguidelines.com/ovarian-cyst-resection-of" target="_blank" nowrap><font color="#336633">Ovarian Cyst, Resection of</font></a></li> <li><a href="http://www.mdguidelines.com/pain-in-limb" target="_blank" nowrap><font color="#336633">Pain in Limb</font></a></li> <li><a href="http://www.mdguidelines.com/pancreatitis" target="_blank" nowrap><font color="#336633">Pancreatitis</font></a></li> <li><a href="http://www.mdguidelines.com/paresthesia" target="_blank" nowrap><font color="#336633">Paresthesia</font></a></li> <li><a href="http://www.mdguidelines.com/parkinsons-disease" target="_blank" nowrap><font color="#336633">Parkinson's Disease</font></a></li> <li><a href="http://www.mdguidelines.com/pharyngitis-acute" target="_blank" nowrap><font color="#336633">Pharyngitis, Acute</font></a></li> <li><a href="http://www.mdguidelines.com/pilonidal-cyst" target="_blank" nowrap><font color="#336633">Pilonidal Cyst</font></a></li> <li><a href="http://www.mdguidelines.com/pre-eclampsia-and-eclampsia" target="_blank" nowrap><font color="#336633">Pre-eclampsia and Eclampsia</font></a></li> <li><a href="http://www.mdguidelines.com/pregnancy-complications" target="_blank" nowrap><font color="#336633">Pregnancy, Complications</font></a></li> <li><a href="http://www.mdguidelines.com/pregnancy-ectopic" target="_blank" nowrap><font color="#336633">Pregnancy, Ectopic</font></a></li> <li><a href="http://www.mdguidelines.com/pregnancy-multiple-gestation" target="_blank" nowrap><font color="#336633">Pregnancy, Multiple Gestation</font></a></li> <li><a href="http://www.mdguidelines.com/pregnancy-normal" target="_blank" nowrap><font color="#336633">Pregnancy, Normal</font></a></li> <li><a href="http://www.mdguidelines.com/premature-labor" target="_blank" nowrap><font color="#336633">Premature Labor</font></a></li> <li><a href="http://www.mdguidelines.com/prostatectomy" target="_blank" nowrap><font color="#336633">Prostatectomy</font></a></li> <li><a href="http://www.mdguidelines.com/psoriasis" target="_blank" nowrap><font color="#336633">Psoriasis</font></a></li> <li><a href="http://www.mdguidelines.com/puncture-wound" target="_blank" nowrap><font color="#336633">Puncture Wound</font></a></li> <li><a href="http://www.mdguidelines.com/pyelonephritis-acute" target="_blank" nowrap><font color="#336633">Pyelonephritis, Acute</font></a></li> <li><a href="http://www.mdguidelines.com/renal-failure-chronic" target="_blank" nowrap><font color="#336633">Renal Failure, Chronic</font></a></li> <li><a href="http://www.mdguidelines.com/repair-ruptured-achilles-tendon" target="_blank" nowrap><font color="#336633">Repair, Ruptured Achilles Tendon</font></a></li> <li><a href="http://www.mdguidelines.com/retinal-detachment" target="_blank" nowrap><font color="#336633">Retinal Detachment</font></a></li> <li><a href="http://www.mdguidelines.com/retinal-detachment-repair" target="_blank" nowrap><font color="#336633">Retinal Detachment Repair</font></a></li> <li><a href="http://www.mdguidelines.com/salpingo-oophorectomy" target="_blank" nowrap><font color="#336633">Salpingo-oophorectomy</font></a></li> <li><a href="http://www.mdguidelines.com/sciatica" target="_blank" nowrap><font color="#336633">Sciatica</font></a></li> <li><a href="http://www.mdguidelines.com/sepsis" target="_blank" nowrap><font color="#336633">Sepsis</font></a></li> <li><a href="http://www.mdguidelines.com/sprains-and-strains" target="_blank" nowrap><font color="#336633">Sprains and Strains</font></a></li> <li><a href="http://www.mdguidelines.com/sprains-and-strains-shoulder-and-upper-arm" target="_blank" nowrap><font color="#336633">Sprains and Strains, Shoulder and Upper Arm</font></a></li> <li><a href="http://www.mdguidelines.com/strep-throat" target="_blank" nowrap><font color="#336633">Strep Throat</font></a></li> <li><a href="http://www.mdguidelines.com/syncope" target="_blank" nowrap><font color="#336633">Syncope</font></a></li> <li><a href="http://www.mdguidelines.com/synovial-cyst" target="_blank" nowrap><font color="#336633">Synovial Cyst</font></a></li> <li><a href="http://www.mdguidelines.com/synovitis" target="_blank" nowrap><font color="#336633">Synovitis</font></a></li> <li><a href="http://www.mdguidelines.com/tachycardia-paroxysmal-supraventricular" target="_blank" nowrap><font color="#336633">Tachycardia, Paroxysmal Supraventricular</font></a></li> <li><a href="http://www.mdguidelines.com/thoracic-spine-pain" target="_blank" nowrap><font color="#336633">Thoracic Spine Pain</font></a></li> <li><a href="http://www.mdguidelines.com/threatened-abortion" target="_blank" nowrap><font color="#336633">Threatened Abortion</font></a></li> <li><a href="http://www.mdguidelines.com/thrombophlebitis" target="_blank" nowrap><font color="#336633">Thrombophlebitis</font></a></li> <li><a href="http://www.mdguidelines.com/thyroidectomy" target="_blank" nowrap><font color="#336633">Thyroidectomy</font></a></li> <li><a href="http://www.mdguidelines.com/tonsillectomy-and-adenoidectomy" target="_blank" nowrap><font color="#336633">Tonsillectomy and Adenoidectomy</font></a></li> <li><a href="http://www.mdguidelines.com/tonsillitis-and-adenoiditis" target="_blank" nowrap><font color="#336633">Tonsillitis and Adenoiditis</font></a></li> <li><a href="http://www.mdguidelines.com/torticollis" target="_blank" nowrap><font color="#336633">Torticollis</font></a></li> <li><a href="http://www.mdguidelines.com/total-reconstruction-of-breast" target="_blank" nowrap><font color="#336633">Total Reconstruction of Breast</font></a></li> <li><a href="http://www.mdguidelines.com/transfer-of-nerve-ulnar" target="_blank" nowrap><font color="#336633">Transfer of Nerve, Ulnar</font></a></li> <li><a href="http://www.mdguidelines.com/transient-ischemic-attack" target="_blank" nowrap><font color="#336633">Transient Ischemic Attack</font></a></li> <li><a href="http://www.mdguidelines.com/trauma" target="_blank" nowrap><font color="#336633">Trauma</font></a></li> <li><a href="http://www.mdguidelines.com/trigeminal-neuralgia" target="_blank" nowrap><font color="#336633">Trigeminal Neuralgia</font></a></li> <li><a href="http://www.mdguidelines.com/tumor-benign" target="_blank" nowrap><font color="#336633">Tumor, Benign</font></a></li> <li><a href="http://www.mdguidelines.com/ulcerative-colitis" target="_blank" nowrap><font color="#336633">Ulcerative Colitis</font></a></li> <li><a href="http://www.mdguidelines.com/upper-respiratory-infection" target="_blank" nowrap><font color="#336633">Upper Respiratory Infection</font></a></li> <li><a href="http://www.mdguidelines.com/urethrocele-with-stress-incontinence" target="_blank" nowrap><font color="#336633">Urethrocele with Stress Incontinence</font></a></li> <li><a href="http://www.mdguidelines.com/urinary-incontinence-in-women" target="_blank" nowrap><font color="#336633">Urinary Incontinence in Women</font></a></li> <li><a href="http://www.mdguidelines.com/varicose-veins" target="_blank" nowrap><font color="#336633">Varicose Veins</font></a></li> <li><a href="http://www.mdguidelines.com/venous-embolism-and-thrombosis" target="_blank" nowrap><font color="#336633">Venous Thrombosis and Embolism</font></a></li> <li><a href="http://www.mdguidelines.com/vertigo" target="_blank" nowrap><font color="#336633">Vertigo</font></a></li></ol></div> <div> <div> <div> <div class="MsoNormal"> <div> <div> <div> <div class="MsoNormal"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt">Atte.</span><span></span></div> <div class="MsoNormal"><font size="5"><span style="FONT-FAMILY: 'Brush Script MT'; FONT-SIZE: 18pt"><strong>Dr.Máximo Cuadros Chávez</strong></span></font></div> <div class="MsoNormal"><strong><span style="FONT-FAMILY: 'Arial Rounded MT Bold'; COLOR: red; FONT-WEIGHT: normal"><font size="2">Celular 99199698<br>rpm #800515</font><br></span></strong></div></div></div></div> <span></span></div> <div style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" class="MsoNormal"><font style="COLOR: rgb(0,0,255)" size="1"><span><a href="http://es.groups.yahoo.com/group/interno_residente_medico_PERU/" rel="nofollow" target="_blank"><font color="#336633">http://es.groups.yahoo.com/group/interno_residente_medico_PERU/</font></a><br> </span></font><font size="1"><a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/" rel="nofollow" target="_blank"><font color="#336633">http://es.groups.yahoo.com/group/SANFERNANDOPERU/</font></a><a href="http://es-la.facebook.com/people/Maximo-Cuadros-Chavez/100001101314342" rel="nofollow" target="_blank"></a></font><br> </div><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(255,0,0)" size="1"><span><span><a href="http://www.facebook.com/home.php?sk=group_150017968368005&ap=1" rel="nofollow" target="_blank"><font color="#336633">http://www.facebook.com/home.php?sk=group_150017968368005&ap=1</font></a><br> <a href="http://medicalia.ning.com/profiles/blog/list?user=1nezbq9ucojf4" rel="nofollow" target="_blank"><font color="#336633">http://medicalia.ning.com/profiles/blog/list?user=1nezbq9ucojf4</font></a><br></span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(255,0,0)" size="1"><span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" size="1"><span>UNYK: 245 HRP<br> Skype: maximocuadros<br></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif" size="1"><span style="COLOR: rgb(0,0,255)"></span></font></div></div></div> <div><br></div></div> <p></p></p></div><br><br></div></div> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Máximo Cuadros</b> <span dir="ltr"><<a href="mailto:maximocuadros@yahoo.es">maximocuadros@yahoo.es</a>></span><br> Fecha: 2 de junio de 2011 01:18<br>Asunto: [SANFERNANDOPERU] MDGuidelines<br>Para: <a href="mailto:interno_residente_medico_PERU@yahoogroups.com">interno_residente_medico_PERU@yahoogroups.com</a><br><br><br> <div style="BACKGROUND-COLOR: #fff"><span> </span> <div> <div> <div> <p> <div style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: #000000; FONT-SIZE: 10pt"> <img align="absMiddle" src="http://www.mdguidelines.com/themeResources/spacer.gif" width="15" height="15"><br> <div><a href="http://www.mdguidelines.com/" target="_blank"><img title="MD Guidelines" border="0" alt="MD Guidelines" src="http://www.mdguidelines.com/themeResources/md-guidelines-logostacked.jpg" width="260" height="111"></a></div> <img align="absMiddle" src="http://www.mdguidelines.com/themeResources/spacer.gif" width="15" height="15"><br> <div><span style="FONT-WEIGHT: bold">MDGuidelines</span> is your one-stop portal for return-to-work and treatment guidelines!<br><a style="BACKGROUND-COLOR: rgb(255,255,0)" href="http://www.mdguidelines.com/" target="_blank">http://www.mdguidelines.com/</a><br> <br>Revised Topics</div> <div> <ol> <li><a href="http://www.mdguidelines.com/abdominal-adhesions" target="_blank" nowrap>Abdominal Adhesions</a></li> <li><a href="http://www.mdguidelines.com/abdominal-aneurysm" target="_blank" nowrap>Abdominal Aneurysm</a></li> <li><a href="http://www.mdguidelines.com/abdominoperineal-resection-of-rectum" target="_blank" nowrap>Abdominoperineal Resection of Rectum</a></li> <li><a href="http://www.mdguidelines.com/abortion-surgical" target="_blank" nowrap>Abortion, Surgical</a></li> <li><a href="http://www.mdguidelines.com/abscess" target="_blank" nowrap>Abscess</a></li> <li><a href="http://www.mdguidelines.com/abscess-peritonsillar" target="_blank" nowrap>Abscess, Peritonsillar</a></li> <li><a href="http://www.mdguidelines.com/actinomycosis" target="_blank" nowrap>Actinomycosis</a></li> <li><a href="http://www.mdguidelines.com/anemia" target="_blank" nowrap>Anemia</a></li> <li><a href="http://www.mdguidelines.com/angina-pectoris" target="_blank" nowrap>Angina Pectoris</a></li> <li><a href="http://www.mdguidelines.com/appendectomy" target="_blank" nowrap>Appendectomy</a></li> <li><a href="http://www.mdguidelines.com/appendicitis" target="_blank" nowrap>Appendicitis</a></li> <li><a href="http://www.mdguidelines.com/arterial-graft" target="_blank" nowrap>Arterial Graft</a></li> <li><a href="http://www.mdguidelines.com/atherosclerosis-and-arteriosclerosis" target="_blank" nowrap>Atherosclerosis and Arteriosclerosis</a></li> <li><a href="http://www.mdguidelines.com/atrial-fibrillation" target="_blank" nowrap>Atrial Fibrillation</a></li> <li><a href="http://www.mdguidelines.com/back-pain" target="_blank" nowrap>Back Pain</a></li> <li><a href="http://www.mdguidelines.com/bells-palsy" target="_blank" nowrap>Bell's Palsy</a></li> <li><a href="http://www.mdguidelines.com/body-contouring" target="_blank" nowrap>Body Contouring</a></li> <li><a href="http://www.mdguidelines.com/bone-spur" target="_blank" nowrap>Bone Spur</a></li> <li><a href="http://www.mdguidelines.com/bone-tumors-benign-and-malignant" target="_blank" nowrap>Bone Tumors (Benign and Malignant)</a></li> <li><a href="http://www.mdguidelines.com/brachial-neuropathy" target="_blank" nowrap>Brachial Neuropathy</a></li> <li><a href="http://www.mdguidelines.com/bronchitis-chronic" target="_blank" nowrap>Bronchitis, Chronic</a></li> <li><a href="http://www.mdguidelines.com/burn-of-head-and-neck-includes-face" target="_blank" nowrap>Burn of Head and Neck (Includes Face)</a></li> <li><a href="http://www.mdguidelines.com/burn-of-wrist-and-hand" target="_blank" nowrap>Burn of Wrist and Hand</a></li> <li><a href="http://www.mdguidelines.com/calculus-renal-and-ureter" target="_blank" nowrap>Calculus, Renal and Ureter</a></li> <li><a href="http://www.mdguidelines.com/cancer" target="_blank" nowrap>Cancer</a></li> <li><a href="http://www.mdguidelines.com/cancer-brain" target="_blank" nowrap>Cancer, Brain</a></li> <li><a href="http://www.mdguidelines.com/cancer-cervix" target="_blank" nowrap>Cancer, Cervix</a></li> <li><a href="http://www.mdguidelines.com/cancer-colon" target="_blank" nowrap>Cancer, Colon</a></li> <li><a href="http://www.mdguidelines.com/cancer-kidney" target="_blank" nowrap>Cancer, Kidney</a></li> <li><a href="http://www.mdguidelines.com/cancer-lung" target="_blank" nowrap>Cancer, Lung</a></li> <li><a href="http://www.mdguidelines.com/cancer-oral-cavity-and-oropharynx" target="_blank" nowrap>Cancer, Oral Cavity and Oropharynx</a></li> <li><a href="http://www.mdguidelines.com/cancer-ovary" target="_blank" nowrap>Cancer, Ovary</a></li> <li><a href="http://www.mdguidelines.com/cancer-prostate" target="_blank" nowrap>Cancer, Prostate</a></li> <li><a href="http://www.mdguidelines.com/cancer-rectum" target="_blank" nowrap>Cancer, Rectum</a></li> <li><a href="http://www.mdguidelines.com/cancer-skin-melanoma" target="_blank" nowrap>Cancer, Skin (Melanoma)</a></li> <li><a href="http://www.mdguidelines.com/cancer-thyroid-gland" target="_blank" nowrap>Cancer, Thyroid Gland</a></li> <li><a href="http://www.mdguidelines.com/cancer-uterus" target="_blank" nowrap>Cancer, Uterus</a></li> <li><a href="http://www.mdguidelines.com/candidiasis" target="_blank" nowrap>Candidiasis</a></li> <li><a href="http://www.mdguidelines.com/cardiac-catheterization" target="_blank" nowrap>Cardiac Catheterization</a></li> <li><a href="http://www.mdguidelines.com/cardiomyopathy" target="_blank" nowrap>Cardiomyopathy</a></li> <li><a href="http://www.mdguidelines.com/cat-scratch-disease" target="_blank" nowrap>Cat Scratch Disease</a></li> <li><a href="http://www.mdguidelines.com/cataract" target="_blank" nowrap>Cataract</a></li> <li><a href="http://www.mdguidelines.com/cervical-dysplasia" target="_blank" nowrap>Cervical Dysplasia</a></li> <li><a href="http://www.mdguidelines.com/cesarean-delivery" target="_blank" nowrap>Cesarean Delivery</a></li> <li><a href="http://www.mdguidelines.com/chickenpox" target="_blank" nowrap>Chickenpox</a></li> <li><a href="http://www.mdguidelines.com/chronic-obstructive-pulmonary-disease" target="_blank" nowrap>Chronic Obstructive Pulmonary Disease</a></li> <li><a href="http://www.mdguidelines.com/cirrhosis-of-the-liver" target="_blank" nowrap>Cirrhosis of the Liver</a></li> <li><a href="http://www.mdguidelines.com/coccydynia" target="_blank" nowrap>Coccydynia</a></li> <li><a href="http://www.mdguidelines.com/colitis" target="_blank" nowrap>Colitis</a></li> <li><a href="http://www.mdguidelines.com/colon-resection" target="_blank" nowrap>Colon Resection</a></li> <li><a href="http://www.mdguidelines.com/colostomy-and-ileostomy" target="_blank" nowrap>Colostomy and Ileostomy</a></li> <li><a href="http://www.mdguidelines.com/concussion-cerebral" target="_blank" nowrap>Concussion, Cerebral</a></li> <li><a href="http://www.mdguidelines.com/contusion-upper-limb" target="_blank" nowrap>Contusion, Upper Limb</a></li> <li><a href="http://www.mdguidelines.com/corneal-transplant" target="_blank" nowrap>Corneal Transplant</a></li> <li><a href="http://www.mdguidelines.com/coronary-balloon-angioplasty" target="_blank" nowrap>Coronary Balloon Angioplasty</a></li> <li><a href="http://www.mdguidelines.com/craniotomy" target="_blank" nowrap>Craniotomy</a></li> <li><a href="http://www.mdguidelines.com/crohns-disease" target="_blank" nowrap>Crohn's Disease</a></li> <li><a href="http://www.mdguidelines.com/cystocele-or-rectocele" target="_blank" nowrap>Cystocele or Rectocele</a></li> <li><a href="http://www.mdguidelines.com/deep-vein-thrombosis" target="_blank" nowrap>Deep Vein Thrombosis</a></li> <li><a href="http://www.mdguidelines.com/deviated-nasal-septum" target="_blank" nowrap>Deviated Nasal Septum</a></li> <li><a href="http://www.mdguidelines.com/diabetes-mellitus-type-i" target="_blank" nowrap>Diabetes Mellitus Type I</a></li> <li><a href="http://www.mdguidelines.com/diabetes-with-peripheral-circulatory-disorders" target="_blank" nowrap>Diabetes with Peripheral Circulatory Disorders</a></li> <li><a href="http://www.mdguidelines.com/dilation-and-curettage" target="_blank" nowrap>Dilation and Curettage</a></li> <li><a href="http://www.mdguidelines.com/disc-calcification" target="_blank" nowrap>Disc Calcification</a></li> <li><a href="http://www.mdguidelines.com/diverticulosis-and-diverticulitis-of-colon" target="_blank" nowrap>Diverticulosis and Diverticulitis of Colon</a></li> <li><a href="http://www.mdguidelines.com/dizziness-and-giddiness" target="_blank" nowrap>Dizziness and Giddiness</a></li> <li><a href="http://www.mdguidelines.com/dysfunctional-uterine-bleeding" target="_blank" nowrap>Dysfunctional Uterine Bleeding</a></li> <li><a href="http://www.mdguidelines.com/dyspnea" target="_blank" nowrap>Dyspnea</a></li> <li><a href="http://www.mdguidelines.com/embolism-pulmonary" target="_blank" nowrap>Embolism, Pulmonary</a></li> <li><a href="http://www.mdguidelines.com/excision-of-bone-spur-foot" target="_blank" nowrap>Excision of Bone Spur, Foot</a></li> <li><a href="http://www.mdguidelines.com/fissurectomy-anal" target="_blank" nowrap>Fissurectomy, Anal</a></li> <li><a href="http://www.mdguidelines.com/fracture" target="_blank" nowrap>Fracture</a></li> <li><a href="http://www.mdguidelines.com/gastric-bypass" target="_blank" nowrap>Gastric Bypass</a></li> <li><a href="http://www.mdguidelines.com/gastritis" target="_blank" nowrap>Gastritis</a></li> <li><a href="http://www.mdguidelines.com/gastroenteritis" target="_blank" nowrap>Gastroenteritis</a></li> <li><a href="http://www.mdguidelines.com/gastroesophageal-reflux" target="_blank" nowrap>Gastroesophageal Reflux</a></li> <li><a href="http://www.mdguidelines.com/glaucoma-acute-angle-closure" target="_blank" nowrap>Glaucoma, Acute (Angle-Closure)</a></li> <li><a href="http://www.mdguidelines.com/gout" target="_blank" nowrap>Gout</a></li> <li><a href="http://www.mdguidelines.com/guillain-barre-syndrome" target="_blank" nowrap>Guillain-Barré Syndrome</a></li> <li><a href="http://www.mdguidelines.com/hallux-rigidus" target="_blank" nowrap>Hallux Rigidus</a></li> <li><a href="http://www.mdguidelines.com/hammertoe" target="_blank" nowrap>Hammertoe</a></li> <li><a href="http://www.mdguidelines.com/head-injury-superficial" target="_blank" nowrap>Head Injury, Superficial</a></li> <li><a href="http://www.mdguidelines.com/heart-failure-congestive" target="_blank" nowrap>Heart Failure, Congestive</a></li> <li><a href="http://www.mdguidelines.com/hepatitis-a" target="_blank" nowrap>Hepatitis A</a></li> <li><a href="http://www.mdguidelines.com/hepatitis-c" target="_blank" nowrap>Hepatitis C</a></li> <li><a href="http://www.mdguidelines.com/hernia-repair-vaginal" target="_blank" nowrap>Hernia Repair, Vaginal</a></li> <li><a href="http://www.mdguidelines.com/hernia-hiatal" target="_blank" nowrap>Hernia, Hiatal</a></li> <li><a href="http://www.mdguidelines.com/hernia-incisional" target="_blank" nowrap>Hernia, Incisional</a></li> <li><a href="http://www.mdguidelines.com/herpes-zoster" target="_blank" nowrap>Herpes Zoster</a></li> <li><a href="http://www.mdguidelines.com/hydatidiform-mole" target="_blank" nowrap>Hydatidiform Mole</a></li> <li><a href="http://www.mdguidelines.com/hyperemesis-gravidarum" target="_blank" nowrap>Hyperemesis Gravidarum</a></li> <li><a href="http://www.mdguidelines.com/high-blood-pressure-benign" target="_blank" nowrap>Hypertension</a></li> <li><a href="http://www.mdguidelines.com/high-blood-pressure-malignant" target="_blank" nowrap>Hypertensive Emergency</a></li> <li><a href="http://www.mdguidelines.com/incision-and-drainage-of-ischiorectal-and-or-perirectal-abscess" target="_blank" nowrap>Incision and Drainage of Ischiorectal and/or Perirectal Abscess</a></li> <li><a href="http://www.mdguidelines.com/infection" target="_blank" nowrap>Infection</a></li> <li><a href="http://www.mdguidelines.com/influenza" target="_blank" nowrap>Influenza</a></li> <li><a href="http://www.mdguidelines.com/influenza-a-h1n1" target="_blank" nowrap>Influenza, A H1N1</a></li> <li><a href="http://www.mdguidelines.com/intervertebral-disc-disorders" target="_blank" nowrap>Intervertebral Disc Disorders</a></li> <li><a href="http://www.mdguidelines.com/intestinal-obstruction" target="_blank" nowrap>Intestinal Obstruction</a></li> <li><a href="http://www.mdguidelines.com/intracranial-hemorrhage" target="_blank" nowrap>Intracranial Hemorrhage</a></li> <li><a href="http://www.mdguidelines.com/joint-disorders" target="_blank" nowrap>Joint Disorders</a></li> <li><a href="http://www.mdguidelines.com/kidney-transplantation" target="_blank" nowrap>Kidney Transplantation</a></li> <li><a href="http://www.mdguidelines.com/labyrinthitis" target="_blank" nowrap>Labyrinthitis</a></li> <li><a href="http://www.mdguidelines.com/laparoscopy" target="_blank" nowrap>Laparoscopy</a></li> <li><a href="http://www.mdguidelines.com/laparotomy" target="_blank" nowrap>Laparotomy</a></li> <li><a href="http://www.mdguidelines.com/leukemia" target="_blank" nowrap>Leukemia</a></li> <li><a href="http://www.mdguidelines.com/lipoma" target="_blank" nowrap>Lipoma</a></li> <li><a href="http://www.mdguidelines.com/lithotripsy-extracorporeal-shock-wave" target="_blank" nowrap>Lithotripsy, Extracorporeal Shock Wave</a></li> <li><a href="http://www.mdguidelines.com/lupus-erythematosus-systemic" target="_blank" nowrap>Lupus Erythematosus, Systemic</a></li> <li><a href="http://www.mdguidelines.com/lymph-node-disorders" target="_blank" nowrap>Lymph Node Disorders</a></li> <li><a href="http://www.mdguidelines.com/malunion-and-nonunion-of-fracture" target="_blank" nowrap>Malunion and Nonunion of Fracture</a></li> <li><a href="http://www.mdguidelines.com/mammoplasty-reduction" target="_blank" nowrap>Mammoplasty, Reduction</a></li> <li><a href="http://www.mdguidelines.com/mastectomy" target="_blank" nowrap>Mastectomy</a></li> <li><a href="http://www.mdguidelines.com/menieres-disease" target="_blank" nowrap>Ménière's Disease</a></li> <li><a href="http://www.mdguidelines.com/migraine-headache" target="_blank" nowrap>Migraine Headache</a></li> <li><a href="http://www.mdguidelines.com/miscarriage" target="_blank" nowrap>Miscarriage</a></li> <li><a href="http://www.mdguidelines.com/multiple-sclerosis" target="_blank" nowrap>Multiple Sclerosis</a></li> <li><a href="http://www.mdguidelines.com/myeloid-leukemia" target="_blank" nowrap>Myeloid Leukemia</a></li> <li><a href="http://www.mdguidelines.com/myomectomy-uterine" target="_blank" nowrap>Myomectomy, Uterine</a></li> <li><a href="http://www.mdguidelines.com/nerve-injury" target="_blank" nowrap>Nerve Injury</a></li> <li><a href="http://www.mdguidelines.com/non-hodgkins-lymphoma" target="_blank" nowrap>Non-Hodgkin's Lymphoma</a></li> <li><a href="http://www.mdguidelines.com/obesity" target="_blank" nowrap>Obesity</a></li> <li><a href="http://www.mdguidelines.com/oophorectomy" target="_blank" nowrap>Oophorectomy</a></li> <li><a href="http://www.mdguidelines.com/osler-weber-rendu-disease" target="_blank" nowrap>Osler-Weber-Rendu Disease</a></li> <li><a href="http://www.mdguidelines.com/osteotomy" target="_blank" nowrap>Osteotomy</a></li> <li><a href="http://www.mdguidelines.com/otitis-media" target="_blank" nowrap>Otitis Media</a></li> <li><a href="http://www.mdguidelines.com/ovarian-cyst-benign" target="_blank" nowrap>Ovarian Cyst, Benign</a></li> <li><a href="http://www.mdguidelines.com/ovarian-cyst-resection-of" target="_blank" nowrap>Ovarian Cyst, Resection of</a></li> <li><a href="http://www.mdguidelines.com/pain-in-limb" target="_blank" nowrap>Pain in Limb</a></li> <li><a href="http://www.mdguidelines.com/pancreatitis" target="_blank" nowrap>Pancreatitis</a></li> <li><a href="http://www.mdguidelines.com/paresthesia" target="_blank" nowrap>Paresthesia</a></li> <li><a href="http://www.mdguidelines.com/parkinsons-disease" target="_blank" nowrap>Parkinson's Disease</a></li> <li><a href="http://www.mdguidelines.com/pharyngitis-acute" target="_blank" nowrap>Pharyngitis, Acute</a></li> <li><a href="http://www.mdguidelines.com/pilonidal-cyst" target="_blank" nowrap>Pilonidal Cyst</a></li> <li><a href="http://www.mdguidelines.com/pre-eclampsia-and-eclampsia" target="_blank" nowrap>Pre-eclampsia and Eclampsia</a></li> <li><a href="http://www.mdguidelines.com/pregnancy-complications" target="_blank" nowrap>Pregnancy, Complications</a></li> <li><a href="http://www.mdguidelines.com/pregnancy-ectopic" target="_blank" nowrap>Pregnancy, Ectopic</a></li> <li><a href="http://www.mdguidelines.com/pregnancy-multiple-gestation" target="_blank" nowrap>Pregnancy, Multiple Gestation</a></li> <li><a href="http://www.mdguidelines.com/pregnancy-normal" target="_blank" nowrap>Pregnancy, Normal</a></li> <li><a href="http://www.mdguidelines.com/premature-labor" target="_blank" nowrap>Premature Labor</a></li> <li><a href="http://www.mdguidelines.com/prostatectomy" target="_blank" nowrap>Prostatectomy</a></li> <li><a href="http://www.mdguidelines.com/psoriasis" target="_blank" nowrap>Psoriasis</a></li> <li><a href="http://www.mdguidelines.com/puncture-wound" target="_blank" nowrap>Puncture Wound</a></li> <li><a href="http://www.mdguidelines.com/pyelonephritis-acute" target="_blank" nowrap>Pyelonephritis, Acute</a></li> <li><a href="http://www.mdguidelines.com/renal-failure-chronic" target="_blank" nowrap>Renal Failure, Chronic</a></li> <li><a href="http://www.mdguidelines.com/repair-ruptured-achilles-tendon" target="_blank" nowrap>Repair, Ruptured Achilles Tendon</a></li> <li><a href="http://www.mdguidelines.com/retinal-detachment" target="_blank" nowrap>Retinal Detachment</a></li> <li><a href="http://www.mdguidelines.com/retinal-detachment-repair" target="_blank" nowrap>Retinal Detachment Repair</a></li> <li><a href="http://www.mdguidelines.com/salpingo-oophorectomy" target="_blank" nowrap>Salpingo-oophorectomy</a></li> <li><a href="http://www.mdguidelines.com/sciatica" target="_blank" nowrap>Sciatica</a></li> <li><a href="http://www.mdguidelines.com/sepsis" target="_blank" nowrap>Sepsis</a></li> <li><a href="http://www.mdguidelines.com/sprains-and-strains" target="_blank" nowrap>Sprains and Strains</a></li> <li><a href="http://www.mdguidelines.com/sprains-and-strains-shoulder-and-upper-arm" target="_blank" nowrap>Sprains and Strains, Shoulder and Upper Arm</a></li> <li><a href="http://www.mdguidelines.com/strep-throat" target="_blank" nowrap>Strep Throat</a></li> <li><a href="http://www.mdguidelines.com/syncope" target="_blank" nowrap>Syncope</a></li> <li><a href="http://www.mdguidelines.com/synovial-cyst" target="_blank" nowrap>Synovial Cyst</a></li> <li><a href="http://www.mdguidelines.com/synovitis" target="_blank" nowrap>Synovitis</a></li> <li><a href="http://www.mdguidelines.com/tachycardia-paroxysmal-supraventricular" target="_blank" nowrap>Tachycardia, Paroxysmal Supraventricular</a></li> <li><a href="http://www.mdguidelines.com/thoracic-spine-pain" target="_blank" nowrap>Thoracic Spine Pain</a></li> <li><a href="http://www.mdguidelines.com/threatened-abortion" target="_blank" nowrap>Threatened Abortion</a></li> <li><a href="http://www.mdguidelines.com/thrombophlebitis" target="_blank" nowrap>Thrombophlebitis</a></li> <li><a href="http://www.mdguidelines.com/thyroidectomy" target="_blank" nowrap>Thyroidectomy</a></li> <li><a href="http://www.mdguidelines.com/tonsillectomy-and-adenoidectomy" target="_blank" nowrap>Tonsillectomy and Adenoidectomy</a></li> <li><a href="http://www.mdguidelines.com/tonsillitis-and-adenoiditis" target="_blank" nowrap>Tonsillitis and Adenoiditis</a></li> <li><a href="http://www.mdguidelines.com/torticollis" target="_blank" nowrap>Torticollis</a></li> <li><a href="http://www.mdguidelines.com/total-reconstruction-of-breast" target="_blank" nowrap>Total Reconstruction of Breast</a></li> <li><a href="http://www.mdguidelines.com/transfer-of-nerve-ulnar" target="_blank" nowrap>Transfer of Nerve, Ulnar</a></li> <li><a href="http://www.mdguidelines.com/transient-ischemic-attack" target="_blank" nowrap>Transient Ischemic Attack</a></li> <li><a href="http://www.mdguidelines.com/trauma" target="_blank" nowrap>Trauma</a></li> <li><a href="http://www.mdguidelines.com/trigeminal-neuralgia" target="_blank" nowrap>Trigeminal Neuralgia</a></li> <li><a href="http://www.mdguidelines.com/tumor-benign" target="_blank" nowrap>Tumor, Benign</a></li> <li><a href="http://www.mdguidelines.com/ulcerative-colitis" target="_blank" nowrap>Ulcerative Colitis</a></li> <li><a href="http://www.mdguidelines.com/upper-respiratory-infection" target="_blank" nowrap>Upper Respiratory Infection</a></li> <li><a href="http://www.mdguidelines.com/urethrocele-with-stress-incontinence" target="_blank" nowrap>Urethrocele with Stress Incontinence</a></li> <li><a href="http://www.mdguidelines.com/urinary-incontinence-in-women" target="_blank" nowrap>Urinary Incontinence in Women</a></li> <li><a href="http://www.mdguidelines.com/varicose-veins" target="_blank" nowrap>Varicose Veins</a></li> <li><a href="http://www.mdguidelines.com/venous-embolism-and-thrombosis" target="_blank" nowrap>Venous Thrombosis and Embolism</a></li> <li><a href="http://www.mdguidelines.com/vertigo" target="_blank" nowrap>Vertigo</a></li></ol></div> <div> <div> <div> <div class="MsoNormal"> <div> <div> <div> <div class="MsoNormal"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt">Atte.</span><span></span></div> <div class="MsoNormal"><font size="5"><span style="FONT-FAMILY: 'Brush Script MT'; FONT-SIZE: 18pt"><strong>Dr.Máximo Cuadros Chávez</strong></span></font></div> <div class="MsoNormal"><strong><span style="FONT-FAMILY: 'Arial Rounded MT Bold'; COLOR: red; FONT-WEIGHT: normal"><font size="2">Celular 99199698<br>rpm #800515</font><br></span></strong></div></div></div></div> <span></span></div> <div style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" class="MsoNormal"><font style="COLOR: rgb(0,0,255)" size="1"><span><a href="http://es.groups.yahoo.com/group/interno_residente_medico_PERU/" rel="nofollow" target="_blank">http://es.groups.yahoo.com/group/interno_residente_medico_PERU/</a><br> </span></font><font size="1"><a href="http://es.groups.yahoo.com/group/SANFERNANDOPERU/" rel="nofollow" target="_blank">http://es.groups.yahoo.com/group/SANFERNANDOPERU/</a><a href="http://es-la.facebook.com/people/Maximo-Cuadros-Chavez/100001101314342" rel="nofollow" target="_blank"></a></font><br> </div><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(255,0,0)" size="1"><span><span><a href="http://www.facebook.com/home.php?sk=group_150017968368005&ap=1" rel="nofollow" target="_blank">http://www.facebook.com/home.php?sk=group_150017968368005&ap=1</a><br> <a href="http://medicalia.ning.com/profiles/blog/list?user=1nezbq9ucojf4" rel="nofollow" target="_blank">http://medicalia.ning.com/profiles/blog/list?user=1nezbq9ucojf4</a><br></span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(255,0,0)" size="1"><span></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif; COLOR: rgb(0,0,255)" size="1"><span>UNYK: 245 HRP<br> Skype: maximocuadros<br></span></font><font style="FONT-FAMILY: arial, helvetica, sans-serif" size="1"><span style="COLOR: rgb(0,0,255)"></span></font></div></div></div> <div><br></div></div> <p></p></p></div></div></div></div></div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-830164873220519472011-05-29T22:02:00.001-07:002011-05-29T22:02:28.848-07:00Aedes aegypti - Dengue<br>Estimados<br> <br>El dengue es un problema de practicamente toda America. Adjunto un link de un video sobre el Aedes aegypti, que ha sido justo ganador de un premio. <br> <br><a href="http://www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?sid=259">http://www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?sid=259</a><br> <br>Saludos<br> <br>Cesar Cabezas<br>__._,_.___<br><br> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">cesar cabezas</b> <span dir="ltr"><<a href="mailto:Salljaruna@yahoo.com">Salljaruna@yahoo.com</a>></span><br>Fecha: 29 de mayo de 2011 20:31<br> Asunto: [SANFERNANDOPERU] Aedes aegypti - Dengue<br>Para: <a href="mailto:SANFERNANDOPERU@yahoogroups.com">SANFERNANDOPERU@yahoogroups.com</a><br>Cc: residentes tropicales <<a href="mailto:infectoperu@yahoogroups.com">infectoperu@yahoogroups.com</a>><br> <br><br> <div style="BACKGROUND-COLOR: #fff"><span> </span> <div> <div> <div> <p> <div style="FONT-FAMILY: Courier New, courier, monaco, monospace, sans-serif; FONT-SIZE: 14pt"> <p>Estimados</p> <p> </p> <p>El dengue es un problema de practicamente toda America. Adjunto un link de un video sobre el <em>Aedes aegypti, </em>que ha sido justo ganador de un premio. </p> <p> </p> <p><a href="http://www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?sid=259" target="_blank">http://www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?sid=259</a></p> <p> </p> <p>Saludos</p> <p> </p> <p>Cesar Cabezas</p></div> <p></p></p></div> <div style="MIN-HEIGHT: 0px; COLOR: #fff">__._,_.___</div></div></div></div></div> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-69261203341058105032011-05-08T22:45:00.001-07:002011-05-08T22:45:34.728-07:00Documento de consenso sobre el tratamiento...<p>Maximo Cuadros Chavez posted in cibermedicos.Maximo Cuadros Chavez6:04pm May 8 </p> <p>Documento de consenso sobre el tratamiento antimicrobiano de las infecciones en el pie diabético</p> <p>Española de Cirujanos (AEC), Asociación; Española de Angiología y Cirugía Vascular (SEACV), Sociedad; Española de Medicina Interna (SEMI), Sociedad; Española de Quimioterapia (SEQ), Sociedad<br>Publicado en Angiologia. 2008;02(60):83-102 - vol.60 núm 02<br> <a href="http://www.facebook.com/l/8fb40Kt1K44BUZdQdbU_lO1nnYQ/www.elsevier.es/sites/default/files/elsevier/pdf/294/294v60n02a13189627pdf001.pdf">http://www.facebook.com/l/8fb40Kt1K44BUZdQdbU_lO1nnYQ/www.elsevier.es/sites/default/files/elsevier/pdf/294/294v60n02a13189627pdf001.pdf</a><br> <br></p> <div class="gmail_quote">---------- Mensaje reenviado ----------<br>De: <b class="gmail_sendername">Maximo Cuadros Chavez</b> <span dir="ltr"><<a href="mailto:notification%2Byfo6tzj9@facebookmail.com">notification+yfo6tzj9@facebookmail.com</a>></span><br> Fecha: 8 de mayo de 2011 18:04<br>Asunto: [cibermedicos] Documento de consenso sobre el tratamiento...<br>Para: Claudio Mori Gonzales <<a href="mailto:clagui57@gmail.com">clagui57@gmail.com</a>><br><br><br> <div style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" dir="ltr"> <table border="0" cellspacing="0" cellpadding="8" width="98%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif" bgcolor="#ffffff" width="100%"> <table border="0" cellspacing="0" cellpadding="0" width="500"> <tbody> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px" valign="top" colspan="2"> <table style="COLOR: #000000; FONT-SIZE: 11px" width="100%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px" valign="top" width="100%" align="left"> <div style="BORDER-BOTTOM: #e9e9e9 1px solid; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; COLOR: #666666; PADDING-TOP: 0px">Maximo Cuadros Chavez <a style="COLOR: #3b5998; TEXT-DECORATION: underline" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&id=188176414552160&mid=4311ec4G5ae37904G270814bG96&bcode=mCsDonZp&n_m=clagui57%40gmail.com" target="_blank">posted in cibermedicos</a>.</div> <div style="MARGIN-BOTTOM: 15px"> <table style="WIDTH: 100%; PADDING-TOP: 7px" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; WIDTH: 57px; PADDING-RIGHT: 5px; PADDING-TOP: 3px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=4311ec4G5ae37904G270814bG96&bcode=mCsDonZp&n_m=clagui57%40gmail.com" target="_blank"><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 50px; WIDTH: 50px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" alt="Documento de consenso sobre el tratamiento antimicrobiano de las infecciones en el pie diabético Española de Cirujanos (AEC), Asociación; Española de Angiología y Cirugía Vascular (SEACV), Sociedad; Española de Medicina Interna (SEMI), Sociedad; Española de Quimioterapia (SEQ), Sociedad Publicado en Angiologia. 2008;02(60):83-102 - vol.60 núm 02 http://www.facebook.com/l/8fb40Kt1K44BUZdQdbU_lO1nnYQ/www.elsevier.es/sites/default/files/elsevier/pdf/294/294v60n02a13189627pdf001.pdf" src="http://profile.ak.fbcdn.net/hprofile-ak-snc4/27419_100001101314342_6017_q.jpg"></a></td> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; PADDING-TOP: 5px" valign="top" align="left"> <table style="PADDING-BOTTOM: 5px; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=4311ec4G5ae37904G270814bG96&bcode=mCsDonZp&n_m=clagui57%40gmail.com" target="_blank">Maximo Cuadros Chavez</a></td> <td style="TEXT-ALIGN: right; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #999999; FONT-SIZE: 11px">6:04pm May 8 </td></tr></tbody></table> <div style="PADDING-BOTTOM: 7px; COLOR: #000000; FONT-SIZE: 11px">Documento de consenso sobre el tratamiento antimicrobiano de las infecciones en el pie diabético<br><br>Española de Cirujanos (AEC), Asociación; Española de Angiología y Cirugía Vascular (SEACV), Sociedad; Española de Medicina Interna (SEMI), Sociedad; Española de Quimioterapia (SEQ), Sociedad<br> Publicado en Angiologia. 2008;02(60):83-102 - vol.60 núm 02<br><a href="http://www.facebook.com/l/8fb40Kt1K44BUZdQdbU_lO1nnYQ/www.elsevier.es/sites/default/files/elsevier/pdf/294/294v60n02a13189627pdf001.pdf" rel="nofollow" target="_blank">http://www.facebook.com/l/8fb40Kt1K44BUZdQdbU_lO1nnYQ/www.elsevier.es/sites/default/files/elsevier/pdf/294/294v60n02a13189627pdf001.pdf</a></div> </td></tr></tbody></table></div></td></tr></tbody></table><br></td></tr> <tr> <td style="PADDING-BOTTOM: 15px; LINE-HEIGHT: 18px; PADDING-LEFT: 10px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #666666; FONT-SIZE: 12px; BORDER-TOP: #e9e9e9 1px solid; PADDING-TOP: 10px" colspan="2"> <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&id=188176414552160&mid=4311ec4G5ae37904G270814bG96&bcode=mCsDonZp&n_m=clagui57%40gmail.com" target="_blank">View Post on Facebook</a> · <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&view=notifications&mid=4311ec4G5ae37904G270814bG96&bcode=mCsDonZp&n_m=clagui57%40gmail.com" target="_blank">Edit Email Settings</a> · Reply to this email to add a comment.<br> </td></tr></tbody></table></td></tr></tbody></table></div></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-47905406735172310542011-04-16T19:56:00.001-07:002011-04-16T19:56:07.435-07:002010 Appropriate Triage of the Victim of Trauma...<p>Maximo Cuadros Chavez posted in cibermedicos.Maximo Cuadros Chavez7:43pm Apr 16 </p> <p>2010 <br>Appropriate Triage of the Victim of Trauma Eastern <br>Association for the Surgery of Trauma<br><a href="http://www.facebook.com/l/f8f80pNmMOt534Koa9L5zux4qOQ/www.east.org/tpg/TraumaTriage.pdf">http://www.facebook.com/l/f8f80pNmMOt534Koa9L5zux4qOQ/www.east.org/tpg/TraumaTriage.pdf</a><br> <br></p> <div class="gmail_quote">---------- Forwarded message ----------<br>From: <b class="gmail_sendername">Maximo Cuadros Chavez</b> <span dir="ltr"><<a href="mailto:notification%2Byfo6tzj9@facebookmail.com">notification+yfo6tzj9@facebookmail.com</a>></span><br> Date: 2011/4/16<br>Subject: [cibermedicos] 2010 Appropriate Triage of the Victim of Trauma...<br>To: Claudio Mori Gonzales <<a href="mailto:clagui57@gmail.com">clagui57@gmail.com</a>><br><br><br> <div style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" dir="ltr"> <table border="0" cellspacing="0" cellpadding="8" width="98%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif" bgcolor="#ffffff" width="100%"> <table border="0" cellspacing="0" cellpadding="0" width="500"> <tbody> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-LEFT: 10px; PADDING-RIGHT: 0px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px; PADDING-TOP: 10px" valign="top" colspan="2"> <table style="COLOR: #000000; FONT-SIZE: 11px" width="100%"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px" valign="top" width="100%" align="left"> <div style="BORDER-BOTTOM: #e9e9e9 1px solid; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; COLOR: #666666; PADDING-TOP: 0px">Maximo Cuadros Chavez <a style="COLOR: #3b5998; TEXT-DECORATION: underline" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&id=184435211592947&mid=41434c8G5ae37904G262b9ecG96&bcode=exhLDOzf&n_m=clagui57%40gmail.com" target="_blank">posted in cibermedicos</a>.</div> <div style="MARGIN-BOTTOM: 15px"> <table style="WIDTH: 100%; PADDING-TOP: 7px" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; WIDTH: 57px; PADDING-RIGHT: 5px; PADDING-TOP: 3px" valign="top"><a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=41434c8G5ae37904G262b9ecG96&bcode=exhLDOzf&n_m=clagui57%40gmail.com" target="_blank"><img style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; MIN-HEIGHT: 50px; WIDTH: 50px; BORDER-TOP: 0px; BORDER-RIGHT: 0px" alt="2010 Appropriate Triage of the Victim of Trauma Eastern Association for the Surgery of Trauma http://www.facebook.com/l/f8f80pNmMOt534Koa9L5zux4qOQ/www.east.org/tpg/TraumaTriage.pdf" src="http://profile.ak.fbcdn.net/hprofile-ak-snc4/27419_100001101314342_6017_q.jpg"></a></td> <td style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; PADDING-TOP: 5px" valign="top" align="left"> <table style="PADDING-BOTTOM: 5px; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #000000; FONT-SIZE: 11px"><a style="COLOR: #3b5998; FONT-WEIGHT: bold; TEXT-DECORATION: none" href="http://www.facebook.com/n/?profile.php&id=100001101314342&mid=41434c8G5ae37904G262b9ecG96&bcode=exhLDOzf&n_m=clagui57%40gmail.com" target="_blank">Maximo Cuadros Chavez</a></td> <td style="TEXT-ALIGN: right; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #999999; FONT-SIZE: 11px">7:43pm Apr 16 </td></tr></tbody></table> <div style="PADDING-BOTTOM: 7px; COLOR: #000000; FONT-SIZE: 11px">2010 <br>Appropriate Triage of the Victim of Trauma Eastern <br>Association for the Surgery of Trauma<br><a href="http://www.facebook.com/l/f8f80pNmMOt534Koa9L5zux4qOQ/www.east.org/tpg/TraumaTriage.pdf" rel="nofollow" target="_blank">http://www.facebook.com/l/f8f80pNmMOt534Koa9L5zux4qOQ/www.east.org/tpg/TraumaTriage.pdf</a></div> </td></tr></tbody></table></div></td></tr></tbody></table><br></td></tr> <tr> <td style="PADDING-BOTTOM: 15px; LINE-HEIGHT: 18px; PADDING-LEFT: 10px; PADDING-RIGHT: 5px; FONT-FAMILY: 'lucida grande', tahoma, verdana, arial, sans-serif; COLOR: #666666; FONT-SIZE: 12px; BORDER-TOP: #e9e9e9 1px solid; PADDING-TOP: 10px" colspan="2"> <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&id=184435211592947&mid=41434c8G5ae37904G262b9ecG96&bcode=exhLDOzf&n_m=clagui57%40gmail.com" target="_blank">View Post on Facebook</a> · <a style="COLOR: #3b5998; TEXT-DECORATION: none" href="http://www.facebook.com/n/?home.php&sk=group_150017968368005&view=notifications&mid=41434c8G5ae37904G262b9ecG96&bcode=exhLDOzf&n_m=clagui57%40gmail.com" target="_blank">Edit Email Settings</a> · Reply to this email to add a comment.<br> </td></tr></tbody></table></td></tr></tbody></table></div></div><br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-8751486181027285472011-04-14T11:01:00.001-07:002011-04-14T11:01:51.144-07:00algo mas que curar en neuro<table border="1" rules="none" cellspacing="0" cellpadding="0" width="100%" align="center"> <tbody> <tr valign="center"> <td class="tdCabecera"><span class="txCabecera">C </span></td> <td class="tdCabecera" nowrap align="right"><a href="http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=2761#"><img border="0" src="http://www.neurologia.com/img/iconos/notMail.gif"></a> <a href="http://www.neurologia.com/sec/RSS/noticiaImprimir.php?id=2761" target="_blank"><img border="0" alt="imprimir" src="http://www.neurologia.com/img/iconos/notImprimir.gif"></a> </td> </tr> <tr> <td style="PADDING-LEFT: 20px; PADDING-TOP: 10px" align="left"><span class="txPeque">06/04/2011 </span></td> <td style="PADDING-RIGHT: 20px" align="right"><span class="txPeque"><b>Redacción</b> </span></td></tr> <tr> <td style="TEXT-ALIGN: justify" class="tdTitulo" width="100%" colspan="2"> <div style="LINE-HEIGHT: 20px"><span style="LINE-HEIGHT: 150%; FONT-FAMILY: Arial; FONT-SIZE: 9pt">El uso de un inhibidor de la histona deacetilasa (HDCA) corrige el daño causado por la enfermedad de Niemann-Pick tipo C (NPC1) y permite que las células del enfermo puedan funcionar con normalidad.</span> <p><span style="LINE-HEIGHT: 150%; FONT-FAMILY: Arial; FONT-SIZE: 9pt">La enfermedad de Niemann-Pick tipo C consiste en un defecto genético que impide que las células usen adecuadamente los lípidos. Las células del cerebro se ven especialmente afectadas y su destrucción normalmente produce la muerte de los enfermos durante la adolescencia. Actualmente no existe tratamiento disponible.</span> </p> <p><span style="LINE-HEIGHT: 150%; FONT-FAMILY: Arial; FONT-SIZE: 9pt">Imágenes detalladas, obtenidas por la Universidad de Cornell, han mostrado pruebas vivas de la eficacia de un medicamento que hace que las células NPC se conviertan en células humanas normales después del tratamiento. Los inhibidores de la HDAC pueden corregir los defectos de almacenamiento de colesterol en las células mutantes NPC1, lo que constituye una base potencial de las opciones de tratamiento para la enfermedad de NPC.</span> </p> <p><span style="LINE-HEIGHT: 150%; FONT-FAMILY: Arial; FONT-SIZE: 9pt">Los inhibidores de la histona deacetilasa tienen una amplia gama de usos potenciales en enfermedades raras y en varias formas de cáncer, incluyendo la leucemia, donde puede aumentar el número de células de la médula ósea.</span></p> </div></td></tr></tbody></table> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0tag:blogger.com,1999:blog-3008889705230833536.post-62535699386964306112011-04-05T10:37:00.001-07:002011-04-05T10:37:34.059-07:00update in internal medicine [Archivos adjuntos 4]<p> </p> <p> </p> <p> </p> <p><br>Murillo Santucci Cesar de Assunção<br>Unidade de Terapia Intensiva adulto<br>Disciplina de Anestesiologia, Dor e Terapia Intensiva<br>Escola Paulista de Medicina<br>Rua Napoleão de Barros,715<br>Vila Clementino - São Paulo - CEP: 04024-002<br> Tel/Fax: +55-11-55757768<br>Tel/Fax: +55-11- 55764069<br><a href="mailto:m.assuncao@unifesp.br">m.assuncao@unifesp.br</a><br><a href="mailto:murilloassuncao@gmail.com">murilloassuncao@gmail.com</a></p> <p> </p> <p> </p> <p><br>Murillo Santucci Cesar de Assunção<br>Unidade de Terapia Intensiva adulto<br>Disciplina de Anestesiologia, Dor e Terapia Intensiva<br>Escola Paulista de Medicina<br>Rua Napoleão de Barros,715<br>Vila Clementino - São Paulo - CEP: 04024-002<br> Tel/Fax: +55-11-55757768<br>Tel/Fax: +55-11- 55764069<br><a href="mailto:m.assuncao@unifesp.br">m.assuncao@unifesp.br</a><br><a href="mailto:murilloassuncao@gmail.com">murilloassuncao@gmail.com</a></p> <p> </p> <p> </p> <p><a href="https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.1&disp=attd&zw">https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.1&disp=attd&zw</a></p> <div><a href="https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.3&disp=attd&zw">https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.3&disp=attd&zw</a></div> <div>\<a href="https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.5&disp=attd&zw">https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.5&disp=attd&zw</a></div> <div><a href="https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.7&disp=attd&zw">https://mail.google.com/mail/?ui=2&ik=14d8f0f8db&view=att&th=12f26a98e7dcbbb5&attid=0.1.7&disp=attd&zw</a></div> <div>4 archivos adjuntos — Explorando en busca de virus... <br>Update in Nephrology- Evidence Published in 2010.pdf<br>193 K Ver <br>Update in Endocrinology- Evidence Published in 2010.pdf<br>246 K Ver <br>Update in Cardiology- Evidence Published in 2010.pdf<br> 194 K Ver <br>Update in Pulmonary and Critical Care Medicine- Evidence Published in 2010.pdf<br>289 K Ver <br><br></div> <div class="gmail_quote">---------- Forwarded message ----------<br>From: <b class="gmail_sendername">Murillo Santucci Cesar de Assunção</b> <span dir="ltr"><<a href="mailto:murilloa@uol.com.br">murilloa@uol.com.br</a>></span><br> Date: 2011/4/5<br>Subject: [SALUD_LORETO] update in internal medicine [Archivos adjuntos 4]<br>To: salud loreto <<a href="mailto:SALUD_LORETO@yahoogroups.com">SALUD_LORETO@yahoogroups.com</a>>, <a href="mailto:interno_residente_medico_PERU@yahoogroups.com">interno_residente_medico_PERU@yahoogroups.com</a>, <a href="mailto:clavesmedicas@yahoogroups.com">clavesmedicas@yahoogroups.com</a><br> <br><br> <div style="WORD-WRAP: break-word"> <div> <blockquote type="cite"> <div style="MARGIN: 0px"><span style="FONT-FAMILY: 'Helvetica'; FONT-SIZE: medium"><br></span></div><br> <div></div></blockquote></div></div><br> <div style="WORD-WRAP: break-word"> <div> <blockquote type="cite"> <div></div></blockquote></div></div><br> <div style="WORD-WRAP: break-word"> <div> <blockquote type="cite"> <div></div></blockquote></div></div><br> <div style="WORD-WRAP: break-word"> <div> <blockquote type="cite"> <div></div></blockquote></div></div><br> <div style="WORD-WRAP: break-word"> <div> <blockquote type="cite"> <div><br>Murillo Santucci Cesar de Assunção<br>Unidade de Terapia Intensiva adulto<br>Disciplina de Anestesiologia, Dor e Terapia Intensiva<br>Escola Paulista de Medicina<br>Rua Napoleão de Barros,715<br>Vila Clementino - São Paulo - CEP: 04024-002<br> Tel/Fax: +55-11-55757768<br>Tel/Fax: +55-11- 55764069<br><a href="mailto:m.assuncao@unifesp.br" target="_blank">m.assuncao@unifesp.br</a><br><a href="mailto:murilloassuncao@gmail.com" target="_blank">murilloassuncao@gmail.com</a><br> <br><br><br></div></blockquote></div><br> <div><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"> <div style="WORD-WRAP: break-word"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"> <div style="WORD-WRAP: break-word"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"> <div style="WORD-WRAP: break-word"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"> <div style="WORD-WRAP: break-word"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"> <div style="WORD-WRAP: break-word"><span style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; BORDER-COLLAPSE: separate; FONT: medium Cambria; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px"> <div style="WORD-WRAP: break-word"> <div>Murillo Santucci Cesar de Assunção</div> <div>Unidade de Terapia Intensiva adulto</div> <div>Disciplina de Anestesiologia, Dor e Terapia Intensiva</div> <div>Escola Paulista de Medicina</div> <div>Rua Napoleão de Barros,715</div> <div>Vila Clementino - São Paulo - CEP: 04024-002</div> <div>Tel/Fax: +55-11-55757768</div> <div>Tel/Fax: +55-11- 55764069</div> <div><a href="mailto:m.assuncao@unifesp.br" target="_blank">m.assuncao@unifesp.br</a></div> <div><a href="mailto:murilloassuncao@gmail.com" target="_blank">murilloassuncao@gmail.com</a></div><br><br></div></span></div></span></div></span></div></span></div></span></div></span></span></span></div><br></div><br></div> <br> Claudio Mori Gonzaleshttp://www.blogger.com/profile/16446075772477324704noreply@blogger.com0